Screening for HIV Infection in Pregnant Women: A Systematic Review for the U.S. Preventive Services Task Force

Prepared for:
Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857
www.ahrq.gov

Contract No. HHSA-290-2015-00009-I, Task Order No. 7

Prepared by:
Pacific Northwest Evidence-Based Practice Center
Oregon Health & Science University
Mail Code: BICC
3181 SW Sam Jackson Park Road
Portland, OR 97239
www.ohsu.edu/epc

Investigators:
Shelley S. Selph, MD, MPH
Christina Bougatsos, MPH
Tracy Dana, MLS
Sara Grusing, BA
Roger Chou, MD

AHRQ Publication No. 18-05246-EF-2
June 2019
This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-209-2015-00009-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators have any affiliations or financial involvement that conflicts with the material presented in this report.

Acknowledgments

The authors also thank the AHRQ Medical Officer, Howard Tracer, MD, as well as the U.S. Preventive Services Task Force.

Suggested Citation

Structured Abstract

Background: A 2012 systematic review on HIV screening for the U.S. Preventive Services Task Force (USPSTF) found strong evidence that antiretroviral therapy (ART) greatly decreases the risk of mother-to-child HIV transmission but that use of ART may be associated with increased risk of preterm delivery. The USPSTF previously found HIV screening tests to be highly accurate.

Purpose: To systematically update the 2012 USPSTF review on HIV screening in pregnancy, focusing on research gaps identified in the prior review.

Data Sources: We searched the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, and MEDLINE (2012 to June 2018) and manually reviewed reference lists, with surveillance through January 25, 2019.

Study Selection: We selected randomized, controlled trials (RCTs) and cohort studies of pregnant women that reported risk of mother-to-child transmission or maternal or infant harms associated with prenatal HIV screening or ART during pregnancy.

Data Extraction: One investigator abstracted data and a second investigator checked data abstraction for accuracy. Two investigators independently assessed study quality using methods developed by the USPSTF.

Data Synthesis (Results): We identified no studies on the benefits or harms of prenatal HIV screening versus no screening, or on the yield of repeat versus one-time screening or screening at different intervals. One new RCT and five new cohort studies were consistent with the 2012 USPSTF review in finding combination ART highly effective at reducing the risk of mother-to-child transmission of HIV infection, especially if started early in pregnancy (rate of mother-to-child transmission <1%). As in the prior USPSTF review, one new RCT and several observational studies found certain ART regimens associated with increased risk of preterm delivery without increased risk of low birth weight. One RCT conducted in Africa found prenatal tenofovir-based ART associated with very preterm delivery and early infant death versus zidovudine-based ART, but the trial had methodological limitations. Prenatal exposure to most currently recommended ART drugs was not associated with increased risk of overall birth defects, but limited evidence found certain ART agents and regimens associated with increased risk of congenital abnormalities, cardiac anomalies, and echocardiographic changes, with no association with adverse neurodevelopmental outcomes. Evidence on long-term maternal harms associated with short-term exposure to ART during pregnancy remains limited, with some evidence of short-term harms.

Limitations: Only English-language articles were included. Observational studies were included. Studies conducted in resource-poor settings were included, which might limit applicability to screening in the United States.

Conclusions: Combination ART is highly effective at reducing risk of mother-to-child HIV transmission. The USPSTF previously determined that avoidance of breastfeeding and Caesarean
delivery in women with HIV ribonucleic acid levels greater than 1,000 copies/mL near the time of delivery is also effective at reducing mother-to-child transmission, and that prenatal screening is accurate at diagnosing HIV infection. Use of certain ART regimens during pregnancy is associated with increased risk of preterm delivery and may be associated with other adverse pregnancy outcomes. Although more evidence is required to better understand short- and long-term maternal and infant harms, selection of ART regimens may help mitigate or reduce harms.
Table of Contents

Chapter 1. Introduction and Background ........................................................................ 1
  Purpose .......................................................................................................................... 1
  Condition Background ............................................................................................... 1
  Condition Definition .................................................................................................... 1
  Prevalence and Burden of Disease/Ilness ................................................................. 1
  Etiology and Natural History .................................................................................... 2
  Risk Factors ................................................................................................................ 2
  Rationale for Screening/Screening Strategies ............................................................ 3
  Interventions/Treatment ............................................................................................. 3
  Current Clinical Practice/Recommendations of Other Groups ................................. 4

Chapter 2. Methods ........................................................................................................ 5
  Key Questions and Analytic Framework ....................................................................... 5
    Key Questions ........................................................................................................... 5
  Search Strategies ......................................................................................................... 5
  Study Selection ............................................................................................................ 5
  Scope of Review ........................................................................................................... 6
  Data Abstraction and Quality Rating ......................................................................... 7
  Data Synthesis ............................................................................................................. 7
  External Review .......................................................................................................... 7
  Response to Public Comments .................................................................................... 8

Chapter 3. Results ........................................................................................................... 9
  Key Question 1. What Are the Benefits of Screening for HIV Infection in Pregnant Women on Risk of Mother-to-Child Transmission of HIV Infection? ................................................................. 9
  Key Question 2. What Is the Yield of Repeat HIV Screening at Different Intervals in Pregnant Women, and How Does the Yield of Screening Vary in Different Risk Groups? ............ 9
    Summary .................................................................................................................... 9
    Evidence .................................................................................................................... 9
  Key Question 3. What Are the Harms of Screening for HIV Infection in Pregnant Women? ....... 10
    Summary .................................................................................................................... 10
    Evidence .................................................................................................................... 11
  Key Question 5. What Are the Harms of Currently Recommended ART Regimens Given During Pregnancy to the Mother and Infant? ........................................................ 12
    Summary .................................................................................................................... 12
    Evidence .................................................................................................................... 13

Chapter 4. Discussion .................................................................................................... 18
  Summary of Review Findings .................................................................................... 18
  Limitations ................................................................................................................... 19
  Emerging Issues/Next Steps ...................................................................................... 20
  Relevance for Priority Populations, Particularly Racial/Ethnic Minorities ................. 20
  Future Research ......................................................................................................... 20
  Conclusions .................................................................................................................. 20

References ..................................................................................................................... 21
Figure
Figure 1. Analytic Framework and Key Questions

Tables
Table 1. U.S.-Relevant Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
Table 2. African-Based Trials of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy
Table 4. Summary of Evidence

Appendixes
Appendix A. Detailed Methods
  Appendix A1. Search Strategies
  Appendix A2. Inclusion and Exclusion Criteria
  Appendix A3. Literature Flow Diagram
  Appendix A4. Included Studies List
  Appendix A5. Excluded Studies List
  Appendix A6. U.S. Preventive Services Task Force Quality Rating Criteria
Appendix B. Evidence Tables and Quality Tables
  Appendix B Table 1. Currently Recommended Initial Regimens for Antiretroviral-Naive Pregnant Women With HIV
  Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics
  Appendix B Table 3. Evidence Table of Included Studies: Results
  Appendix B Table 4. Quality Assessment of Cohort Studies
  Appendix B Table 5. Quality Assessment of Randomized Trials
Chapter 1. Introduction and Background

Purpose

HIV infection is transmissible during pregnancy and the postpartum period. The purpose of this report is to update a previous review commissioned by the U.S. Preventive Services Task Force (USPSTF) on benefits and harms of prenatal screening for HIV infection. This report will be used to update the USPSTF’s 2013 recommendation, which states that clinicians screen all pregnant women for HIV, including those who present in labor who are untested and whose HIV status is unknown (“A” recommendation), a confirmation of the USPSTF’s 2005 recommendation on prenatal HIV screening. The confirmation was based on prior findings that antiretroviral therapy (ART) is acceptable to pregnant women and that early detection and treatment of HIV is associated with large reductions in the risk of mother-to-child transmission, as well as some evidence that newer antiretroviral regimens are more effective than older regimens for preventing perinatal transmission. Although the USPSTF found some evidence that perinatal ART is associated with increased risk of preterm delivery, there was no clear association with low birth weight, congenital abnormalities, or impaired infant neurodevelopment, and no data indicating serious maternal harms.

Condition Background

Condition Definition

HIV is a ribonucleic acid (RNA) retrovirus that infects human immune cells, in particular CD4+ helper T lymphocyte (CD4) cells. Left untreated, HIV infection results in progressive immunodeficiency and AIDS. AIDS is a life-threatening condition characterized by presence of HIV infection and severe immune dysfunction (CD4 count ≤200 cells/mm$^3$) or one or more AIDS-defining neoplastic conditions or opportunistic infections. HIV-1 infection is the most common variant in the United States. HIV-2 infection is rare in the United States, less clinically severe, and endemic in parts of West Africa.

In HIV-infected pregnant women, HIV can cross the placenta, is present in cervical secretions in blood, and is present in breast milk. Therefore, transmission of HIV infection from mother to child can occur during pregnancy, during labor and delivery, and in the postpartum period through breastfeeding.

Prevalence and Burden of Disease/Illness

In 2017, women accounted for 19 percent of all new diagnoses of HIV infection among adults and adolescents in the United States. Between 2012 and 2017, the number of new HIV diagnoses in women declined 11 percent. About 235,004 women in the United States were living with HIV infection in 2016, with 7,312 new cases. Approximately 258 new diagnoses were in women ages 13 to 19 years. An estimated 60 percent of infections were in black
women, 20 percent in white women, and 15 percent in Hispanic/Latina women. An estimated 12 percent of women with HIV infection are unaware of their status. Approximately 8,500 HIV-positive women give birth each year in the United States. In 2005 to 2008, approximately 30 percent of HIV-infected women were unaware of their status prior to pregnancy and approximately 4 percent were undiagnosed prior to the time of delivery. Mother-to-child transmission accounts for approximately three-quarters of pediatric HIV infections in the United States and 90 percent of pediatric cases of AIDS. Through 2013, there have been nearly 5,000 cumulative deaths of U.S. children younger than age 13 years with perinatally acquired HIV infection. The number of cases of perinatal HIV infection in the United States peaked at about 1,650 in 1992, declining dramatically following the widespread adoption of routine prenatal screening, coupled with the use of effective therapies for preventing mother-to-child transmission. There were an estimated 215 to 370 cases of perinatal transmission in 2005 and 99 cases in 2016. The Centers for Disease Control and Prevention (CDC) estimates that between 1994 and 2010, 21,956 cases of perinatally acquired HIV infection were prevented. The overall annual rate of perinatally acquired HIV infection decreased from 6.0 cases per 100,000 live births in 2008 to 1.8 cases per 100,000 live births in 2013. Rates of perinatally acquired HIV infection differ according to age group. In 2013, among black persons, the rate of HIV infection was 11.3 cases per 100,000 live births (from 23.6 cases per 100,000 live births in 2008), compared with 1.8 cases among Hispanic persons and 0.6 cases in white persons.

Etiology and Natural History

Peripartum transmission of HIV infection can occur during pregnancy (intrauterine), during labor and delivery (intrapartum), and following delivery (postpartum). In the absence of breastfeeding, intrauterine transmission is thought to account for 25 to 40 percent of vertically infected infants, with the remaining cases occurring during labor and delivery. Most intrauterine transmission is thought to occur shortly before delivery. HIV is present in and transmitted through breast milk and breastfeeding is thought to be the only important mode of postpartum transmission to newborns and infants. In resource-poor settings in which women breastfeed for prolonged periods, postpartum transmission accounts for about 44 percent of infant cases. Antiretroviral treatment of the mother and infant does not completely eliminate breastfeeding transmission risk. In the United States, HIV-infected women are advised against breastfeeding, given the risk of transmission and the availability of affordable and safe alternatives.

Risk Factors

Most (87%) new HIV diagnoses in women (regardless of pregnancy status) are attributed to acquisition via heterosexual sex, followed by injection drug use (12%). In HIV-infected pregnant women, about 50 percent were exposed to HIV through heterosexual contact, 8 percent through injection drug use, and 8 percent through some other exposure category (such as blood transfusion or perinatal exposure). In about one-third of women, HIV exposure was unknown. Well-established risk factors for perinatal transmission include higher viral load,
immunologically or clinically advanced disease in the mother, prolonged rupture of membranes, maternal infection with other sexually transmitted infections, and labor and delivery procedures and events associated with an increased probability of bodily fluid contact between mother and infant (such as abruptio placentae, fetal scalp electrode use, episiotomy, and second-degree or greater perineal laceration).  

Risk factors for clinical progression of HIV infection (in particular, high viral load and low CD4 count) appear to be similar for pregnant and nonpregnant women. In developed countries, pregnancy itself does not appear to be an important independent predictor of clinical progression in chronically-infected HIV-positive women.  

**Rationale for Screening/Screening Strategies**

A major goal of prenatal screening for HIV is to reduce the risk of mother-to-child transmission through provision of subsequent interventions. Other important goals are to improve long-term clinical outcomes in HIV-infected women through initiation of ART and other interventions (e.g., prophylaxis for opportunistic infections in women with immunologically advanced disease), facilitate early identification of infected newborns, help women to make more informed future reproductive choices, and reduce risk of horizontal transmission through effects on risky behaviors. The prior USPSTF review on prenatal HIV screening found that ART in combination with avoidance of breastfeeding and elective Caesarean delivery in women with viremia substantially reduces risk of mother-to-child transmission, from 9 to 22 percent with no ART to less than 1 to 2.4 percent with full-course combination ART.  

**Interventions/Treatment**

The current standard of care to prevent perinatal transmission of HIV infection in the United States is combination ART started at the time of diagnosis in all HIV-infected women (regardless of viral load or CD4 count), intravenous zidovudine and elective Caesarean delivery before labor or rupture of membranes in women with HIV RNA levels greater than 1,000 copies/mL or unknown HIV RNA levels near the time of delivery, antiretroviral treatment of the infant in the postnatal period, and avoidance of breastfeeding. The selection of antiretroviral drugs is based on evidence on effectiveness for reducing perinatal transmission, risks to the fetus, side effect profile, and other factors, such as the potential for drug interactions or the possibility of inducing antiretroviral drug resistance, and may be informed by results of antiretroviral drug resistance testing. Because delayed treatment may reduce effectiveness of ART on risk of mother-to-child transmission, current guidelines recommend that clinicians consider initiating ART as soon as HIV is diagnosed during pregnancy, and not delay selection of the initial ART while awaiting results of drug resistance testing. For women who present in labor with unknown HIV status, rapid testing with initiation of maternal (intravenous zidovudine during labor) and infant (combination ART) prophylaxis is recommended, with continuation of infant prophylaxis based on results of confirmatory testing. Consistent with management of nonpregnant persons with HIV infection, guidelines now recommend that HIV-positive women diagnosed during pregnancy be offered long-term ART following delivery, regardless of CD4 count.
HIV-positive women identified during pregnancy may also benefit from other interventions that would be considered in nonpregnant persons with HIV infection, including long-term ART, prophylaxis for opportunistic infections, immunizations, and counseling to reduce high-risk behaviors for horizontal transmission; in addition, male sexual partners may benefit from pre-exposure prophylaxis with ART. 29

Current Clinical Practice/Recommendations of Other Groups

The diagnostic accuracy of standard HIV testing is thought to be similar for pregnant and nonpregnant persons. 30 A large, prospective cohort study of 5,744 pregnant women presenting in labor in six U.S. cities (HIV prevalence, 0.59%) found rapid testing (prior to confirmation) associated with a sensitivity of 100 percent, specificity of 99.9 percent, positive predictive value of 90 percent, and negative predictive value of 100 percent. 31 Point-of-care rapid tests are recommended for women presenting in labor who have not received prenatal care or who were not tested earlier in pregnancy for other reasons. 32 Basing therapeutic decisions on a positive rapid test prior to confirmation is only recommended in situations in which decisions to initiate treatments cannot wait, such as in women presenting in active labor. Otherwise, confirmation of positive rapid tests prior to initiating interventions is recommended due to the possibility of false-positive tests, 31 which could result in unnecessary exposure to antiretroviral or other therapies.

Current practice in the United States for HIV screening in pregnant women includes “opt-out” HIV screening at the initial prenatal visit as part of the standard prenatal test panel. 23 Opt-out screening refers to screening that is performed after informing the woman about the test, unless the woman specifically declines. The CDC recommends that clinicians consider repeat testing in all women in the third trimester for those who test negative initially, and recommends repeat testing for women who continue to practice high-risk behaviors or who live in a high-incidence setting. 32

In the United States, about 85 percent of HIV-infected women receive ART during pregnancy, with about 40 percent undergoing an elective cesarean delivery. 11 More than 95 percent of infants born to HIV-infected women receive ART during the postnatal period.

Many groups, including the American College of Obstetricians and Gynecologists, 33 the American Academy of Pediatrics, 34,35 the American College of Physicians, 36 and the CDC 32,37 recommend voluntary “opt out” testing for HIV in all pregnant women as part of routine prenatal care. The CDC 32,37 and the American College of Obstetricians and Gynecologists 33 recommend repeat testing for women with risk factors and those who live or receive care in high-incidence settings, and recommend that clinicians consider repeat testing for all women with a negative test result early in pregnancy. The USPSTF recommends that women screened during a previous pregnancy be rescreened in subsequent pregnancies, but does not address repeat screening during the same pregnancy. 4 The American Academy of Family Physicians follows the 2013 USPSTF recommendation. 38
Chapter 2. Methods

Key Questions and Analytic Framework

Using the methods developed by the USPSTF, the USPSTF and the Agency for Healthcare Research and Quality determined the scope and Key Questions for this review. Investigators created an analytic framework with the Key Questions and the patient populations, interventions, and outcomes reviewed (Figure 1). Key informants with expertise in HIV screening and HIV infection during pregnancy were surveyed for input, and the draft Research Plan was posted for public comment prior to finalization. The target population for HIV screening was pregnant women (including adolescents, defined as women ages 13 to <18 years) without signs or symptoms of HIV infection.

Key Questions

1. What are the benefits of screening for HIV infection in pregnant women on risk of mother-to-child transmission of HIV infection?
2. What is the yield of repeat HIV screening at different intervals in pregnant women, and how does the yield of screening vary in different risk groups?
3. What are the harms of screening for HIV infection in pregnant women?
4. What is the effectiveness of currently recommended ART regimens for reducing mother-to-child transmission of HIV infection?
5. What are the harms of currently recommended ART regimens given during pregnancy to the mother and infant?

Search Strategies

We searched the Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Ovid MEDLINE (2012 through June 2018) for relevant studies and systematic reviews. Search strategies are available in Appendix A1. We also reviewed reference lists of relevant articles.

After June 2018, we conducted surveillance through article alerts and targeted searches of high-impact journals to identify major studies that may affect conclusions. The last surveillance was conducted on January 25, 2019 and identified no primary research that would meet inclusion criteria for this review.

Study Selection

All titles and abstracts identified through searches were independently reviewed by two members of the research team for eligibility against predefined inclusion and exclusion criteria, as specified using the PICOTS (population, intervention, comparator, outcome, timing, study
design/setting) framework (Appendix A2). Studies marked for possible inclusion by either reviewer underwent full-text review. All results were tracked using EndNote® reference management software (Thomson Reuters, New York, NY).

Each full-text article was independently reviewed by two trained members of the research team for inclusion or exclusion on the basis of the eligibility criteria. If the reviewers disagreed, conflicts were resolved by discussion and consensus or by consulting another member of the review team. Results of the full-text review were also tracked in the EndNote database, including the reason for exclusion for full-text publications. The selection of literature is summarized in the literature flow diagram (Appendix A3). Appendix A4 lists the included studies, and Appendix A5 lists the excluded studies with reasons for exclusion.

**Scope of Review**

The prior USPSTF recommendation on prenatal HIV screening was an “A” recommendation, based on convincing evidence that the benefits of prenatal screening substantially outweigh harms. This review focuses on key areas for which evidence was lacking in the prior USPSTF review, including direct evidence on benefits and harms (including false-positive results and anxiety) of screening and the yield of repeat screening during pregnancy. Given changes in ART regimens that are used in pregnant women, this review addresses evidence on effectiveness and harms of ART, with a focus on regimens currently recommended by the U.S. Department of Health and Human Services Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. A list of currently recommended ART regimens in pregnant women is shown in Appendix B Table 1. Most studies that reviewed various ART regimens evaluated outcomes associated with components of ART regimens, rather than entire regimens; we included studies that evaluated currently recommended regimens or ART agents that are part of currently recommended regimens. We excluded regimens and ART agents that are no longer recommended in current U.S. practice.

This update does not address diagnostic accuracy of screening, which the USPSTF previously found to be high. This update also does not rereview effects of avoidance of breastfeeding and elective cesarean delivery in women with viremia on risk of perinatal transmission, as the effectiveness of these interventions is well established and part of standard U.S. practice. Effects of early initiation of long-term ART are addressed in a separate report on screening for HIV infection in nonpregnant adolescents and adults.

The population of interest for prenatal screening is asymptomatic pregnant women not known to be HIV-positive. For Key Questions on benefits and harms of ART, the population was HIV-infected pregnant women. Patient subgroups included those defined by age and race/ethnicity. The screening intervention was standard or rapid HIV antibody testing with confirmatory testing. Outcomes were mother-to-child transmission, yield of screening (number of cases of HIV infection identified per number of tests performed), harms of screening (including labeling, anxiety, and other harms), and maternal and infant harms of treatment, including long-term harms following in utero exposure to ART. For Key Questions on screening, comparisons were screening versus no screening, one-time versus repeat screening, and repeat screening at different intervals. For Key Questions on benefits and harms of ART, we included studies that compared...
full-course (initiated in first or early second trimester) combination ART versus no ART, abbreviated courses of ART, or one- or two-drug therapy. For all Key Questions, we included randomized, controlled trials (RCTs), cohort studies, and case-control studies. We included studies conducted in primary care–applicable settings (e.g., prenatal, antenatal, and family planning clinics) and other health care settings in which screening is commonly performed (e.g., emergency room, urgent care, or labor and delivery). Although the target for treatment studies was those conducted in the United States and other high-income/low HIV prevalence countries, we also included RCTs on effects of ART on mother-to-child transmission conducted in low- and middle-income settings. For harms associated with prenatal ART, we included RCTs and cohort studies from any setting but restricted cohort studies to those that adjusted for potential confounders.

Data Abstraction and Quality Rating

For studies meeting inclusion criteria, we abstracted data on characteristics of study populations, interventions, comparators, outcomes, study designs, settings, and methods. For each study, data abstraction was conducted by one investigator and reviewed for completeness and accuracy by another investigator.

Predefined criteria were used to assess the quality of individual controlled trials, systematic reviews, and observational studies developed by the USPSTF. Studies were rated as “good,” “fair,” or “poor” quality in accordance with USPSTF methods, based on the seriousness of the methodological shortcomings (Appendix A6). For each study, quality assessment was independently performed by two team members. Any disagreements were resolved by consensus.

Data Synthesis

We did not attempt meta-analysis of studies on effectiveness of ART on mother-to-child transmission or on harms of ART due to differences across studies in ART regimens and comparisons evaluated, harms outcomes, geographic settings, and methodological factors (e.g., observational studies performed statistical adjustment on different variables). There were too few studies to consider meta-analysis for other Key Questions.

For all Key Questions, the overall quality of evidence was determined using the approach described in the USPSTF Procedure Manual. Evidence was rated “good,” “fair,” or “poor,” based on the number, quality, and size of studies, consistency of results between studies, and directness of evidence, and is summarized in a table.

External Review

The draft report was reviewed by content experts (Appendix A7), USPSTF members, Agency for Healthcare Research and Quality Project Officers, and collaborative partners, and was posted
for public comment; it has been revised accordingly.

**Response to Public Comments**

The draft report was posted for public comment from November 20, 2018 to December 26, 2018, and few comments were received. In response to the comments, we added a reference in the Discussion section to a systematic review on the safety of tenofovir disoproxil fumarate (TDF) in pregnancy.⁴³
Chapter 3. Results

A total of 1,232 new references from electronic database searches and manual searches of recently published studies were reviewed and 162 full-text papers were evaluated for inclusion. Twenty-nine new studies (in 36 articles) were included, and 33 studies (in 35 articles) were carried forward from the prior USPSTF report. Included studies and quality ratings are described in Appendix B.

Key Question 1. What Are the Benefits of Screening for HIV Infection in Pregnant Women on Risk of Mother-to-Child Transmission of HIV Infection?

As in the prior USPSTF review, no RCT or observational study compared clinical outcomes (including risk of perinatal transmission) between pregnant women screened and not screened for HIV infection. As previously noted by the USPSTF, the number of infants with perinatally-acquired HIV transmission has markedly declined in the United States, likely due to a combination of screening during pregnancy and increased effectiveness and use of interventions to prevent transmission.

Key Question 2. What Is the Yield of Repeat HIV Screening at Different Intervals in Pregnant Women, and How Does the Yield of Screening Vary in Different Risk Groups?

Summary

No study compared the yield of one-time versus repeat screening or different frequencies of screening for HIV in pregnancy. Three studies conducted in the United States or the United Kingdom identified no cases of HIV infection among women who were rescreened for HIV during the third trimester of pregnancy; details regarding HIV risk status were not reported and not all women were rescreened.

Evidence

As in the prior USPSTF review, we identified no RCT or observational study on the yield of repeat prenatal HIV screening compared with one-time screening, or that compared the yield of different strategies for repeat screening (e.g., risk-based repeat screening vs. a routine repeat test). Three studies reported rescreening rates and positive screening results in 3,473 pregnant women, but did not meet inclusion criteria because they did not compare different screening strategies. One retrospective study of pregnant women (n=1,632) was conducted in Baltimore, Maryland, a state that mandates that pregnant women be screened for syphilis at presentation and again in the third trimester, providing an opportunity for HIV rescreening as
well.\textsuperscript{115} HIV rescreening was performed in 28 percent of women, with no cases of HIV infection identified. A second study of 2,392 women in the United Kingdom with an initial negative prenatal HIV screening result found no cases of HIV infection in those retested during the third trimester.\textsuperscript{116} The third study retested 75 women in ambulatory obstetrics-gynecology clinics in Philadelphia with a rapid HIV test in the third trimester and identified no new cases of HIV infection.\textsuperscript{117} In these studies, details were unavailable regarding risk of HIV acquisition (e.g., HIV risk category or prevalence of HIV risk behaviors), and not all women were rescreened.

Repeat screening and the optimal timing of repeat testing during pregnancy depends on the incidence of new HIV infections following an initial negative prenatal screening result. One modeling study discussed in the 2005 USPSTF review estimated that repeat testing in the third trimester after a negative test in the first trimester would detect 5.3 new infections per 100,000 average-risk women tested and 192 infections per 100,000 high-risk women tested.\textsuperscript{118}

**Key Question 3. What Are the Harms of Screening for HIV Infection in Pregnant Women?**

As in the prior USPSTF review, no study compared psychological or other harms associated with screening for HIV infection in pregnant women or adverse clinical consequences of interventions given as a result of false-positive results.

**Key Question 4. What Is the Effectiveness of Currently Recommended ART Regimens for Reducing Mother-to-Child Transmission of HIV Infection?**

**Summary**

The 2012 USPSTF review included eight cohort studies\textsuperscript{105-108,110-113} that found full-course (starting in first trimester or early in second trimester) combination ART associated with rates of mother-to-child transmission of less than 1 to 2.4 percent, compared with 9 to 22 percent with no ART. Consistent with the prior USPSTF review, five new European, North American, and Israeli cohort studies published since 2012 found perinatal full-course triple ART associated with a risk of mother-to-child transmission that ranged from less than 1 to 2.8 percent.\textsuperscript{51,60,61,63,74}

Two African RCTs included in the prior USPSTF review found combination ART started at 26 to 28 weeks of gestation associated with mother-to-child transmission rates of 1 to 5 percent.\textsuperscript{86,87} One new RCT conducted primarily in Africa found combination ART after 14 weeks of gestation associated with a lower rate of mother-to-child transmission than zidovudine monotherapy (0.5% vs. 1.8%).\textsuperscript{44} Across studies, including four African RCTs included in the prior USPSTF review,\textsuperscript{80,81,84,88} later initiation of ART during pregnancy or treatment with fewer than three antiretroviral medications was associated with increased risk of mother-to-child transmission.
Evidence

The landmark Pediatric AIDS Clinical Trials Group protocol 076 study found that a three-phase maternal and infant zidovudine regimen starting at 14 to 34 weeks of gestation through 6 weeks postpartum decreased the risk of mother-to-child transmission in nonbreastfeeding women to 8 percent compared with 25 percent with placebo.119 The 2012 USPSTF review identified no completed trials on full-course combination ART during pregnancy in nonresource-poor, nonbreastfeeding settings. It included eight U.S. or European cohort studies that found full-course combination ART associated with rates of mother-to-child transmission ranging from less than 1 to 2.4 percent, compared with 9 to 22 percent with no ART. The prior USPSTF review also included two RCTs of breastfeeding women in Africa that found triple ART started at 26 to 28 weeks of gestation associated with mother-to-child transmission rates of 1 to 5 percent.86,87 Four other African trials in the prior USPSTF review found shorter courses of perinatal ART and regimens using fewer than three drugs associated with a lower risk of mother-to-child transmission of HIV infection compared with the expected transmission rate without therapy, but generally higher transmission rates than with full-course, three-drug regimens.80,81,84,88 These RCTs are likely to be most applicable in the United States to HIV-infected women identified later in pregnancy, who cannot receive full-course regimens.

We identified no new RCTs on full-course combination ART during pregnancy in nonresource-poor, nonbreastfeeding settings. Five fair-quality cohort studies conducted in high-income settings and published since the prior USPSTF review evaluated the effectiveness of combination ART during pregnancy on risk of mother-to-child transmission51,60,61,63,74 (Table 1, Appendix B Tables 2–5). Results were consistent with the findings from the prior review (Table 1). One large study (n=4,459) conducted an individual patient data meta-analysis of infants born between 1996 and 2010 in seven cohorts from six European countries who were at high risk of acquiring HIV infection (mother with viral load >50 copies/mL in the last 8 weeks of pregnancy, or mother only received intrapartum ART or received no antenatal or intrapartum ART).51 More than 25 percent of women did not receive ART during pregnancy. In women who received ART, the timing of initiation during pregnancy was not reported. Treatment with three or more antiretroviral drugs was associated with decreased risk of mother-to-child transmission compared to zero drugs (2.8% vs. 14.3%; adjusted odds ratio (OR), 0.36 [95% confidence interval (CI), 0.23 to 0.57]). One or two antiretroviral drugs were also associated with decreased risk of mother-to-child transmission compared with no ART (adjusted OR, 0.33 [95% CI, 0.19 to 0.55] and OR, 0.12 [95% CI, 0.04 to 0.40], respectively).

The French Perinatal Cohort is an ongoing observational study involving 95 percent of all HIV-infected women in 90 perinatal centers throughout France.61 Between 2000 and 2011, combination ART was initiated during pregnancy in 4,583 women (8% in the first trimester, 32% in the second trimester, 12% in the third trimester, and 47% before conception). Most regimens were protease inhibitor–based triple therapy (82.5%). There were 50 cases of mother-to-child HIV transmission (1.2% of births). The rate of mother-to-child HIV transmission was highest in women who initiated ART during the third trimester and in whom viral loads nearest delivery were detectable (4.4% [95% CI, 2.1 to 7.9]). There were no HIV transmissions among 2,651 women who started ART before pregnancy, continued ART throughout pregnancy, and had a viral load less than 50 copies/mL at the time of delivery.
Two smaller cohort studies, one from Canada and one from the United Kingdom and Ireland, reported rates of mother-to-child HIV transmission with combination ART of 1 and 0.5 percent, respectively. In the U.K./Ireland study, ritonavir-boosted lopinavir was associated with a higher transmission rate when ART was initiated during the third trimester (1.9%). Some mother-infant pairs in this study may have been included in the individual patient data meta-analysis discussed above. An Israeli cohort study found combination ART during pregnancy associated with decreased risk of vertical transmission (adjusted OR, 0.4 [95% CI, 0.1 to 0.8]); transmission rates were 1.5 percent with vaginal delivery and 0.6 percent with Caesarean delivery. Results were not stratified by timing of ART delivery.

One new fair-quality RCT (the Promoting Maternal and Infant Survival Everywhere [PROMISE] trial; n=3,490) was conducted in India and Africa among HIV-infected women with CD4 counts at or above 350 cells/mm$^3$ who were at or beyond 14 weeks of gestation (Table 2). The rate of mother-to-child transmission at 1 week after birth was 1.8 percent with zidovudine alone; 0.5 percent with ART with zidovudine, lamivudine, and lopinavir-ritonavir; and 0.6 percent with ART with tenofovir, emtricitabine, and lopinavir/ritonavir (difference in rate for combined ART regimens vs. zidovudine alone, -1.3% [95% CI, -2.1 to -0.4]). The proportion of women who breastfed was 92 percent.

**Key Question 5. What Are the Harms of Currently Recommended ART Regimens Given During Pregnancy to the Mother and Infant?**

**Summary**

New evidence (two trials and 21 cohort studies in 30 publications) on infant and maternal harms associated with perinatal exposure to ART was generally consistent with the evidence included in the 2012 USPSTF review. One fair-quality RCT conducted in Africa and seven cohort studies published since the last review found antenatal ART associated with increased risk of preterm birth compared with no treatment or zidovudine monotherapy. The trial and 12 cohort studies found mixed results for the association between ART given during pregnancy and low birth weight, small size for gestational age, and stillbirth. Five cohort studies, including the Antiretroviral Pregnancy Registry, found that most antiretroviral drugs recommended in the United States as initial therapy for HIV in pregnancy were not associated with increased risk of birth defects. The trial reported increased risk of neonatal death with ART with tenofovir, emtricitabine, and lopinavir/ritonavir (4.4%) compared with ART with zidovudine, lamivudine, and lopinavir/ritonavir (0.6%), but there was no difference between the tenofovir combination ART regimen and zidovudine monotherapy in risk of early infant death (4.4% vs. 3.2%; p=0.43). Some methodological limitations were present in this trial.
Evidence

Birth Outcomes

The 2012 USPSTF review\(^1\) included one RCT\(^83\) and three prospective cohort studies\(^92,94,99\) published after 2005 that found maternal exposure to combination ART with a protease inhibitor associated with increased risk of preterm delivery (<37 weeks) compared with nonnucleoside reverse transcriptase-based ART (OR, 2.0 [95% CI, 1.3 to 3.3]),\(^83\) combination ART without a protease inhibitor (adjusted OR, 1.8 [95% CI, 1.1 to 3.0]),\(^92\) dual therapy (adjusted OR, 1.2 [95% CI, 1.0 to 1.4]),\(^99\) or monotherapy (adjusted OR, 3.4 [95% CI, 1.1 to 10])\(^94\) (Table 3). A fourth cohort study\(^100\) found combination therapy associated with increased risk of preterm delivery (adjusted OR, 1.4 [95% CI, 1.1 to 1.8]) compared with monotherapy or dual therapy, with no difference in risk according to whether the antiretroviral regimen included a protease inhibitor or not. There was no clear association between maternal exposure to ART and increased risk of other adverse birth outcomes (e.g., low birth weight, small size for gestational age).

One open-label, Africa-based RCT\(^44\) and 21 cohort studies in 30 publications\(^46-50,52-59,61,62,64-73,75-79\) published since the prior USPSTF review evaluated the association between maternal exposure to ART and risk of preterm delivery, low birth weight, and other birth outcomes (Table 3; Appendix B Tables 2–5). Sample sizes ranged from 183 to 13,124 (total N=71,472). Eight studies were conducted in the United States, seven studies in Canada or Europe, and the remainder in Africa or Latin America. One cohort study, the Antiretroviral Pregnancy Registry\(^47\) (n=22,360), is an international (69 countries) voluntary registry with 74 percent of data currently from the United States and its territories. ART regimens and comparisons varied across studies. Most cohort studies did not include a control group of women who did not receive ART; other methodological limitations were high attrition and unclear blinding of outcome assessors or data analysts.

The new fair-quality RCT (PROMISE; n=3,490) (see Key Question 4 for study details)\(^44\) found ART with zidovudine, lamivudine, and lopinavir/ritonavir associated with increased risk of preterm delivery versus zidovudine monotherapy (20.5% vs. 13.1%; p<0.001). Zidovudine-containing combination therapy was also associated with increased risk of low birth weight (23% vs. 12%; p<0.001) and “any adverse birth outcome” (defined as low birth weight, preterm delivery, spontaneous abortion, stillbirth, or congenital anomaly; 40% vs. 27.5%; p<0.001). ART with tenofovir, emtricitabine, and lopinavir/ritonavir was associated with increased risk of low birth weight (16.9% vs. 8.9%; p=0.004) and any neonatal adverse event (34.7% vs. 27.2%; p=0.04) versus zidovudine monotherapy; effects on risk of preterm delivery were not statistically significant (18.5% vs. 13.5%; p=0.09). Tenofovir-containing ART was associated with increased risk of early infant death versus zidovudine-containing ART (4.4% vs. 0.6%; p<0.001) and increased risk of very preterm (<34 weeks) delivery (6.0% vs. 2.6%; p=0.04), but there was no difference between tenofovir-containing ART versus zidovudine monotherapy in risk of early infant death (4.4% vs. 3.2%; p=0.43). There were also no differences in the rates of stillbirth between treatments. Methodological limitations of the trial included open-label design and changes in randomization from two ART groups (period 1) to three groups (period 2), resulting in a smaller sample for tenofovir-containing ART. Comparisons between zidovudine-containing...
ART and zidovudine monotherapy included outcomes from both period 1 and period 2 (N=3,084), whereas comparisons between tenofovir-containing ART (N=406) and zidovudine-containing ART (N=410) or zidovudine monotherapy (N=413) included only outcomes from period 2. In addition, there were unexplained differences in rates of events with zidovudine-containing ART between period 1 and period 2 for neonatal death (1.2% vs. 0.6%) and stillbirth (3.3% vs. 0.9%).

Consistent with the prior USPSTF review, one new RCT\(^44\) and three new cohort studies\(^{54,72,75,78}\) found ART containing a boosted protease inhibitor associated with an approximate 30 percent increased risk of preterm birth versus treatment not containing a boosted protease inhibitor (N=7,584). However, two new cohort studies (N=1,140) found treatment with a protease inhibitor associated with a 50 percent decreased risk of preterm delivery\(^{54}\) or no difference in risk\(^{52}\) when compared with no ART.

Like the prior review,\(^1\) new evidence identified for this update also found mixed evidence on other adverse birth outcomes. Four new cohort studies evaluated effects of ART on risk of low birth weight.\(^{56,62,66,69}\) Two studies found combination ART associated with an approximate 80 percent decreased risk of low birth weight versus no ART (two studies; N=3,192).\(^{56,62}\) One study found no association between ART versus no ART and low birth weight (one study; N=2,599),\(^{66}\) and two studies found no difference between tenofovir-containing versus nontenofovir-containing ART in risk of low birth weight (two studies; N=3,650).\(^{67,69}\)

Ten new cohort studies (in 11 publications) evaluated the association between ART and risk of small for gestational age.\(^{46,50,52,57,62,66,69,73,75,78,79}\) Four new cohort studies found about a 40 percent decreased risk of small for gestational age with some regimens (three studies, N=8,404),\(^{46,78,79}\) and one study (N=1,814) reported a decrease risk of small for gestational age with the ART regimen tenofovir, emtricitabine, and efavirenz compared with no ART (adjusted OR, 0.25 [95% CI, 0.07 to 0.87]).\(^{62}\) Other studies found no effect between different ART regimens on risk of small for gestational age.\(^{46,52,69,73,75}\) or no effect of ART versus no ART on risk of small for gestational age.\(^{52,66}\) One new cohort study (n=5,726) found treatment with the ART regimen zidovudine, lamivudine, and either nevirapine- or ritonavir-boosted lopinavir associated with increased risk of small for gestational age versus zidovudine monotherapy (adjusted OR, 1.5 [95% CI, 1.2 to 1.9]),\(^{50}\) while two other studies reported no difference between ART and zidovudine monotherapy.\(^{57,66}\)

Five studies evaluated the association between ART and risk of stillbirth.\(^{56,62,65,78,79}\) One cohort study (n=5,726) found treatment with ART associated with increased risk of stillbirth versus zidovudine monotherapy (adjusted OR, 2.5 [95% CI, 1.6 to 3.9]),\(^{50}\) while two studies reported a significantly decreased risk of stillbirth compared with no ART.\(^{56,62}\) Stillbirth was less likely with the regimen tenofovir, emtricitabine, and efavirenz compared with zidovudine, lamivudine, and nevirapine (n=3,837; adjusted relative risk [RR], 0.43 [95% CI, 0.31 to 0.61]),\(^{78}\) but the difference was not statistically significant when tenofovir, emtricitabine, and efavirenz was compared with other ART regimens grouped together (n=3,226; adjusted OR, 0.6 [95% CI, 0.3 to 1.3]).\(^{79}\) Two new cohort studies (n=4,381) reported no increase in risk of neonatal death with tenofovir-based ART\(^{65,78}\) but one study (n=2,639) found increased risk of neonatal death with the ART regimen zidovudine, lamivudine, and ritonavir-boosted lopinavir compared with tenofovir,
emtricitabine, and efavirenz (adjusted RR, 4.01 [95% CI, 1.78 to 9.11]). A combined analysis of two studies (n=1,621) found no difference in risk of fetal loss (undefined in this study but normally would include spontaneous abortion, fetal demise, and stillbirth) between initial therapy with tenofovir and emtricitabine combined with either ritonavir-boosted lopinavir or atazanavir versus zidovudine and lamivudine combined with ritonavir-boosted lopinavir. This study also found no difference in risk of neonatal death within 14 days after birth between the three treatment regimens.

Overall Congenital Abnormalities

The 2012 USPSTF review found no association between perinatal exposure to ART and overall congenital abnormalities, based on three cohort studies. Five new cohort studies (N=40,436), including the Antiretroviral Pregnancy Registry, evaluated the association between combination ART in HIV-infected pregnant women and risk of congenital anomalies (Table 3). All of the newer cohort studies included patients who received one or more of the preferred nucleoside reverse transcriptase inhibitors for use in pregnancy (abacavir, lamivudine, tenofovir, or emtricitabine). Most antiretroviral agents and classes were not associated with an increased risk of congenital abnormalities, but findings were limited by small numbers of studies, imprecision in estimates, and multiple comparisons. One study found no antiretroviral agent associated with increased risk of birth defects. One study found an association between atazanavir, ritonavir, or any protease inhibitor and increased risk of congenital abnormalities versus nonexposure; one study found an association between lamivudine, first-trimester exposure to abacavir, and first-trimester exposure to zidovudine and risk of congenital abnormalities; one study found an association between first-trimester exposure to efavirenz and risk of congenital abnormalities; and one study found emtricitabine associated with decreased risk of congenital anomalies. The Antiretroviral Pregnancy Registry found zidovudine associated with increased risk of overall birth defects, but ritonavir associated with decreased risk.

One of the cohort studies (n=2,580) also reported specific categories of birth defects in children exposed in utero to ART. Atazanavir was associated with increased risk of congenital musculoskeletal and skin anomalies (adjusted OR, 2.57 [95% CI, 1.30 to 5.08] and 6.01 [95% CI, 1.43 to 25.3], respectively). Ritonavir as booster therapy was associated with musculoskeletal birth defects (adjusted OR, 1.79 [95% CI, 1.02 to 3.14]) and zidovudine was associated with increased risk of male genital defects (primarily hypospadias and cryptorchidism; adjusted OR, 3.18 [95% CI, 1.10 to 9.22]). An additional cohort study found exposure to ART during the first trimester associated with malformation of the small intestine (adjusted OR, 10 [95% CI, 2.85 to 37]), but there was no increase in risk of birth defects with prenatal ART exposure on the urogenital, musculoskeletal, nervous, and circulatory systems.

Cardiovascular Congenital Anomalies

The 2012 USPSTF review included one cohort study that found no association between in utero exposure to zidovudine and acute or chronic abnormalities in left ventricular structure or function, although another study found an association between in utero ART and echocardiographic findings of unknown clinical significance in children age 2 years or younger.
We identified one subsequent RCT and two cohort studies (in three publications) that also reported somewhat mixed results on the association between ART exposure and cardiac findings\textsuperscript{58,70,76} (Appendix B Tables 2 and 3). A U.S.-based cohort study (the Surveillance Monitoring for ART Toxicities [SMARTT] study) of 2,580 HIV-uninfected children born between 1995 and 2008 with in utero ART exposure found no currently recommended ART drug associated with increased risk of cardiovascular defects, although there was a trend toward increased risk with ritonavir (adjusted OR, 1.83 [95% CI, 0.96 to 3.49]).\textsuperscript{76} A large French cohort study of 12,888 children born between 1994 and 2010 found first-trimester exposure to zidovudine associated with congenital heart defects compared with no zidovudine exposure (1.5% vs. 0.77%; adjusted OR, 2.2 [95% CI, 1.5 to 3.2]).\textsuperscript{70,71} The most common condition was ventricular septal defect. A second analysis of 400 HIV-uninfected children exposed to ART in utero\textsuperscript{58} found that at age 2 to 7 years (median, 4 years), exposure to some antiretroviral drugs, particularly during the first trimester, was associated with reduced stress velocity index, reduced left ventricular short-axis dimension, and increased left ventricular posterior wall thickness. None of the echocardiographic findings were associated with significant cardiovascular compromise.

Another study evaluated the association between in utero exposure to ART and echocardiographic measures. A nested RCT within a cohort (Protease Inhibitor Monotherapy Evaluation [PRIMEVA] French National Agency for Research on AIDS and Viral Hepatitis [ANRS] 135 study) of combination ART (zidovudine, lamivudine, and ritonavir-boosted lopinavir) versus protease inhibitor monotherapy (ritonavir-boosted lopinavir alone) performed echocardiographic assessments at 1 month (n=53) and 1 year (n=42). There was no difference in echocardiographic parameters in boys, but in girls combination therapy was associated with higher left ventricular shortening fraction at 1 month (a measure of decreased left ventricular systolic function; p=0.02) and a trend toward increased posterior wall thickness at 1 year (p=0.07).\textsuperscript{70}

A third study (n=367) found no effect of ART versus no ART exposure during the first trimester on cardiovascular congenital anomalies (adjusted OR, 0.75 [95% CI, 0.31 to 1.85]).\textsuperscript{48}

**Neurodevelopmental Outcomes in Children**

The 2012 USPSTF review included three cohort studies that found no association between in utero exposure to ART and long-term adverse effects on child growth and development.\textsuperscript{89,93,103} We identified two publications of a U.S.-based surveillance cohort (the SMARTT study) of HIV-exposed, uninfected infants and children (Appendix B Table 2).\textsuperscript{64,77} One study measured the Wechsler Preschool and Primary Scale of Intelligence-III at age 5 years (n=369) and the Wechsler Abbreviated Scale of Intelligence and the Wechsler Individual Achievement Test at ages 7, 9, 11, and 13 years (n=451).\textsuperscript{64} There was no association between in utero exposure to ART and lower scores on these tests, although test scores were lower overall than in population norms. In younger children, in utero exposure to tenofovir was associated with higher performance intelligence quotient, based on the Wechsler Preschool and Primary Scale of Intelligence-III, compared with children not exposed to tenofovir (p<0.05). Another publication from the SMARTT study found in utero exposure to combination ART associated with less neurodevelopmental impairment than no in utero exposure to ART (adjusted RR, 0.47 [95% CI,
0.27 to 0.83]) (Appendix B Tables 2 and 3).77

**Maternal Harms**

The 2012 USPSTF review included one study that found receipt of ART during pregnancy associated with increased risk of gestational diabetes (adjusted OR, 3.5 [95% CI, 1.2 to 10]) and anemia (adjusted OR, 1.6 [95% CI, 1.1 to 2.4]) compared with no ART.101 Two additional studies reported a trend toward increased risk of gestational diabetes with ART compared with monotherapy or no ART (RR, 9.37 [95% CI, 0.57 to 153]102 and RR, 1.86 [95% CI, 0.65 to 5.29]97). We identified no new studies on the association between use of ART during pregnancy versus no ART and risk of diabetes or gestational diabetes. One RCT conducted in three African countries (n=8,848) of women with CD4 counts of 200 to 500 cells/mm<sup>3</sup> found no difference in risk of anemia between combination ART (zidovudine, lamivudine, and ritonavir-boosted lopinavir) beginning between 28 and 36 weeks of gestation and zidovudine monotherapy starting from 34 to 36 weeks of gestation until onset of labor followed by zidovudine and a single dose of nevirapine at the onset of labor (Appendix B Tables 2 and 3).45 Women were given iron and folic acid supplementation upon study enrollment.

In the previously discussed PROMISE trial (n=3,490; see Key Question 4 for study details), antenatal zidovudine-based combination ART was associated with a higher rate of maternal grade 2 or higher adverse events than zidovudine alone (21% vs. 17%; p=0.008; specific adverse events not reported) and increased risk of abnormalities in blood chemistry values (5.8% vs. 1.3%; p<0.001), primarily elevation in alanine aminotransferase levels.44 There was also an increased risk of abnormal blood chemistry values (not specified) with tenofovir-based ART than with zidovudine monotherapy (2.9% vs. 0.8%; p=0.03). Few women withdrew from the study due to adverse events.
Chapter 4. Discussion

Summary of Review Findings

This report updates a 2012 USPSTF review on prenatal screening for HIV infection.\textsuperscript{1,2} Evidence reviewed for this update is summarized in Table 4. As in the 2012 USPSTF review, we found no direct evidence on effects of prenatal screening versus no screening on risk of mother-to-child HIV transmission or maternal or infant clinical outcomes. We also identified no studies on the yield of repeat prenatal screening versus one-time screening or different frequencies of screening for HIV in pregnancy. Although three studies conducted in the United States or the United Kingdom identified no cases of HIV infection among women who were rescreened for HIV during the third trimester of pregnancy,\textsuperscript{115-117} results were difficult to interpret because the HIV risk of women who underwent rescreening was unclear, and not all women underwent rescreening. As discussed in the prior USPSTF report, the yield of repeat prenatal screening depends on HIV infection incidence during pregnancy. In addition, detecting HIV acquired during pregnancy may be important because some data suggest markedly higher risk of mother-to-child transmission compared with HIV acquired prior to pregnancy.\textsuperscript{120}

New evidence identified for this update\textsuperscript{51,60,61,74} confirm findings from the 2012 USPSTF review that full-course combination ART is highly effective at reducing the risk of mother-to-child transmission, with some cohort studies reporting rates of mother-to-child transmission of less than 1 percent when started early in pregnancy.\textsuperscript{61,74} Cohort studies and RCTs also found that combination therapy started in the second or third trimester are effective at reducing the risk of mother-to-child transmission. Shorter courses of ART were not as effective as full-course regimens, but also reduce risk of mother-to-child transmission compared with no ART, supporting benefits of screening and initiation of therapy later in pregnancy.\textsuperscript{44,80-82}

New evidence on harms of ART was also largely consistent with the 2012 USPSTF review. Although some ART agents and regimens may be associated with increased risk of infant or maternal harms, such harms may be mitigated or reduced through appropriate selection of ART regimens. As in the prior USPSTF review, evidence from primarily observational studies found prenatal combination ART with a boosted protease inhibitor associated with increased risk of preterm delivery.\textsuperscript{44,54,72,78} An African RCT found tenofovir-containing, lopinavir/ritonavir-based combination ART associated with greater risk of early infant death than zidovudine-containing, lopinavir/ritonavir-based combination ART.\textsuperscript{44} However, there were methodological limitations with this trial, including two periods with different randomization protocols, and different rates of some adverse birth outcomes depending on period of randomization. The RCT found no difference in early infant death between tenofovir-based combination ART and treatment with zidovudine alone and no difference between treatments in risk of stillbirth. Tenofovir is a preferred nucleoside reverse transcriptase inhibitor for use in pregnancy in most, but not all, guidelines due to its demonstrated efficacy, acceptable toxicity, ease of use, and no established teratogenicity; however, the use of lopinavir, rather than a preferred protease inhibitor, makes the ART combination evaluated in this trial an alternative regimen (lopinavir is associated with more nausea than preferred protease inhibitors).\textsuperscript{47} The increased risk of early infant death in the trial could be related to a higher risk of very preterm delivery associated with this tenofovir-contained regimen.
containing ART regimen, which is associated with increased risk of infant mortality in low-income settings. Other African studies found no association between tenofovir-based ART and risk of stillbirth or neonatal death. A recent review of TDF in pregnancy and breastfeeding did not identify safety issues versus non-TDF regimens, but included HIV-negative women and unpublished studies.

For other birth outcomes (low birth weight, small for gestational age, stillbirth, and overall birth defects), results were mixed and depended on the specific antiretroviral drug or drug regimen given and timing of prenatal therapy. As in the prior USPSTF review, some evidence indicated that ART may be associated with cardiac findings such as ventricular septal defects and echocardiographic changes, although the clinical significance of findings is unclear. Evidence on congenital abnormalities was limited by small numbers of studies and imprecise estimates, although some studies found exposure to different drugs in the first trimester associated with increased risk of congenital abnormalities. Studies in older children exposed to ART in utero suggested no association with worse neurodevelopmental outcomes compared with unexposed children.

Evidence on long-term maternal harms associated with short-term exposure to ART during pregnancy or ART started during pregnancy and continued after pregnancy remains sparse, although one new study found evidence of increased short-term nonspecific adverse events. Women found to be HIV-infected through prenatal screening would also benefit from standard HIV treatments following pregnancy, including long-term combination ART, prophylaxis for opportunistic infections, immunizations, and indicated screenings.

**Limitations**

We excluded non-English–language articles, which could result in language bias, although we identified no non-English–language studies that would have met inclusion criteria. We did not attempt to pool studies because of differences in study designs, populations, study setting, antiretroviral regimens evaluated, and outcomes assessed. Because we could not pool studies, we also could not formally assess for publication bias with graphical or statistical methods. We included observational studies, which are more susceptible to bias and confounding than well-conducted RCTs, although we restricted inclusion to observational studies that performed statistical adjustment for potential confounding. Another limitation is that RCTs of combination ART have only been conducted in Africa. The applicability of studies conducted in resource-poor and high-prevalence settings to U.S. practice is limited by differences in the antiretroviral drugs evaluated, evaluation of shorter regimens, inclusion of women who breastfeed, and other factors. Although we focused on new studies published since 2012, in most studies results were reported for individual ART agents and classes, rather than for currently recommended ART regimens, which could reduce applicability of findings to current U.S. practice. Restricting analyses to studies in which patients received treatment after 2006 (the earliest year a current preferred regimen was approved), or in whom results for currently recommended regimens could clearly be identified, did not appear to change conclusions, although formal stratified analyses were not possible.
Emerging Issues/Next Steps

ART regimens for use during pregnancy and indications for initiating long-term ART continue to evolve. Regularly updated guidelines on selection of ART in pregnant women are available.\(^47\)

Relevance for Priority Populations, Particularly Racial/Ethnic Minorities

HIV disproportionately affects women from racial/ethnic minority populations, who often have less access to prenatal care, leading to reduced opportunities for early screening and initiation of ART during pregnancy. Identification of HIV infection during pregnancy provides an opportunity to link affected women to long-term care and treatment. Therefore, improving access to prenatal care is an important challenge for reducing the effect of HIV infection in these populations.

Future Research

Although there are no studies comparing the effects of screening for HIV in pregnancy versus no screening, such studies may no longer be indicated given epidemiological evidence showing marked decreases in the number of children with perinatally acquired HIV infection in the United States and strong evidence on the effectiveness of ART on preventing mother-to-child transmission. Studies comparing one-time screening versus repeat screening or that perform rescreening in well-defined cohorts of women would be helpful for understanding the yield of rescreening and for understanding when rescreening is indicated. Future research is needed to further clarify the effectiveness and harms of currently recommended antiretroviral regimens, effects of in utero exposure to ART on pregnancy outcomes, and long-term harms in exposed children to optimize selection of ART regimens during pregnancy and to understand the effects of screening and treatment with ART in pregnant adolescents.

Conclusions

Combination ART is highly effective at reducing risk of mother-to-child HIV transmission. The USPSTF previously determined that avoidance of breastfeeding and Caesarean delivery in women with HIV RNA levels greater than 1,000 copies/mL near the time of delivery is also effective at reducing mother-to-child transmission, and that prenatal screening is accurate at diagnosing HIV infection. Use of certain ART regimens during pregnancy is associated with increased risk of preterm delivery and other adverse pregnancy outcomes. Although more evidence is required to better understand short- and long-term maternal and infant harms, selection of ART regimens may help mitigate or reduce harms.
References


Screening for HIV in Pregnant Women


94. Grosch-Woerner I, Puch K, Maier RF, et al. Increased rate of prematurity associated with antenatal antiretroviral therapy in a German/Austrian cohort of HIV-1-infected women.


107. Italian Register for Human Immunodeficiency Virus Infection in Children. Determinants of mother-to-infant human immunodeficiency virus 1 transmission before and after the


**Key Questions**

1. What are the benefits of screening for HIV infection in pregnant women on risk of mother-to-child transmission of HIV infection?
2. What is the yield of repeat HIV screening at different intervals in pregnant women, and how does the yield of screening vary in different risk groups?
3. What are the harms of screening for HIV infection in pregnant women?
4. What is the effectiveness of currently recommended ART regimens for reducing mother-to-child transmission of HIV infection?
5. What are the harms of currently recommended ART regimens given during pregnancy to the mother and infant?
<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Setting</th>
<th>Intervention</th>
<th>Sample</th>
<th>Mother-to-child transmission rates by treatment group</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garcia-Tejedor et al, 2009&lt;sup&gt;110&lt;/sup&gt;</td>
<td>Spain Maternity hospitals</td>
<td>ART A: No treatment B: Mono/dual therapy C: ART</td>
<td>489 mother-infant pairs analyzed</td>
<td>A: 18% (39/214) B: 8.6% (10/116) C: 0.8% (1/159) p&lt;0.001</td>
<td>Fair</td>
</tr>
<tr>
<td>Harris et al, 2007&lt;sup&gt;111&lt;/sup&gt;</td>
<td>U.S. Population surveillance data from areas reporting &gt;60 HIV-positive women giving birth per year</td>
<td>ART A: No treatment B: Prenatal, intrapartum, and neonatal ART*</td>
<td>7,344 HIV-exposed infants with ART data</td>
<td>A: 22% (59/265); OR referent B: 2.4% (139/5,757); AOR, 0.09 (95% CI, 0.06 to 0.12) Prenatal ART regimen and infant infection status among 3 treatment arms: ZDV: OR referent ZDV + other drugs with PI: AOR, 0.4 (95% CI, 0.3 to 0.7) ZDV + other drugs with no PI: AOR, 0.5 (95% CI, 0.3 to 0.8) Other drugs with PI, no ZDV: AOR, 0.6 (95% CI, 0.2 to 1.4) Other drugs with no PI, no ZDV: AOR, 0.3 (95% CI, 0.1 to 1.5) n=5,602 due to exclusions</td>
<td>Fair</td>
</tr>
<tr>
<td>Townsend et al, 2008&lt;sup&gt;113&lt;/sup&gt;</td>
<td>Ireland, U.K. Population surveillance data from NSHPC</td>
<td>Antepartum treatment A: ART therapy B: Dual therapy C: Monotherapy D: No therapy</td>
<td>5,027 mother-infant pairs with ART data</td>
<td>A: 1.0% (40/4,120) B: 0.8% (1/126) C: 0.5% (3/638) D: 9.1% (13/143) n=4,084 due to exclusions</td>
<td>Fair</td>
</tr>
<tr>
<td>Tariq et al, 2011&lt;sup&gt;112&lt;/sup&gt;</td>
<td>U.K., Ireland, Belgium, Denmark, Germany, Italy, the Netherlands, Poland, Spain, Sweden Population surveillance data from the ECS and NSHPC</td>
<td>ART A: ZDV-containing B: ZDV-sparing</td>
<td>7,573 mother-child pairs analyzed</td>
<td>0.9% (56/6,130) (95% CI, 0.7 to 1.0) of infants were infected (infection status available for 80% [6,130/7,645] of infants at analysis) A: 0.9% (n=5,214); AOR, 1 B: 0.8% (n=897); AOR, 1.8 (95% CI, 0.8 to 4.3); p=0.18</td>
<td>Fair</td>
</tr>
</tbody>
</table>
Table 1. U.S.-Relevant Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Setting</th>
<th>Intervention</th>
<th>Sample</th>
<th>Mother-to-child transmission rates by treatment group</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chiappini et al, 2013</td>
<td>EPPICC; 7 cohorts from 6 countries; (Ukraine excluded due to heterogeneity)</td>
<td>A. ≥3 drugs</td>
<td>4,459 high-risk mother-infant pairs: no therapy (28%), only intrapartum prophylaxis (17%), and ART received but mother’s viral load remained detectable (55%); % screen-detected HIV during pregnancy NR; 45% no antenatal or only intrapartum ART None breastfed (Ukraine cohort not included in transmission analysis) Timing of infant HIV testing NR</td>
<td>A. 2.8% (65/2,355); AOR, 0.36 (95% CI, 0.23 to 0.57); p&lt;0.001 B. 1.2% (3/255); AOR, 0.12 (95% CI, 0.04 to 0.40); p&lt;0.001 C. 3.1% (21/681); AOR, 0.33 (95% CI, 0.19 to 0.55); p&lt;0.005 D. 14.3% (158/1,107); AOR, 1 reference</td>
<td>Fair</td>
</tr>
<tr>
<td>Lu et al, 2014</td>
<td>Canada, CPHSP</td>
<td>ART A. Complete ART during pregnancy, ZDV during labor, infant received ZDV B. Incomplete ART C. No therapy</td>
<td>645 mother-child pairs analyzed Rate of Caesarean delivery 43% Breastfeeding rate NR Followup NR Proportion of mothers born in HIV-endemic country 65% Analysis of data over 12-year study period; % screen-detected HIV during pregnancy NR; 13% were considered late diagnoses (diagnosed at or after delivery) Timing of infant HIV testing NR</td>
<td>A. 1% (3/251) B. 2% (8/336) C. 67% (39/58)</td>
<td>Fair</td>
</tr>
<tr>
<td>Mandelbrot et al, 2015</td>
<td>France, national prospective multicenter French Perinatal Cohort (ANSR-EPF)</td>
<td>First ART A. Triple NRTI B. PI-based C. NNRTI-based D. Three classes E. Other</td>
<td>8,075 mother-child pairs analyzed Rate of Caesarean delivery 57% Breastfeeding rate 0% Followup: Clinicians encouraged to followup from birth to ages 18 to 24 months Analysis of data over 11-year study period; % screen-detected HIV during pregnancy NR; 57% initiated ART during pregnancy; 72% of mothers born in Africa Timing of infant HIV testing NR</td>
<td>Transmission rates did not differ based on choice of initial ART (PI- vs. NNRTI-based) Transmission based on timing of ART initiation Before conception, 0.2%; AOR, 1 (reference) 1st trimester, 0.4%; AOR, 2.9 (95% CI, 0.6 to 17.7) 2nd trimester, 0.9%; AOR, 6.0 (95% CI, 1.7 to 29.7) 3rd trimester, 2.2%; AOR, 7.8 (95% CI, 2.1 to 28.8)</td>
<td>Fair</td>
</tr>
<tr>
<td>Mor et al, 2017</td>
<td>Israel, all HIV-infected women who delivered in Israel (and were citizens) between 1988 and 2011</td>
<td>A. HAART (392) B. No HAART (404)</td>
<td>796 mother-infant pairs; 82% of mothers born in Ethiopia; 8 infants were breastfed Timing of infant HIV testing NR</td>
<td>HAART vs. no HAART during pregnancy: AOR, 0.4 (95% CI, 0.1 to 0.8) Overall transmission: 3% (25/796) Transmission with HAART and vaginal delivery: 1.5% Transmission with HAART and Caesarean delivery: 0.6%</td>
<td>Fair</td>
</tr>
</tbody>
</table>
### Table 1. U.S.-Relevant Studies of Mother-to-Child HIV Transmission While Using Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Setting</th>
<th>Intervention</th>
<th>Sample</th>
<th>Mother-to-child transmission rates by treatment group</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tookey et al, 2016&lt;sup&gt;74&lt;/sup&gt;</td>
<td>U.K. and Ireland, NSHPC</td>
<td>A. LPV/r + ZDV + 3TC</td>
<td>4,864 enrolled; 2,406 mother-infant pairs (2008–2012); 67% were given LPV/r + ZDV + 3TC; proportion of mothers born in sub-Saharan Africa 77%; some mother-infant pairs at high risk for HIV transmission likely also counted in the Chiappini study</td>
<td>By timing of LPV/r initiation: Overall: 12/2,406 (0.5% [95% CI, 0.2% to 0.8%]) Before conception: 2/635 (0.3% [95% CI, 0.1% to 1.1%]) First trimester: 0/77 (0%) Second trimester: 5/1,397 (0.4% [95% CI, 0.2% to 0.8%]) Third trimester: 5/264 (1.9% [95% CI, 0.8% to 4.4%])</td>
<td>Fair</td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. LPV/r + TDF-FTC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. LPV/r + ABC + 3TC</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. LPV/r + other or missing NRTIs</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** 3TC = lamivudine; ABC = abacavir; ANRS-EPF = French Agence Nationale de Recherche sur le SIDA-Enquête Périnatale Française; AOR = adjusted odds ratio; ART = antiretroviral therapy; CI = confidence interval; CPHSP = Canadian Perinatal HIV Surveillance Program; ECS = European Collaborative Study; EPPICC = European Pregnancy and Paediatric HIV Cohort Collaboration; FTC = emtricitabine; HAART = highly active antiretroviral therapy; LPV/r = lopinavir/ritonavir; NSHPC = National Study of HIV in Pregnancy and Childhood; NR = not reported; NNRTI = nonnucleoside reverse transcriptase inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; OR = odds ratio; TDF = tenofovir disoproxil fumarate; U.K. = United Kingdom; ZDV = zidovudine.
<table>
<thead>
<tr>
<th>Author, year</th>
<th>Setting</th>
<th>Prenatal intervention</th>
<th>Peripartum intervention</th>
<th>Postpartum intervention</th>
<th>Sample</th>
<th>Mother-to-child transmission rates by treatment group</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chi et al, 2008</td>
<td>Zambia</td>
<td>From 32 weeks: ZDV to all groups</td>
<td>A: TDF-FTC + NVP B: NVP</td>
<td>All neonates: NVP dose in hospital + ZDV for 1 week</td>
<td>355 mother-infant pairs analyzed 92% of infants breastfed in both groups</td>
<td>6 weeks postpartum A: 6% B: 8% p=0.4</td>
<td>Fair</td>
</tr>
<tr>
<td>Other publication: Chi et al, 2007</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>de Vincenzi et al, 2011</td>
<td>Burkina Faso, Kenya, South Africa</td>
<td>From 28 weeks: A: ZDV + 3TC + LPV/r B: ZDV</td>
<td>A: ZDV, 3TC, LPV/r B: ZDV + sdNVP</td>
<td>A: Maternal ZDV, 3TC, LPV/r until cessation of breastfeeding (maximum 6.5 months postpartum) B: Maternal 3TC and ZDV for 1 week postpartum* All neonates: ZDV for 1 week,* NVP dose within 72 hours of birth, cotrimoxazole from age 6 weeks to 12 months unless not HIV infected after cessation of breastfeeding</td>
<td>805 live-born infants 77% of infants in group A and 78% in group B were ever breastfed</td>
<td>Age 12 months A: 5.4% (21/333) (95% CI, 3.6 to 8.1) B: 9.5% (37/305) (95% CI, 7.0 to 13) RR reduction, 0.43 p=0.03</td>
<td>Good</td>
</tr>
<tr>
<td>Other publication: Kesho Bora Study Group, 2010</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gray et al, 2006</td>
<td>South Africa</td>
<td>From 34 weeks gestation: A: D4T B: ddl C: D4T + ddl D: ZDV</td>
<td>A: D4T B: ddl C: D4T + ddl D: ZDV</td>
<td>Infants received same ART regimen as mother until age 6 weeks</td>
<td>362 mother-infant pairs analyzed No infants breastfed</td>
<td>24 weeks postpartum A: 12% (11/91) (95% CI, 6.2 to 21) B: 11% (10/94) (95% CI, 5.2 to 19) C: 4.6% (4/88) (95% CI, 1.3 to 11) D: 5.6% (5/89) (95% CI, 1.9 to 13) All groups: 8.3% (30/362) (95% CI, 5.7 to 12)</td>
<td>Fair</td>
</tr>
<tr>
<td>Other publication: Included in prior report</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shapiro et al, 2010</td>
<td>Botswana</td>
<td>Randomization groups† From 26 weeks: A: ABC + ZDV + 3TC B: LPV/r + ZDV + 3TC Observational group‡ From 18 weeks: C: NVP + ZDV + 3TC</td>
<td>A: ABC + ZDV + 3TC B: LPV/r + ZDV + 3TC C: NVP + ZDV + 3TC</td>
<td>A: ABC + ZDV + 3TC B: LPV + RTV + ZDV + 3TC Above to continue until weaning or 6 months postpartum, whichever came first C: NVP + ZDV + 3TC to continue indefinitely All neonates: sdNVP at birth + ZDV from birth to 4 weeks</td>
<td>709 live-born infants (including 156 in the observational group) 97% of live-born infants breastfed and 71% continued for &gt;5 months</td>
<td>Age 6 months A: 2.1% (6/283) B: 0.4% (1/270) Percentage point difference, 1.7 (95% CI, -2.0 to 7.1)§ All groups: 1.1% (8/709) (95% CI, 0.5 to 2.2)</td>
<td>Fair</td>
</tr>
<tr>
<td>Other publication: Included in prior report</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Author, year</td>
<td>Setting</td>
<td>Prenatal intervention</td>
<td>Peripartum intervention</td>
<td>Postpartum intervention</td>
<td>Sample</td>
<td>Mother-to-child transmission rates by treatment group</td>
<td>Quality rating</td>
</tr>
<tr>
<td>-------------</td>
<td>---------</td>
<td>-----------------------</td>
<td>-------------------------</td>
<td>-------------------------</td>
<td>--------</td>
<td>---------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Shapiro et al, 2006*&lt;sup&gt;1&lt;/sup&gt;</td>
<td>Botswana</td>
<td>From 34 weeks: ZDV to all groups&lt;sup&gt;1&lt;/sup&gt;</td>
<td>A: sdNVP B: Placebo</td>
<td>All neonates: NVP at birth and ZDV from birth to age 1 month&lt;sup&gt;4&lt;/sup&gt;</td>
<td>694 live, first-born infants 50% of infants in both groups were breastfed Infant followup until age 1 month</td>
<td>Age 1 month A: 4.3% ± 2.3 (SD, 2) (15/345) B: 3.7% ± 2.2 (SD, 2) (13/346) 95% CI for difference, -2.4% to 3.8% (met equivalence)</td>
<td>Fair</td>
</tr>
<tr>
<td>Thistle et al, 2007&lt;sup&gt;48&lt;/sup&gt;</td>
<td>Zimbabwe</td>
<td>None</td>
<td>A: ZDV/sdNVP B: sdNVP</td>
<td>A: Infant ZDV for 72 hours after delivery and NVP dose within 72 hours of delivery B: Infant NVP dose within 72 hours of delivery</td>
<td>Study terminated secondary to futility 609 infants with data 89% of infants in group A and 91% in group B were breastfed at 6 weeks (1 infant in group A was breast and formula fed)</td>
<td>Age 6 weeks A: 14% (45/312) HIV+, 7.4% (23/312) mortality, 22% (68/312) met primary outcome (death or HIV infection) B: 17% (49/297) HIV+, 7.1% (21/297) mortality, 24% (70/297) met primary outcome</td>
<td>Fair</td>
</tr>
<tr>
<td>Fowler et al, 2016&lt;sup&gt;44&lt;/sup&gt;</td>
<td>India, Malawi, South Africa, Tanzania, Uganda, Zambia, Zimbabwe</td>
<td>Randomized From 14 weeks: A. ZDV B. ZDV + 3TC + LPV/r C. TDF + FTC + LPV/r A. sdNVP (ZDV-only group)</td>
<td>A. TDF + FTC (6–14 days; ZVD-only group) B. ZDV + 3TC + LPV/r C. TDF + FTC + LPV/r</td>
<td>3,202 live-born infants; mothers primarily black African; 92% breastfed; % screen-detected HIV during pregnancy NR</td>
<td>A. 1.8% (25/1,386) B. 0.5% (7/1,385) C. 0.6% (2/325) B + C vs. A: Difference in percentage point, -1.3 (95% CI, -2.1 to -0.4)</td>
<td>Fair</td>
<td></td>
</tr>
</tbody>
</table>

*Began after protocol change in December 2006 (enrollment commenced June 2005).
<sup>1</sup>Women with CD4 count >200 cells/mm<sup>3</sup>.
<sup>2</sup>Women with CD4 count <200 cells/mm<sup>3</sup> or with AIDS-defining illness.
<sup>3</sup>Study not powered for between-group comparisons of transmission rates.
<sup>4</sup>ART was offered to women with CD4 counts <200 cells/mm<sup>3</sup> or AIDS-defining illness at any point in study participation. If women started ART before delivery, they did not receive peripartum nevirapine or placebo.
<sup>5</sup>Infants confirmed to be HIV-infected were also given ART.

**Abbreviations:** 3TC=lamivudine; ABC=abacavir; ART=antiretroviral therapy; CI=confidence interval; D4T=zidovudine; ddl=didanosine; FTC=emtricitabine; LPV/r=lopinavir/ritonavir; NVP=nevirapine; RR=relative risk; RTV=ritonavir; sdNVP=single-dose nevirapine; SD=standard deviation; TDF=tenofovir disoproxil fumarate; ZDV=zidovudine.
### Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm Delivery</td>
<td>Cotter et al, 2006U.S. University of Miami study Included in prior report</td>
<td>A. None (n=338; 25%)&lt;br&gt;B. Monotherapy (n=492; 37%)&lt;br&gt;C. Combination therapy with PI (n=134; 10%)&lt;br&gt;D. Combination therapy without PI (n=373; 28%)&lt;br&gt;Total N=1,337</td>
<td>Preterm delivery &lt;37 weeks&lt;br&gt;Very preterm &lt;32 weeks</td>
<td>Median at delivery 39 weeks</td>
<td>Combination with vs. without PI:&lt;br&gt;&lt;37 weeks: 1.8 (1.1 to 3.0); p=0.03&lt;br&gt;Combination + PI:&lt;br&gt;&lt;37 weeks: 36.6% of women; p&lt;0.05&lt;br&gt;&lt;32 weeks: 2.2% of women; p-value NS</td>
</tr>
<tr>
<td></td>
<td>Grosch-Warner et al, 2008Germany, Austria Included in prior report</td>
<td>A. Monotherapy (n=76; 42%)&lt;br&gt;B. Dual therapy (n=32; 17%)&lt;br&gt;C. ART without PI (n=54; 30%)&lt;br&gt;D. ART with PI (n=21; 11%)&lt;br&gt;Total N=183</td>
<td>Preterm delivery &lt;36 weeks</td>
<td>&lt;36 weeks 34%* (crude rate)</td>
<td>A. 1 reference&lt;br&gt;C. ART (-) PI: 0.89 (0.38 to 2.12); p=0.8&lt;br&gt;D. ART (+) PI: 3.40 (1.13 to 10.2); p=0.03</td>
</tr>
<tr>
<td></td>
<td>Powis et al, 2011Botswana Included in prior report</td>
<td>A. PI group (LPV/r with ZDV/3TC) (n=275; 49%)&lt;br&gt;B. NRTI group, TZV (n=285; 51%)&lt;br&gt;Total N=560</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>&lt;37 weeks 11.8%*&lt;br&gt;Triple NRTI; 21.4% PI-based&lt;br&gt;&lt;32 weeks 2.6% (n=12); 8/12 associated with ART + PI; 4/12 triple NRTI</td>
<td>A. ART (+) PI: 2.03 (1.26 to 3.27); p=0.004&lt;br&gt;B. ART (-) PI (NRTI-based): 1.0</td>
</tr>
<tr>
<td></td>
<td>Schulte et al, 2007U.S. Pediatric Spectrum of HIV Disease cohort Included in prior report</td>
<td>A. None (n=2,565; 29%)&lt;br&gt;B. Monotherapy (n=2,621; 30%)&lt;br&gt;C. Dual therapy (n=1,044; 12%)&lt;br&gt;D. Triple therapy: ART, non-PI (n=1,781; 20%)&lt;br&gt;E. Triple therapy: ART, PI (n=782; 9%)&lt;br&gt;Total N=8,793</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>Mean 37 weeks (range, 26 to 42)</td>
<td>C. 1 reference&lt;br&gt;E. 1.21 (1.04 to 1.48); p-value NR</td>
</tr>
<tr>
<td></td>
<td>Townsend et al, 2007U.K., Ireland Included in prior report</td>
<td>A. ART (n=3,384; 69%)&lt;br&gt;B. Mono/dual therapy (n=1,061; 21%)&lt;br&gt;C. Untreated; not included in analyses (n=494; 10%)&lt;br&gt;Total N=4,939</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>&lt;37 weeks 14.1%*&lt;br&gt;&lt;35 weeks 7.8%&lt;br&gt;&lt;32 weeks 1.4%</td>
<td>A. &lt;37 weeks: 1.39 (1.05 to 1.83); p=0.02&lt;br&gt;A. &lt;35 weeks: 2.02 (1.35 to 3.04); p=0.001&lt;br&gt;A. &lt;32 weeks: 2.63 (1.3 to 5.33); p=0.007&lt;br&gt;B. 1 reference all comparisons</td>
</tr>
</tbody>
</table>
### Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm Delivery</td>
<td>Chagomerana et al, 2017 Malawi</td>
<td>Started ART before 27 weeks or not at all A. ART (2,909; 95%) B. No ART (165; 5%) Total N=3,074</td>
<td>Preterm delivery 27 to 37 weeks</td>
<td>24%</td>
<td>Delivery after 27 weeks: A. 1 reference B. aRR, 1.14 (0.84 to 1.55)</td>
</tr>
<tr>
<td></td>
<td>Chen et al, 2012 Botswana</td>
<td>A. Initiated HAART during pregnancy (ZVD/3TC/NVP or ZVD/3TC/LVP/r) (1.101; 12%) B. Initiated ZVD only during pregnancy (4,625; 51%) C. No ART (1,234; 13%) D. HAART continued from before pregnancy (2,189; 24%) Total N=9,149</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>24%*</td>
<td>Initiated HAART vs. initiated ZDV: 1.4 (1.2 to 1.8) Continued HAART vs. all others: 1.2 (1.1 to 1.4)</td>
</tr>
<tr>
<td></td>
<td>Duryea et al, 2015 U.S.</td>
<td>A. ART with PI (597; 59%) B. ART without PI (230; 23%) C. No ART (177; 18%) Total N=1,004</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>13% to 21% depending on ART regimen</td>
<td>A. 1 reference B. 0.9 (0.5 to 1.5) C. 1.0 (0.5 to 2.0)</td>
</tr>
<tr>
<td></td>
<td>Kakkar et al, 2015 Canada</td>
<td>A. NRTI/NNRTI (159; 30%) B. Boosted PI (119; 23%) C. Unboosted PI (195; 37%) D. No treatment (52; 10%) Total N=526</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>14%*</td>
<td>A. 0.67 (0.27 to 1.63); p=0.37 B. 2.17 (1.05 to 4.51); p=0.038 C. 1 reference D. 1.50 (0.33 to 6.78); p=0.60</td>
</tr>
<tr>
<td></td>
<td>Kreitchmann et al, 2014 Latin America Caribbean</td>
<td>At least 28 days in 3rd trimester: A. HAART + PI (888; 59%) B. HAART no PI (410; 27%) C. Non-HAART (134; 9%) D. No ARV (80; 5%) Total N=1,512</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>21%*</td>
<td>Receiving vs. not receiving ART at conception: 1.53 (1.11 to 2.09)</td>
</tr>
<tr>
<td></td>
<td>Li et al, 2016 Tanzania</td>
<td>A. Initiated ZDV during pregnancy (1,768; 53%) B. Initiated HAART during pregnancy (512; 15%) C. Continued HAART from before pregnancy (582; 18%) D. No ART (452; 14%) Total N=3,314</td>
<td>Preterm delivery &lt;37 weeks Very preterm &lt;34 weeks</td>
<td>No infants had HIV &lt;37 weeks 29%* &lt;34 weeks 10%*</td>
<td>HAART vs. ZDV started during pregnancy: &lt;37 weeks: 0.85 (0.70 to 1.02); p=0.14 &lt;34 weeks: 0.87 (0.60 to 1.25); p=0.45</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
</table>
| Preterm Delivery | Lopez et al, 2012 Spain | A. HAART entire pregnancy (226; 44%)  
B. HAART 2nd half of pregnancy only (72; 14%)  
C. PI during pregnancy (178; 34%)  
D. No HAART (221; 43%)  
Total N=697 | Preterm delivery <37 weeks | 20%* | Spontaneous preterm birth:  
A. 0.55 (0.20 to 1.51)  
B. 0.55 (0.18 to 1.68)  
C. 1.95 (0.87 to 4.38)  
D. HIV-uninfected women  
Iatrogenic preterm birth:  
A. 3.42 (0.80 to 14.63)  
B. 6.16 (1.42 to 26.8)  
C. 0.44 (0.18 to 1.10)  
D. HIV-uninfected women |
| | Moodley et al, 2016 South Africa | A. No ART (148; 4%)  
B. AZT + NVP (974; 26%)  
C. D4T + 3TC + NVP (907; 25%)  
D. EFV + TDF–FTC (1,666; 45%)  
Total N=3,695 | Preterm delivery <37 weeks | 22.3% | A. 1 reference  
B. 0.20 (0.08 to 0.51); p=0.001  
C. 0.21 (0.08 to 0.55); p=0.001  
D. 0.31 (0.11 to 0.90); p=0.03 |
| | Pintye et al, 2017 Kenya and Uganda | A. TDF-containing ART (208; 49%)  
B. Non-TDF–containing ART (214; 51%)  
Total N=422 | Preterm delivery <37 weeks | 8% | A vs. B: Adjusted prevalence rate ratio 0.37 (0.15 to 0.89); p=0.03 |
| | Ramokolo et al, 2017 South Africa | A. Postconception ART (780; 30%)  
B. ZDV (873; 34%)  
C. No ART (330; 13%)  
D. Preconception ART (616; 24%)  
Total N=2,599 | Preterm delivery <37 weeks | 12.5% | A. 1 reference  
B. 1.4 (0.9 to 2.0); p=0.11  
C. 1.9 (1.1 to 3.1); p=0.01  
D. 1.7 (1.1 to 2.5); p=0.02 |
| | Rough et al, 2018 U.S. PHACS and IMPAACT | A. TDF–FTC + LPV/r (128; 8%)  
B. ZDV + 3TC + LPV/r (954; 59%)  
C. TDF–FTC + ATV/r (539; 33%)  
Total N=1,621 | Preterm delivery <37 weeks  
Very preterm delivery <34 weeks | 18% Preterm delivery  
5% Very preterm delivery | Preterm delivery, adjusted OR:  
A vs. B: 0.90 (0.60 to 1.33)  
C vs. B: 0.69 (0.51 to 0.94)  
A vs. C: 1.14 (0.75 to 1.72)  
Very preterm delivery, unadjusted OR:  
A vs. B: 0.85 (0.34 to 2.13)  
C vs. B: 1.04 (0.60 to 1.83)  
A vs. C: 0.82 (0.31 to 2.17) |
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country</th>
<th>Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preterm Delivery</td>
<td>Short et al, 2013 U.K.</td>
<td>A. ZDV (65; 20%)</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>13%*</td>
<td>Short-term combination ART vs. ZVD: 5.00 (1.49 to 16.79)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Dual NRTI (7; 2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Triple NRTI (5; 2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Short-term combination ART (59; 18%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Preconception combination ART (131; 40%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>F. New continuous combination ART (56; 17%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>G. No therapy (8; 2%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=331</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>Sibiude et al, 2012 France</td>
<td>A. HAART (6,738; 59%)</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>14%*</td>
<td>A. 1.69 (1.38 to 2.07) Boosted PI, 2.03 (1.06 to 3.89); p=0.03 vs. nonboosted PI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAART with boosted PI (1,066; 9%)</td>
<td></td>
<td></td>
<td>B. 1.24 (0.96 to 1.60)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>HAART without nonboosted PI (187; 2%)</td>
<td></td>
<td></td>
<td>C. 1 reference</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Dual therapy (1,664; 15%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Monotherapy (2,975; 26%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=11,377</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>Snijdewind et al, 2018 The Netherlands</td>
<td>A. PI-based (928; 67%)</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>15%</td>
<td>Unadjusted OR:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. NNRTI-based (438; 31%)</td>
<td></td>
<td></td>
<td>A. 1 (reference)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Both or NRTI (12; 1%)</td>
<td></td>
<td></td>
<td>B. 1.30 (0.95 to 1.77); p=0.11</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=1,378</td>
<td></td>
<td></td>
<td>C. 1.15 (0.41 to 3.19); p=0.78</td>
<td></td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>Watts et al, 2013 U.S. PHACS/SMARTT</td>
<td>A. Combination, with PI (1,319; 74%)</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>Any preterm birth: &lt;37 weeks 19%*</td>
<td>Any preterm birth: A. 1.49 (0.83 to 2.67); p=0.18</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Combination, with NNRTI, no PI (160; 9%)</td>
<td></td>
<td></td>
<td>B. 1.28 (0.62 to 2.66); p=0.50</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. Combination, with ≥3 NRTIs (193; 10%)</td>
<td></td>
<td></td>
<td>C. 1.04 (0.50 to 2.14); p=0.93</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=1,672</td>
<td></td>
<td></td>
<td>Spontaneouspreterm birth: &lt;37 weeks 10%*</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A vs. B (all CD4 counts): A. 1.41 (0.66 to 2.99); p=0.38</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. 1.53 (0.62 to 3.81); p=0.36</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>C. 0.88 (0.34 to 2.29); p=0.80 (all vs. monotherapy or dual therapy)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=3,226</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CD4 counts &gt;350 cells/mm³</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. TDF-FTC/EFV (1,054; 33%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Other ART (2,172; 64%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=3,226</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CD4 counts &gt;350 cells/mm³</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. TDF-FTC/EFV (335; 31%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. ZDV (752; 69%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=1,087</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>Zash et al, 2016 Botswana</td>
<td>All CD4 counts:</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>27%</td>
<td>A vs. B (all CD4 counts): 0.7 (0.5 to 1.1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. TDF-FTC/EFV (1,054; 33%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. Other ART (2,172; 64%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Total N=3,226</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>CD4 counts &gt;350 cells/mm³</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. TDF-FTC/EFV (335; 31%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>B. ZDV (752; 69%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harm category</td>
<td>Study, year</td>
<td>Country</td>
<td>Study name</td>
<td>ART regimen (n; %)</td>
<td>Birth outcome Definition</td>
<td>Birth outcome Distribution</td>
</tr>
<tr>
<td>---------------</td>
<td>-------------</td>
<td>---------</td>
<td>------------</td>
<td>---------------------</td>
<td>--------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>Preterm Delivery</td>
<td>Zash et al, 2017&lt;sup&gt;78&lt;/sup&gt; Botswana</td>
<td></td>
<td></td>
<td>A. TDF-FTC/EFV (2,472; 49%)</td>
<td>Preterm delivery &lt;37 weeks</td>
<td>22% Preterm delivery 5% Very preterm delivery</td>
</tr>
<tr>
<td>Low Birth Weight</td>
<td>Kreitchmann et al, 2014&lt;sup&gt;88&lt;/sup&gt; Latin America Caribbean</td>
<td></td>
<td></td>
<td>At least 28 days in 3rd trimester: A. HAART + PI (888; 59%)</td>
<td>Low birth weight &lt;2,500 g</td>
<td>16%*</td>
</tr>
<tr>
<td>Moodley et al, 2016&lt;sup&gt;82&lt;/sup&gt; South Africa</td>
<td></td>
<td></td>
<td>A. No ART (148; 4%)</td>
<td>Low birth weight &lt;2,500 g</td>
<td>13.5%</td>
<td>A. 1 reference B. 0.06 (0.02 to 0.18); p&lt;0.001 C. 0.09 (0.03 to 0.24); p&lt;0.001 D. 0.12 (0.04 to 0.37); p&lt;0.001</td>
</tr>
<tr>
<td>Ramokolo et al, 2017&lt;sup&gt;86&lt;/sup&gt; South Africa</td>
<td></td>
<td></td>
<td>A. Postconcept ART (780; 30%)</td>
<td>Low birth weight &lt;2,500 g</td>
<td>10.7%</td>
<td>A. 1 reference B. 0.8 (0.6 to 1.1); p=0.14 C. 1.1 (0.8 to 1.6); p=0.47 D. 0.9 (0.6 to 1.3); p=0.54</td>
</tr>
<tr>
<td>Rough et al, 2018&lt;sup&gt;87&lt;/sup&gt; U.S. PHACS and IMPAACT</td>
<td></td>
<td></td>
<td>A. TDF-FTC + LPV/r (128; 8%)</td>
<td>Low birth weight &lt;2,500 g</td>
<td>18% Low birth weight 2% Very low birth weight</td>
<td>Low birth weight, adjusted OR: A vs. B: 1.13 (0.78 to 1.64) C vs. B: 0.80 (0.60 to 1.09) A vs. C: 1.45 (0.96 to 2.17) Very low birth weight, unadjusted OR: A vs. B: 0.41 (0.06 to 3.06) C vs. B: 0.89 (0.40 to 2.00) A vs. C: 0.49 (0.07 to 3.57)</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Birth Weight</td>
<td>Siberry et al, 2012 U.S. PHACS/SMARTT</td>
<td>A. TDF-containing ART (449; 22%) B. Non-TDF-containing ART (1,580; 78%) Total N=2,029</td>
<td>Low birth weight &lt;2,500 g</td>
<td>19%</td>
<td>A vs. B: 0.73 (0.48 to 1.11); p=0.14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>A. PI-based (928; 67%) B. NNRTI-based (438; 31%) C. Both or NRTI (12; 1%) Total N=1,378</td>
<td>Low birth weight &lt;2,500 g</td>
<td>16%</td>
<td>Unadjusted OR: A. 1 (reference) B. 1.19 (0.88 to 3.97); p=0.26 C. 1.47 (0.54 to 3.97); p=0.45</td>
</tr>
<tr>
<td>Small Size for Gestational Age</td>
<td>Aaron et al, 2012 U.S. Drexel University study</td>
<td>A. NRTI + NNRTI (39; 21%) B. NRTI + PI (117; 64%) C. NRTI alone (27; 15%) Total N=183</td>
<td>SGA &lt;10th percentile of birth weight by gestational age (based on infant sex and mother’s parity)</td>
<td>&lt;10th percentile: A. 0.28 (0.10 to 0.75); p&lt;0.05 vs. others B. 1.68 (0.79 to 3.55); p&gt;0.05 vs. others &lt;3rd percentile: A. 0.16 (0.03 to 0.91); p&lt;0.05 vs. others B. 2.73 (0.83 to 9.00); p&gt;0.05 vs. others</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chen et al, 2012 Botswana</td>
<td>A. Initiated HAART during pregnancy (ZVD/3TC/NVP or ZVD/3TC/LVP/r) (1,101; 12%) B. Initiated ZVD only during pregnancy (4,625; 51%) C. No ART (1,234; 13%) D. HAART continued from before pregnancy (2,189; 24%) Total N=9,149</td>
<td>SGA &lt;10th percentile</td>
<td>13.5%*</td>
<td>Initiated HAART vs. initiated ZDV: 1.5 (1.2 to 1.9) Continued HAART vs. initiated HAART: 1.3 (1.0 to 1.5) Continued HAART vs. all others: 1.8 (1.6 to 2.1)</td>
</tr>
<tr>
<td></td>
<td>Duryea et al, 2015 U.S. University of Texas study</td>
<td>A. ART with PI (597; 59%) B. ART without PI (230; 23%) C. No ART (177; 18%) Total N=1,004</td>
<td>SGA &lt;10th percentile of birth weight by gestational age</td>
<td>4% to 10% depending on ART regimen</td>
<td>A. 1 reference B. 1.3 (0.8 to 1.9) C. 1.1 (0.6 to 2.0)</td>
</tr>
<tr>
<td></td>
<td>Li et al, 2016 Tanzania</td>
<td>A. Initiated ZDV during pregnancy (1,768; 53%) B. Initiated HAART during pregnancy (512; 15%) C. Continued HAART from before pregnancy (582; 18%) D. No ART (452; 14%) Total N=3,314</td>
<td>SGA &lt;10th percentile of birth weight by gestational age</td>
<td>3rd–10th percentile: A. 0.37 (0.10 to 1.45); p=0.15 B. 0.29 (0.08 to 1.07); p=0.06 C. 0.25 (0.07 to 0.87); p=0.03</td>
<td>HAAHT vs. ZDV started during pregnancy: 3rd–10th percentile: 1.09 (0.88 to 1.35); p=0.41 &lt;3rd percentile: 1.47 (1.09 to 1.98); p=0.01</td>
</tr>
<tr>
<td></td>
<td>Moodley et al, 2016 South Africa</td>
<td>A. No ART (148; 4%) B. AZT + NVP (974; 26%) C. D4T + 3TC + NVP (907; 25%) D. EFV + TDF-FTC (1,666; 45%) Total N=3,695</td>
<td>SGA</td>
<td>8.2%</td>
<td>A. 1 reference B. 0.37 (0.10 to 1.45); p=0.15 C. 0.29 (0.08 to 1.07); p=0.06 D. 0.25 (0.07 to 0.87); p=0.03</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country</th>
<th>Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small Size for Gestational Age</td>
<td>Ramokolo et al, 2017 South Africa</td>
<td>66</td>
<td>A. Postconception ART (780; 30%) B. ZDV (873; 34%) C. No ART (330; 13%) D. Preconception ART (616; 24%) Total N=2,599</td>
<td>SGA &lt;10th percentile of birth weight by gestational age</td>
<td>14.9%</td>
<td>A. 1 reference B. 0.7 (0.5 to 1.0); p=0.05 C. 0.7 (0.4 to 1.1); p=0.08 D. 0.9 (0.6 to 1.3); p=0.52</td>
</tr>
<tr>
<td></td>
<td>Siberry et al, 2012 U.S. PHACS/SMARTT</td>
<td>69</td>
<td>A. TDF-containing ART (449; 22%) B. Non-TDF-containing ART (1,580; 78%) Total N=2,029</td>
<td>SGA</td>
<td>8.6%</td>
<td>A vs. B: 0.96 (0.60 to 1.52); p=0.85</td>
</tr>
<tr>
<td></td>
<td>Snijdewind et al, 2018 The Netherlands</td>
<td>73</td>
<td>A. PI-based (928; 67%) B. NNRTI-based (438; 31%) C. Both or NRTI (12; 1%) Total N=1,378</td>
<td>SGA &lt;10th percentile of birth weight by gestational age</td>
<td>24%</td>
<td>Unadjusted OR: A. 1 (reference) B. 1.04 (0.80 to 1.16); p=0.76 C. 2.51 (1.16 to 5.53); p=0.02 Adjusted OR: A. 1 (reference) B. 0.95 (0.71 to 1.27); p=0.73 C. 2.11 (0.98 to 4.57); p=0.06</td>
</tr>
<tr>
<td></td>
<td>Watts et al, 2013 U.S. PHACS/SMARTT</td>
<td>75</td>
<td>A. Combination, with PI (1,319; 74%) B. Combination, with NNRTI, no PI (160; 9%) C. Combination, with ≥3 NRTIs (193; 10%) Total N=1,672</td>
<td>SGA &lt;10th percentile of birth weight by gestational age</td>
<td>7%*</td>
<td>All vs. no ARV in 1st trimester: A. 0.79 (0.49 to 1.26); p=0.32 B. 1.17 (0.54 to 2.54); p=0.70 C. 0.99 (0.34 to 2.86); p=0.99 All vs. monotherapy or dual therapy: A. 1.79 (0.64 to 5.04); p=0.27 B. 1.77 (0.53 to 5.99); p=0.36 C. 1.45 (0.43 to 4.89); p=0.55</td>
</tr>
<tr>
<td></td>
<td>Zash et al, 2016 Botswana</td>
<td>79</td>
<td>All CD4 counts: A. TDF-FTC/EFV (1,054; 33%) B. Other ART (2,172; 64%) Total N=3,226 CD4 count &gt;350 cells/mm³ A. TDF-FTC/EFV (335; 31%) B. ZDF (752; 69%) Total N=1,087</td>
<td>SGA &lt;10th percentile of birth weight by gestational age (Botswana norms)</td>
<td>19%</td>
<td>A vs. B (all CD4 counts): 0.4 (0.3 to 0.6) A vs. B (CD4 &gt;350 cells/mm³): 0.6 (0.4 to 1.0)</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small Size for Gestational Age</td>
<td>Zash et al, 2017&lt;sup&gt;78&lt;/sup&gt; Botswana</td>
<td>A. TDF-FTC/EFV (2,472; 49%) B. TDF-FTC/NVP (760; 15%) C. TD-/FTC/LPV/r (231; 5%) D. ZDV/3TC/NVP (1,365; 27%) E. ZDV/3TC/LPV/r (167; 3%) Total N=4,995</td>
<td>SGA &lt;10th percentile of birth weight by gestational age VSGA &lt;3rd percentile</td>
<td>22% SGA 10% VSGA</td>
<td>aRR: A. 1 reference B. 1.44 (1.24 to 1.68) SGA B. 1.52 (1.18 to 1.94) VSGA C. 1.56 (1.25 to 1.97) SGA C. 1.81 (1.26 to 2.59) VSGA D. 1.66 (1.46 to 1.87) SGA D. 1.76 (1.44 to 2.16) VSGA E. 1.13 (0.82 to 1.56) SGA E. 1.70 (1.10 to 2.62) VSGA</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>Chen et al, 2012&lt;sup&gt;50&lt;/sup&gt; Botswana</td>
<td>A. Initiated HAART during pregnancy (ZDV/3TC/NVP or ZDV/3TC/LVPr (1,101; 12%) B. Initiated ZDV only during pregnancy (4,625; 51%) C. No ART (1,234; 13%) D. HAART continued from before pregnancy (2,189; 24%) Total N=9,149</td>
<td>Stillbirth (fetal death with APGAR of 0)</td>
<td>3.3%*</td>
<td>HAART initiation vs. ZDV initiation: 2.5 (1.6 to 3.9) Continued HAART vs. all others: 1.5 (1.2 to 1.8)</td>
</tr>
<tr>
<td>Kreitchmann et al, 2014&lt;sup&gt;46&lt;/sup&gt; Latin America Caribbean</td>
<td>At least 28 days in 3rd trimester: A. HAART with PI (888; 59%) B. HAART with no PI (410; 27%) C. Non-HAART (134; 9%) D. No ARV (80; 5%) Total N=1,512</td>
<td>Stillbirth Birth at 20 weeks of gestation or later with no signs of life</td>
<td>2%*</td>
<td>HAART with PI vs. no ART: 0.14 (0.05 to 0.34) HAART with no PI vs. no ART: 0.11 (0.04 to 0.34)</td>
<td></td>
</tr>
<tr>
<td>Moodley et al, 2016&lt;sup&gt;62&lt;/sup&gt; South Africa</td>
<td>A. No ART (148; 4%) B. AZT + NVP (974; 26%) C. D4T + 3TC + NVP (907; 25%) D. EFV + TDF-FTC (1,666; 45%) Total N=3,695</td>
<td>Stillbirth</td>
<td>3.1%</td>
<td>A. 1 reference B. 0.08 (0.04 to 0.16); p&lt;0.001 C. 0.20 (0.11 to 0.38); p&lt;0.001 D. 0.18 (0.10 to 0.34); p&lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Rough et al, 2018&lt;sup&gt;67&lt;/sup&gt; U.S. PHACS and IMPAACT</td>
<td>A. TDF-FTC + LPV/r (128; 8%) B. ZDV + 3TC + LPV/r (954; 59%) C. TDF-FTC + ATV/r (539; 33%) Total N=1,621</td>
<td>Fetal loss was undefined, included stillbirth (likely also included spontaneous abortion and fetal demise)</td>
<td>0.6%</td>
<td>Unadjusted OR (our analysis) for initial drug regimen: A vs. B: 2.51 (0.50 to 13) A vs. C: 4.26 (0.60 to 31) B vs. C: 1.70 (0.34 to 8.45)</td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country</th>
<th>Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
</table>
| Stillbirth    | Zash et al, 2016    | Botswana   | All CD4 counts:  
A. TDF-FTC/EFV (1,054; 33%)  
B. Other ART (2,172; 64%)  
Total N=3,226  
CD4 counts >350 cells/mm³  
A. TDF-FTC/EFV (335; 31%)  
B. ZDF (752; 69%)  
Total N=1,087 | Stillbirth | 3% | A vs. B (all CD4 counts): 0.6 (0.3 to 1.3)  
A vs. B (CD4 >350 cells/mm³): 0.9 (0.4 to 2.1) |
| Neonatal Death | Pintye et al, 2017 | Kenya and Uganda | A. TDF-containing ART (208; 49%)  
B. Non-TDF-containing ART (214; 51%)  
Total N=422 | Neonatal death within 3 days of live birth | 2% | A vs. B: Adjusted prevalence rate ratio, 0.55 (0.17 to 1.77); p=0.30 |
| Neonatal Death | Rough et al, 2018   | U.S. PHACS and IMPAACT | A. TDF-FTC + LPV/r (128; 8%)  
B. ZDV + 3TC + LPV/r (954; 59%)  
C. TDF-FTC + ATV/r (539; 33%)  
Total N=1,621 | Neonatal death within 14 days of live birth | 0.1% (2 events) | Unadjusted OR (our analysis) for initial drug regimen:  
A vs. B: 2.47 (0.10 to 61)  
A vs. C: 1.40 (0.06 to 34)  
B vs. C: 0.56 (0.04 to 9.04) |
| Stillbirth    | Zash et al, 2017    | Botswana   | A. TDF-FTC/EFV (2,472; 49%)  
B. TDF-FTC/NVP (760; 15%)  
C. TDF-FTC/LPV/r (231; 5%)  
D. ZDV/3TC/NVP (1,365; 27%)  
E. ZDV/3TC/LPV/r (167; 3%)  
Total N=4,995 | Stillbirth | 3.6% | aRR:  
A. 1 reference  
B. 1.15 (0.70 to 1.89)  
C. 1.81 (0.94 to 3.50)  
D. 2.31 (1.64 to 3.26)  
E. 1.53 (0.67 to 3.49) |
| Neonatal Death | Zash et al, 2017    | Botswana   | A. TDF-FTC/EFV (2,472; 49%)  
B. TDF-FTC/NVP (760; 15%)  
C. TDF-FTC/LPV/r (231; 5%)  
D. ZDV/3TC/NVP (1,365; 27%)  
E. ZDV/3TC/LPV/r (167; 3%)  
Total N=4,995 | Neonatal death at less than 28 days | 1.6% | aRR:  
A. 1 reference  
B. 1.57 (0.81 to 3.06)  
C. 1.60 (0.56 to 4.56)  
D. 1.94 (1.13 to 3.33)  
E. 4.01 (1.78 to 9.11) |
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital Abnormalities</td>
<td>Antiretroviral Pregnancy Registry Interim Report (1989 through 2018) Multinational (69 countries), 75% U.S. and its territories</td>
<td>Preferred initial treatment drugs in U.S.: A. ABC (1,131; 12%) B. 3TC (5,008; 54%) C. TDF (3,535; 38%) D. FTC (2,785; 30%) E. ATV (1,279; 14%) F. RTV (3,155; 34%) G. DRV (456; 5%) H. RAL (291; 3%) Alternative initial treatment drugs in U.S.: I. ZDV (4,178; 45%) J. LPV (1,418; 15%) K. EFV (1,023; 11%) L. RPV (297; 3%) Total N=9,336</td>
<td>Birth defects Centers for Disease Control and Prevention guidelines</td>
<td>2.73% First trimester exposure 2.77% Any trimester exposure</td>
<td>1st-trimester exposed vs. unexposed, unadjusted OR (our analysis): A. 1.04 (0.72 to 1.52) B. 1.26 (0.98 to 1.63) C. 0.77 (0.59 to 1.01) D. 0.85 (0.64 to 1.13) E. 0.77 (0.52 to 1.15) F. 0.74 (0.56 to 0.97) G. 0.88 (0.48 to 1.61) H. 1.14 (0.58 to 2.24) I. 1.38 (1.08 to 1.77) J. 0.74 (0.50 to 1.09) K. 0.84 (0.55 to 1.29) L. 0.36 (0.11 to 1.12)</td>
</tr>
<tr>
<td></td>
<td>Floridia et al, 2013 Italy</td>
<td>Preferred initial treatment drugs in U.S.: A. ABC (88; 7%) B. 3TC (544; 43%) C. TDF (173; 14%) D. FTC (87; 7%) E. ATV (63; 5%) F. RTV (231; 18%) Alternative initial treatment drugs in U.S.: G. ZDV (358; 28%) H. LPV (140; 11%) I. EFV (80; 6%) J. Any NRTI (716; 56%) K. Any PI (353; 28%) L. Any NNRTI (273; 21%) Total N=1,257</td>
<td>Birth defects Not defined</td>
<td>3.4%*</td>
<td>Not clear if ORs are adjusted; 1st-trimester exposure vs. unexposed: ABC, 1.01 (0.29 to 3.47); p=0.99 3TC, 1.14 (0.61 to 2.15); p=0.67 TDF, 0.85 (0.31 to 2.31); p=0.75 FTC, 0.67 (0.15 to 2.93); p=0.60 ATV, 0.93 (0.21 to 4.11); p=0.93 RTV, 1.02 (0.44 to 2.37); p=0.96 ZDV, 0.65 (0.28 to 1.51); p=0.32 LPV, 1.28 (0.50 to 3.26); p=0.61 EFV, 0.73 (0.17 to 3.20); p=0.68 Any NRTI, 0.95 (0.51 to 1.76); p=0.86 Any PI, 0.92 (0.43 to 1.95); p=0.82 Any NNRTI, 1.20 (0.56 to 2.55); p=0.64</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
</table>
| Congenital Abnormalities       | Knapp et al, 2012 U.S. (IMPAACT) | Preferred initial treatment drugs in U.S.: | Birth defects MACDP classification | 5%* | All vs. unexposed:  
  ABC 1st T, 1.45 (0.68 to 3.10)  
  ABC 2-3 T, 1.25 (0.62 to 2.51)  
  3TC 1st T, 1.68 (0.61 to 4.58)  
  3TC 2-3 T, 1.52 (0.56 to 4.08)  
  TDF 1st T, 1.69 (0.83 to 3.44)  
  TDF 2-3 T, 1.01 (0.38 to 2.65)  
  FTC 1st T, 1.33 (0.49 to 3.60)  
  FTC 2-3 T, 0.56 (0.06 to 3.21)  
  ATV 1st T, 1.83 (0.73 to 4.58)  
  ATV 2-3 T, 0.87 (0.10 to 3.65)  
  RTV 1st T, 1.60 (0.64 to 3.99)  
  RTV 2-3 T, 1.18 (0.29 to 3.54)  
  ZDV 1st T, 1.02 (0.45 to 2.28)  
  ZDV 2-3 T, 1.02 (0.48 to 2.17)  
  LPVr 1st T, 1.66 (0.81 to 3.38)  
  LPVr 2-3 T, 0.80 (0.35 to 1.82)  
  **EFV 1st T, 2.84 (1.13 to 7.16)**  
  EFV 2-3 T, NA (0 to 9.05)  
  Any NRTI 1st T, 0.84 (0.11 to 39.45)  
  Any NRTI 2-3 T, 0.62 (0.08 to 29.05)  
  Any PI 1st T, 1.32 (0.64 to 2.71)  
  Any PI 2-3 T, 1.15 (0.58 to 2.29)  
  Any NNRTI 1st T, 1.53 (0.72 to 3.25)  
  Any NNRTI 2-3 T, 0.77 (0.14 to 2.69) |
<p>| These patients may also be represented in the Antiretroviral Pregnancy Registry | |  |  |  |</p>
<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country</th>
<th>Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital Abnormalities</td>
<td>Sibiude et al, 2014 FRance</td>
<td></td>
<td>Preferred initial treatment drugs in U.S.:</td>
<td>EUROCAT 4.4%* MACDP 7.0%*</td>
<td></td>
<td>All vs. unexposed (EUROCAT): ABC 1st T, 1.39 (1.06 to 1.83)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. ABC (1,104; 8%)</td>
<td></td>
<td></td>
<td>ABC 2-3 T, 1.16 (0.90 to 1.51)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B. 3TC (9,170; 70%)</td>
<td></td>
<td></td>
<td>3TC 1st T, 1.37 (1.06 to 1.73)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C. TDF (1,031; 8%)</td>
<td></td>
<td></td>
<td>3TC 2-3 T, 1.26 (1.01 to 1.57)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D. FTC (670; 5%)</td>
<td></td>
<td></td>
<td>TDF 1st T, 0.75 (0.51 to 1.10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. ATV (513; 4%)</td>
<td></td>
<td></td>
<td>TDF 2-3 T, 0.82 (0.40 to 1.69)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F. RTV (5,087; 39%)</td>
<td></td>
<td></td>
<td>FTC 1st T, 0.52 (0.30 to 0.90)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Alternative initial treatment drugs in U.S.:</td>
<td></td>
<td></td>
<td>FTC 2-3 T, 1.38 (0.63 to 3.02)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>G. ZDV (10,760; 82%)</td>
<td></td>
<td></td>
<td>ATV 1st T, 0.58 (0.32 to 1.05)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>H. LPV (3,704; 28%)</td>
<td></td>
<td></td>
<td>ATV 2-3 T, 1.23 (0.38 to 4.01)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I. EFV (389; 3%)</td>
<td></td>
<td></td>
<td>RTV 1st T, 0.86 (0.67 to 1.10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>J. Any NRTI (12,663; 96%)</td>
<td></td>
<td></td>
<td>RTV 2-3 T, 0.92 (0.74 to 1.15)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>K. Any PI (7,235; 55%)</td>
<td></td>
<td></td>
<td>ZDV 1st T, 1.39 (1.06 to 1.83)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>L. Any NNRTI (1,504; 11%)</td>
<td></td>
<td></td>
<td>ZDV 2-3 T, 1.16 (0.90 to 1.51)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Total N=13,124</td>
<td></td>
<td></td>
<td>LPV 1st T, 0.92 (0.68 to 1.23)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>LPV 2-3 T, 1.13 (0.90 to 1.41)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Birth defects EUROCAT and MACDP classifications</td>
<td></td>
<td></td>
<td>EFV 1st T, 1.16 (0.73 to 1.85)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>EFV 2-3 T, 1.83 (0.23 to 14.5)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any NRTI 1st T, 2.36 (0.86 to 6.47)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any NRTI 2-3 T, 2.04 (0.75 to 5.59)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any PI 1st T, 0.91 (0.73 to 1.13)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any PI 2-3 T, 0.94 (0.77 to 1.16)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any NNRTI 1st T, 1.02 (0.76 to 1.37)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Any NNRTI 2-3 T, 1.21 (0.72 to 2.03)</td>
</tr>
</tbody>
</table>
Table 3. Studies Examining the Association Between Birth Outcomes and HIV Antiretroviral Therapy

<table>
<thead>
<tr>
<th>Harm category</th>
<th>Study, year Country Study name</th>
<th>ART regimen (n; %)</th>
<th>Birth outcome Definition</th>
<th>Birth outcome Distribution</th>
<th>Magnitude of risk: adjusted OR (95% CI); p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital Abnormalities</td>
<td>Williams et al, 2015* U.S. PHACS/SMARTT</td>
<td>Preferred initial treatment drugs in U.S.: A. ABC (222; 9%) B. 3TC (797; 32%)  C. TDF (431; 17%)  D. FTC (374; 15%)  E. ATV (222; 9%)  F. RTV (635; 25%)  G. DRV (54; 2%) Alternative initial treatment drugs in U.S.: H. ZDV (726; 29%)  I. LPV (341; 9%)  J. EFV (94; 4%)  K. Any NRTI (1,211; 48%)  L. Any PI (887; 35%)  M. Any NNRTI (214; 9%)  Total N=2,580</td>
<td>Birth defects Antiretroviral Pregnancy Registry modification to MACDP classifications</td>
<td>6.8%</td>
<td>All vs. unexposed: A. 0.94 (0.53 to 1.65)  B. 1.14 (0.81 to 1.60)  C. 1.14 (0.76 to 1.71)  D. 1.14 (0.74 to 1.74)  E. <strong>1.95 (1.24 to 3.05)</strong>  F. <strong>1.56 (1.11 to 2.20)</strong>  G. 0.30 (0.04 to 2.21)  H. 1.10 (0.78 to 1.56)  I. 1.37 (0.90 to 2.09)  J. 1.13 (0.51 to 2.50)  K. 1.19 (0.86 to 1.65)  L. <strong>1.39 (1.00 to 1.92)</strong>  M. 0.97 (0.54 to 1.74)</td>
</tr>
</tbody>
</table>

Note: Studies that adjusted for confounders. *Percent of study population.

Abbreviations: 3TC=lamivudine; ABC=abacavir; APGAR=appearance, pulse, grimace, activity, respiration; aRR=adjusted risk ratio; ART=antiretroviral therapy; ARV=antiretroviral; ATV=atazanavir; ATV/r=atazanavir/ritonavir; AZT=azidothymidine; CD4=cluster of differentiation 4; CI=confidence interval; D4T=stavudine; DRV=darunavir; EFV=efavirenz; EUROCAT=European Surveillance of Congenital Anomalies; FTC=emtricitabine; HAART=highly-active antiretroviral therapy; IMPAACT=International Maternal Pediatric Adolescents AIDS Clinical Trials Network; LPV=lopinavir; LPVr=lopinavir/ritonavir; MACDP=Metropolitan Atlanta Congenital Defects Program; NA=not assessed; NR=not reported; NNRTI=nonnucleoside reverse transcriptase inhibitor; NRTI=nucleoside reverse transcriptase inhibitor; NS=not significant; NVP=nevirapine; OR=odds ratio; PHACS=Pediatric HIV/AIDS Cohort Study; PI=protease inhibitor; RAL=raltegravir; RPV=rilpivirine; RR=relative risk; RTV=ritonavir; SGA=small size for gestational age; SMARTT=Surveillance Monitoring for ART Toxicities study; 1st T=first trimester; 2-3 T=second and third trimester; TDF=tenofovir disoproxil fumarate; TZV=abacavir/zidovudine/lamivudine; U.K.=United Kingdom; U.S.=United States; VSGA=very small size for gestational age; ZDV=zidovudine.
### Table 4. Summary of Evidence

<table>
<thead>
<tr>
<th>Key Question</th>
<th>No. of Studies (k)</th>
<th>No. of Participants (n)</th>
<th>Study Design</th>
<th>Summary of Findings by Outcome</th>
<th>Consistency/ Precision</th>
<th>Reporting Bias</th>
<th>Overall Risk of Bias/ Quality</th>
<th>Other Limitations</th>
<th>Strength of Evidence</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ 1. Benefits of screening</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
</tr>
<tr>
<td>KQ 2. Yield of repeat HIV screening at different intervals</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
</tr>
<tr>
<td>KQ 3. Harms of screening</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
<td>No studies</td>
</tr>
<tr>
<td>KQ 4. Effectiveness of currently recommended ART regimens</td>
<td>2012 USPSTF review: 6 RCTs (N=3,534) and 8 cohort studies (N=27,776) New: 1 RCT (n=3,490), 4 cohort studies (N=14,344), and 1 individual patient data analysis of 7 cohorts (n=4,459)</td>
<td>Prior USPSTF review included 8 cohort studies that found full-course combination ART associated with mother-to-child transmission rates of &lt;1% to 2.4%, compared with 9% to 22% with no ART. Five new cohort studies found full-course combination ART associated with risk of mother-to-child transmission of &lt;1% to 2.8%. One African RCT reported a mother-to-child transmission rate of 0.5%. Consistent No imprecision</td>
<td>No reporting bias detected</td>
<td>Moderate</td>
<td>Most evidence observational, with no RCT conducted in the U.S. or other high-income setting</td>
<td>High</td>
<td>Cohort studies conducted in high-income settings but RCT was conducted in Africa. Exact ART regimen not specified in most studies. Variability in timing of ART initiation.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key Question</td>
<td>No. of Studies (k)</td>
<td>No. of Participants (n)</td>
<td>Study Design</td>
<td>Summary of Findings by Outcome</td>
<td>Consistency/Precision</td>
<td>Reporting Bias</td>
<td>Overall Risk of Bias/Quality</td>
<td>Other Limitations</td>
<td>Strength of Evidence</td>
<td>Applicability</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>-------------------------------</td>
<td>-----------------------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>---------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>KQ 5. Harms of currently recommended ART regimens</td>
<td><strong>Preterm Birth</strong> 2012 USPSTF review: 1 RCT (n=560), 4 cohort studies (N=15,252) New: 1 RCT (n=3,490) and 17 cohort studies (N=48,452)</td>
<td></td>
<td></td>
<td><em>Preterm Birth</em> Prior USPSTF review included 1 RCT and 4 cohort studies that found increased preterm birth associated with ART. 1 RCT and 3 cohort studies that found increased risk of preterm birth associated with ART that included a PI. One new RCT and 4 new cohort studies found increased risk of preterm birth with ART; 3 new cohort studies (all from Africa) found decreased risk of preterm birth with ART. One RCT and 3 cohort studies found ART that included a boosted PI associated with increased risk of preterm birth.</td>
<td>Inconsistent No imprecision</td>
<td>No reporting bias detected</td>
<td>Moderate</td>
<td>No U.S. RCTs or trials from nonresource-poor countries</td>
<td>Low</td>
<td>Cohort studies conducted in all settings; RCT was conducted primarily in Africa. Exact ART regimen not specified in most studies. Variability in timing of ART initiation.</td>
</tr>
<tr>
<td>Overall Birth Defects 2012 USPSTF review: 4 cohort studies (N=21,113) New: 5 cohort studies (N=27,409)</td>
<td><strong>Overall Birth Defects</strong> Prior USPSTF review found no association between ART and birth defects. Five new cohort studies found most currently recommended ART drugs not associated with increased risk of birth defects.</td>
<td></td>
<td></td>
<td><em>Overall Birth Defects</em></td>
<td>Consistent Precise</td>
<td>No reporting bias detected</td>
<td>Moderate</td>
<td>No RCTs</td>
<td>Moderate</td>
<td>Cohort studies conducted in high-resource settings. Individual ART drugs specified.</td>
</tr>
</tbody>
</table>
Table 4. Summary of Evidence

<table>
<thead>
<tr>
<th>Key Question</th>
<th>No. of Studies (k)</th>
<th>No. of Participants (n)</th>
<th>Study Design</th>
<th>Summary of Findings by Outcome</th>
<th>Consistency/ Precision</th>
<th>Reporting Bias</th>
<th>Overall Risk of Bias/ Quality</th>
<th>Other Limitations</th>
<th>Strength of Evidence</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Birth Weight</td>
<td>2012 USPSTF review: 5 cohort studies (N=17,976) New: 1 RCT (n=3,490) and 5 cohort studies (N=11,213)</td>
<td></td>
<td></td>
<td>Low Birth Weight Prior evidence: No clear association between prenatal ART and low birth weight or intrauterine growth restriction. One new RCT and 4 cohort studies found no clear association between ART and low birth weight.</td>
<td>Consistent Imprecise</td>
<td>No reporting bias detected</td>
<td>Moderate</td>
<td>No U.S. RCTs or trials from nonresource-poor countries</td>
<td>Low</td>
<td>Cohort studies conducted in all settings; RCT was conducted in Africa. Exact ART regimen not specified in most studies. Variability in timing of ART initiation.</td>
</tr>
<tr>
<td>Small Size for Gestational Age</td>
<td>2012 USPSTF review: 1 cohort study (n=7,635) New: 10 cohort studies (N=37,670)</td>
<td></td>
<td></td>
<td>Small Size for Gestational Age Nine new cohort studies found no clear association between ART and small size for gestational age.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stillbirth</td>
<td>2012 USPSTF review: None New: 6 cohort studies (N=30,417)</td>
<td></td>
<td></td>
<td>Stillbirth Three new cohort studies found no clear association between ART and stillbirth; 3 new cohort studies found mixed results for treatment with tenofovir disoproxil fumarate/emtricitabine vs. zidovudine/lamivudine.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neonatal Death</td>
<td>2012 USPSTF review: None New: 1 RCT (n=3,490) and 3 cohort studies (N=7,038)</td>
<td></td>
<td></td>
<td>Neonatal Death One new RCT and 3 cohort studies found mixed results for neonatal death.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 4. Summary of Evidence

<table>
<thead>
<tr>
<th>Key Question</th>
<th>No. of Studies (k) No. of Participants (n) Study Design</th>
<th>Summary of Findings by Outcome</th>
<th>Consistency/ Precision</th>
<th>Reporting Bias</th>
<th>Overall Risk of Bias/ Quality</th>
<th>Other Limitations</th>
<th>Strength of Evidence</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ 5 cont.</td>
<td></td>
<td><strong>Infant Cardiac Harms</strong> Prior USPSTF review included 1 cohort study that reported reduced left ventricular mass and increased left ventricular contractility at age 2 years with in utero ART exposure and 1 study found no association; no echocardiographic differences in children ages 2 to 5 years. Three new cohort studies found mixed evidence for zidovudine exposure in first trimester for increased congenital heart defects; mixed evidence for several ART drugs and echocardiographic changes but not clinical changes.</td>
<td>Consistent Imprecise No reporting bias detected</td>
<td>Moderate</td>
<td>No RCTs; no studies of in utero exposed, HIV-uninfected children beyond age 7 years</td>
<td>Low</td>
<td>Cohort studies conducted in high-resource settings. Variability in timing of ART initiation.</td>
<td></td>
</tr>
<tr>
<td>Infant Neurodevelopmental Harms</td>
<td></td>
<td><strong>Infant Neurodevelopmental Harms</strong> Prior USPSTF review found no association between in utero ART exposure and worse neurodevelopmental outcomes. New evidence from the SMARTT cohort found no positive association between ART and neurological development.</td>
<td>Consistent Precise No reporting bias detected</td>
<td>Moderate</td>
<td>No RCT; drug regimens often not provided</td>
<td>Low</td>
<td>Cohort studies conducted in high-income settings. Variability in timing of ART initiation.</td>
<td></td>
</tr>
</tbody>
</table>
### Table 4. Summary of Evidence

<table>
<thead>
<tr>
<th>Key Question</th>
<th>No. of Studies (k)</th>
<th>No. of Participants (n)</th>
<th>Study Design</th>
<th>Summary of Findings by Outcome</th>
<th>Consistency/ Precision</th>
<th>Reporting Bias</th>
<th>Overall Risk of Bias/ Quality</th>
<th>Other Limitations</th>
<th>Strength of Evidence</th>
<th>Applicability</th>
</tr>
</thead>
<tbody>
<tr>
<td>KQ 5 cont.</td>
<td>Maternal Harms</td>
<td>2012 USPSTF review: 1 meta-analysis (n=1,391) and 3 cohort studies (N=4,117)</td>
<td>New: 2 RCTs (N=12,338)</td>
<td>Maternal Harms No association between zidovudine monotherapy and maternal death or long-term harms; possible association between increased risk for gestational diabetes; increased risk of anemia. Anemia in HIV-infected pregnant women improved with ART, iron, and folic acid; treatment with zidovudine-based or tenofovir-based ART resulted in increased risk for any grade 2 or higher maternal adverse event compared with zidovudine monotherapy, but few women left the study due to adverse events.</td>
<td>Inconsistent Precise</td>
<td>No reporting bias detected</td>
<td>Moderate</td>
<td>No U.S. RCTs or trials from nonresource-poor countries</td>
<td>Low</td>
<td>Cohort studies conducted in all settings; RCT conducted in Africa. Exact ART regimen not specified in most studies. Variability in timing of ART initiation.</td>
</tr>
</tbody>
</table>

**Abbreviations:** ART=antiretroviral therapy; KQ=key question; PI=protease inhibitor; RCT=randomized, controlled trial; SMARTT=Surveillance Monitoring for ART Toxicities Study; U.S.=United States; USPSTF=U.S. Preventive Services Task Force.
Appendix A1. Search Strategies

Screening

Database: Ovid MEDLINE(R) without Revisions
1 exp HIV/
2 HIV Antibodies/
3 HIV Antigens/
4 HIV Seroprevalence/
5 HIV Seropositivity/
6 HIV Seronegativity/
7 AIDS Serodiagnosis/
8 human immunodeficiency virus.ti,ab
9 hiv.ti,ab.
10 Mass Screening/
11 screen$.ti.
12 or/1-9
13 10 or 11
14 12 and 13
15 limit 14 to (english language and humans)
16 limit 15 to yr="2012 - 2018"
17 16 and pregnan*.ti,ab.
18 16 and mother*.ti,ab.
19 17 or 18

Database: EBM Reviews - Cochrane Central Register of Controlled Trials
1 exp HIV/
2 HIV Antibodies/
3 HIV Antigens/
4 HIV Seroprevalence/
5 HIV Seropositivity/
6 HIV Seronegativity/
7 AIDS Serodiagnosis/
8 human immunodeficiency virus.ti.
9 hiv.ti,ab.
10 Mass Screening/
11 screen$.ti.
12 or/1-9
13 10 or 11
14 12 and 13
15 limit 14 to yr="2012 - 2018"
16 limit 15 to english language
17 16 and (pregnan* or mother*).ti,ab.

Treatment

Database: Ovid MEDLINE(R) without Revisions and EBM Reviews - Cochrane Central Register of Controlled Trials
1 exp HIV Infections/dt, pc, th
2 exp Anti-Retroviral Agents/ad, tu
3 Antiretroviral Therapy, Highly Active/
4 or/1-3
5 Infectious Disease Transmission, Vertical/
6 ((mother* or child*) and transmission).mp.
7 5 or 6
8 4 and 7
9 limit 8 to yr="2012 - 2018"
Appendix A1. Search Strategies

10 limit 9 to (clinical trial, all or comparative study or meta analysis or randomized controlled trial or systematic reviews)
11 9 and (random* or control* or cohort).ti,ab.
12 10 or 11 (630)
13 12 and pregnan*.mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] (450)

Treatment harms
Database: Ovid MEDLINE(R) without Revisions and EBM Reviews - Cochrane Central Register of Controlled Trials
1 exp HIV Infections/dt, pc, th [
2 exp Anti-Retroviral Agents/ad, tu
3 Antiretroviral Therapy, Highly Active/
4 or/1-3
5 4 and (harm* or safety or adverse).ti,ab.
6 limit 5 to yr="2012 - 2018"
7 6 and (pregnan* or mother*).mp.

Screening and treatment
Database: EBM Reviews - Cochrane Database of Systematic Reviews
1 (hiv or "human immunodeficiency virus").ti.
2 1 and screen*.ti.
3 1 and (treatment or antiretroviral or therapy).ti.
4 2 or 3
5 4 and pregnan*.mp.
## Appendix A2. Inclusion and Exclusion Criteria

<table>
<thead>
<tr>
<th>Category</th>
<th>Include</th>
<th>Exclude</th>
</tr>
</thead>
</table>
| Settings                  | **KQs 1–3:** Primary care or other settings generalizable to primary care (e.g., prenatal, antenatal, and family planning clinics) and other health care settings in which screening is commonly performed (e.g., emergency room or urgent care)  
**KQs 4–5:** Focus on studies conducted in the United States and other high-income countries with low prevalence of HIV infection and in which management of HIV infection is similar to that in the United States, except for RCTs of ART and harms of treatment if currently recommended regimens or drugs are used | Studies of screening conducted in low- and middle-income countries, unless fair- or good-quality studies in the United States are not available |
| Populations               | **KQs 1–3:** Asymptomatic pregnant women not known to be HIV positive, including adolescents (ages 13 to 18 years)  
**KQ 4:** Pregnant women living with HIV and their infants  
**KQ 5:** Women who received ART regimens while pregnant; neonates, infants, and children who were exposed to ART in utero | **KQs 1–3:** Women who have known HIV infection, are on dialysis, are posttransplant, or have occupational exposure (because of risk of needle stick or other parenteral exposure); women with known infection with hepatitis C virus, hepatitis B virus, or tuberculosis  
**KQs 4, 5:** Women who are already or were previously taking ART prior to pregnancy; women with acute HIV infection; studies limiting enrollment to persons with hepatitis C virus, hepatitis B virus, or tuberculosis coinfection |
| Interventions             | **KQs 1–3:** Rapid or standard HIV antibody testing with confirmatory testing  
**KQs 4, 5:** Currently recommended ART regimens or drugs, or studies published since 2012 that reported outcomes for combination antiretroviral regimens and reported the categorizations for ART regimens used in the study | **KQs 4, 5:** Regimens that are clearly outside of current U.S. practice; Women who discontinued ART during pregnancy; women with treatment interruption |
| Comparisons               | **KQs 1, 3:** HIV screening vs. no screening  
**KQ 2:** Repeat HIV screening during pregnancy vs. one-time screening; screening at one interval vs. another  
**KQs 4, 5:** Currently recommended ART regimens; full-course combination ART vs. no ART, abbreviated courses of ART, or one- or two-drug therapy |                                                                                                                                                                                                       |
| Outcomes                  | **KQs 1, 4:** Mother-to-child HIV transmission rates  
**KQ 2:** Yield of screening (number of cases of HIV infection identified per number of tests performed)  
**KQ 3:** Harms of screening, including false-positive results, anxiety and effects of labeling, and partner discord, abuse, or violence  
**KQ 5:** Maternal and infant harms of treatment, including long-term harms following in utero exposure to ART | **KQs 1, 5:** Pharmacokinetic outcomes |
| Study designs/ countries  | **KQs 1–3:** RCTs and controlled observational studies  
**KQ 4:** RCTs in any country as long as recommended ART regimens were evaluated, and observational studies in countries similar to the United States  
**KQ 5:** RCTs and observational studies that controlled for potential confounders; any countries as long as recommended ART regimens were evaluated | **KQs 1–4:** Modeling studies |
| Timing                    | **KQ 5:** Any timing |                                                                                                                                                                                                       |

**Abbreviations:** ART=antiretroviral therapy; KQ=key question; RCT= randomized, controlled trial.
Appendix A3. Literature Flow Diagram

1239 Citations identified through literature database searches

89 Citations identified through other sources*

35 Citations identified from previous reviews

1232 Citations screened after duplicates removed

1070 Citations excluded based on review of title and abstract

162 Full-text articles reviewed for eligibility for all Key Questions

91 Articles excluded
  13 Wrong population
  5 Wrong intervention
  16 Wrong outcome
  8 Wrong comparator
  11 Wrong study design for key question
  9 Not a study
  1 Inadequate duration
  1 Sample size too small
  6 Systematic review or meta-analysis used as a source document only to identify individual studies
  6 Wrong country
  15 Did not adjust for confounders and/or did not provide adequate data

36 new articles (29 studies) included†

0 articles included for Key Question 1

0 articles included for Key Question 2

0 articles included for Key Question 3

1 trial and 5 cohort studies included for Key Question 4

2 trials and 21 cohort studies (29 articles) included for Key Question 5

*Other sources include reference lists of relevant articles, studies, and systematic reviews and suggestions from reviewers; also includes background articles.

†In addition, 33 studies (in 35 articles) were carried forward from the prior U.S. Preventive Services Task Force reviews.
Appendix A4. Included Studies List


Appendix A4. Included Studies List


Appendix A5. Excluded Studies List


Appendix A5. Excluded Studies List


Appendix A5. Excluded Studies List


Appendix A5. Excluded Studies List


Appendix A5. Excluded Studies List


Appendix A5. Excluded Studies List


Villatoro CM, Luarte ME, Natareno GV, et al. Highly active antiretroviral treatment (HAART) for the prevention of HIV mother to child transmission (PMTCT) at Roosevelt Hospital's Infectious Diseases Clinic in Guatemala: the role of (LPV/r) standard dose. World J AIDS. 2012;2(03):259. Excluded: did not adjust for confounders and/or did not provide adequate data.


Appendix A6. Criteria for Assessing Internal Validity of Individual Studies

**Systematic Reviews**

Criteria:
- Comprehensiveness of sources considered/search strategy used
- Standard appraisal of included studies
- Validity of conclusions
- Recency and relevance (especially important for systematic reviews)

Definition of ratings based on above criteria:

**Good:** Recent, relevant review with comprehensive sources and search strategies; explicit and relevant selection criteria; standard appraisal of included studies; and valid conclusions

**Fair:** Recent, relevant review that is not clearly biased but lacks comprehensive sources and search strategies

**Poor:** Outdated, irrelevant, or biased review without systematic search for studies, explicit selection criteria, or standard appraisal of studies

**Case-Control Studies**

Criteria:
- Accurate ascertainment of cases
- Nonbiased selection of cases/controls, with exclusion criteria applied equally to both
- Response rate
- Diagnostic testing procedures applied equally to each group
- Measurement of exposure accurate and applied equally to each group
- Appropriate attention to potential confounding variables

Definition of ratings based on above criteria:

**Good:** Appropriate ascertainment of cases and nonbiased selection of case and control participants; exclusion criteria applied equally to cases and controls; response rate equal to or greater than 80 percent; accurate diagnostic procedures and measurements applied equally to cases and controls; and appropriate attention to confounding variables

**Fair:** Recent, relevant, and without major apparent selection or diagnostic workup bias, but response rate less than 80 percent or attention to some but not all important confounding variables

**Poor:** Major selection or diagnostic workup bias, response rate less than 50 percent, or inattention to confounding variables

**RCTs and Cohort Studies**

Criteria:
- Initial assembly of comparable groups:
  - For RCTs: Adequate randomization, including first concealment and whether potential confounders were distributed equally among groups
  - For cohort studies: Consideration of potential confounders, with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
Appendix A6. Criteria for Assessing Internal Validity of Individual Studies

- Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements: equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- All important outcomes considered
- Analysis: adjustment for potential confounders for cohort studies or intention-to-treat analysis for RCTs

Definition of ratings based on above criteria:

**Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup ≥80%); reliable and valid measurement instruments are used and applied equally to all groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention to confounders is accounted for. Intention-to-treat analysis is used for RCTs.

**Fair:** Studies are graded “fair” if any or all of the following problems occur, without the fatal flaws noted in the “poor” category below: Generally comparable groups are assembled initially, but some question remains whether some (although not major) differences occurred with followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is used for RCTs.

**Poor:** Studies are graded “poor” if any of the following fatal flaws exist: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. Intention-to-treat analysis is lacking for RCTs.

**Diagnostic Accuracy Studies**

Criteria:
- Screening test relevant, available for primary care, and adequately described
- Credible reference standard, performed regardless of test results
- Reference standard interpreted independently of screening test
- Indeterminate results handled in a reasonable manner
- Spectrum of patients included in study
- Sample size
- Reliable screening test

Definition of ratings based on above criteria:

**Good:** Evaluates relevant available screening test; uses a credible reference standard; interprets reference standard independently of screening test; assesses reliability of test; has few or handles indeterminate results in a reasonable manner; includes large number (>100) of broad-spectrum patients with and without disease

**Fair:** Evaluates relevant available screening test; uses reasonable although not best standard; interprets reference standard independent of screening test; has moderate sample size (50 to 100 subjects) and a “medium” spectrum of patients
Appendix A6. Criteria for Assessing Internal Validity of Individual Studies

**Poor:** Has a fatal flaw, such as: Uses inappropriate reference standard; improperly administers screening test; biased ascertainment of reference standard; has very small sample size or very narrow selected spectrum of patients


- Maggie Czarnogorski, MD, MPH, Deputy Director, Comprehensive Women’s Health, U.S. Department of Veterans Affairs
- Brenna Hughes, MD, MSc, Division of Maternal Fetal Medicine, Duke University
- Margaret Lampe, RN, MPH, Centers for Disease Control and Prevention
- Lynne Mofenson, MD, Elizabeth Glaser Pediatric AIDS Foundation
- Brandy Peaker, MD, MPH, Centers for Disease Control and Prevention
- George Siberry, MD, Pediatric Technical Advisor for the U.S. President’s Emergency Plan for AIDS Relief, State Department

Note: Reviewers provided comments on a prior version of the draft report and may or may not agree with the report findings.
Appendix B Table 1. Currently Recommended Initial Regimens for Antiretroviral-Naive Pregnant Women With HIV

<table>
<thead>
<tr>
<th>Preferred Regimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-NRTI Backbones</td>
</tr>
<tr>
<td>ABC/3TC*</td>
</tr>
<tr>
<td>TDF/FTC or TDF/3TC†</td>
</tr>
<tr>
<td>INSTI Regimens</td>
</tr>
<tr>
<td>DTG/ABC/3TC or DTG plus a preferred 2-NRTI backbone (after the first trimester)‡</td>
</tr>
<tr>
<td>RAL plus a preferred 2-NRTI backbone</td>
</tr>
<tr>
<td>PI Regimens</td>
</tr>
<tr>
<td>ATV/r plus a preferred 2-NRTI backbone</td>
</tr>
<tr>
<td>DRV/r plus a preferred 2-NRTI backbone</td>
</tr>
<tr>
<td>Alternative Regimens</td>
</tr>
<tr>
<td>2-NRTI Backbones</td>
</tr>
<tr>
<td>ZDV/3TC§</td>
</tr>
<tr>
<td>PI Regimens</td>
</tr>
<tr>
<td>LPV/r plus a preferred 2-NRTI backbone</td>
</tr>
<tr>
<td>NNRTI Regimens</td>
</tr>
<tr>
<td>EFV/TDF/FTC or EFV/TDF/3TC or EFV plus a preferred 2-NRTI backbone§</td>
</tr>
<tr>
<td>RPV/TDF/FTC or RPV plus a preferred 2-NRTI backbone¶</td>
</tr>
</tbody>
</table>

* ABC should not be used in patients who test positive for the HLA-B*5701 gene because of the risk of a hypersensitivity reaction.
† TDF has potential renal toxicity; thus, TDF-based dual-NRTI combinations should be used with caution in patients with renal insufficiency.
‡ Should not be initiated during the first trimester because of concerns about a possible increased risk of neural tube defects.
§ Increased potential for hematologic and other toxicities.
¶ Birth defects have been seen in primate studies of EFV, but there has been no evidence of an increased risk of birth defects in human studies and extensive experience in pregnancy; higher rate of adverse events than for other preferred drugs.
¶ RPV is not recommended in patients with pretreatment HIV RNA >100,000 copies/mL or CD4 cell counts <200 cells/mm³; do not use with PPIs.


Abbreviations: 3TC=lamivudine; ABC=abacavir; ATV=raltcovir/ritonavir; CD4=CD4 T lymphocyte cell; DRV=darunavir/ritonavir; DTG=dolutegravir; EFV=efavirenz; FTC=emtricitabine; INSTI=integrase strand transfer inhibitor; LPV=lopinavir/ritonavir; NNRTI=nonnucleoside reverse transcriptase inhibitor; PI=protease inhibitor; PPI=proton pump inhibitor; RAL=raltegravir; RNA=ribonucleic acid; RPV=rilpivirine; TDF=tenofovir disoproxil fumarate; ZDV=zidovudine.
<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron, 2012&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>1 site U.S. (Philadelphia, PA)</td>
<td>Through birth January 2000 through January 2011</td>
<td>A. Any ART initiation during pregnancy (n=137) B. NNRTI use (n=39) C. PI use (n=117)</td>
<td>HIV-infected, pregnant, and older than age 17 years</td>
<td>Maternal age: mean, 28 years Race/ethnicity: 74.7% African American; 25.3% other Started medication in pregnancy: 74.9%</td>
<td>183</td>
<td>Fair</td>
<td>NR</td>
</tr>
<tr>
<td>Antiretroviral Pregnancy Registry, 2018&lt;sup&gt;47&lt;/sup&gt;</td>
<td>Cohort (=1,000 women prospectively included)</td>
<td>Multinational (69 countries), 75% U.S. and its territories</td>
<td>January 1989 through January 2018</td>
<td>Preferred initial treatment drugs in U.S.: A. ABC (1,131; 12%) B. 3TC (5,008; 54%) C. TDF (3,535; 38%) D. FTC (2,785; 30%) E. ATV (1,279; 14%) F. RTV (3,155; 34%) G. DRV (456; 5%) H. RAL (291; 3%) Alternative initial treatment drugs in U.S.: I. ZDV (4,178; 45%) J. LPV (1,418; 15%) K. EFV (1,023; 11%) L. RPV (297; 3%)</td>
<td>Pregnant women exposed to antiretroviral drug for treatment of HIV and HBV infection and prevention of HIV infection (PrEP or postexposure prophylaxis)</td>
<td>Pregnancies enrolled in database (n=19,449): Maternal age: median 28 years Indications for ART at start of pregnancy: 89.4% HIV infected, 1.7% prophylaxis (HIV uninfected), 4.1% HBV monoinfected, 2.3% unknown, 2.4% missing CD4 count at start of pregnancy: 30.9% ≥ 500 cells/mm&lt;sup&gt;3&lt;/sup&gt;, 39.4% 200–499 cells/mm&lt;sup&gt;3&lt;/sup&gt;, 14.1% &lt;200 cells/mm&lt;sup&gt;3&lt;/sup&gt;</td>
<td>9,336</td>
<td>Fair</td>
<td>Cosponsored and cofunded by 26 pharmaceutical companies that manufacture drugs used in ART</td>
</tr>
<tr>
<td>Berard, 2017&lt;sup&gt;48&lt;/sup&gt; Quebec Pregnancy Cohort</td>
<td>Prospective cohort</td>
<td>Database study (Quebec Drug Plan) Canada</td>
<td>From birth in 1998 to 2015</td>
<td>A. No ART exposure (n=214,042) B. First-trimester ART exposure (n=198)</td>
<td>Age 15 and 45 years on the first day of gestation, continuously insured by the RAMQ drug plan for at least 6 months before the first day of gestation and during pregnancy, and have a singleton live birth</td>
<td>A vs. B Maternal age: 31.5 vs. 28.3 years Welfare recipient: 54% vs. 23% Infant gestational age: 38.2 vs. 38.8 weeks</td>
<td>214,240</td>
<td>Fair</td>
<td>Canadian Institutes of Health Research, Fonds de l’Antiretroviral la Recherche du Québec–Santé</td>
</tr>
<tr>
<td>Chagomerana, 2017&lt;sup&gt;49&lt;/sup&gt;</td>
<td>Retrospective cohort</td>
<td>1 hospital Malawi</td>
<td>Through birth Period April 2012 to November 2015</td>
<td>A. ART (n=2,909) B. No ART (n=165)</td>
<td>HIV+ pregnant women who initiated ART before 27 weeks of gestation or did not receive ART and</td>
<td>A vs. B Maternal age: 27 to 30 vs. 26 years Gestation at delivery: 38 vs. 38 weeks</td>
<td>3,074</td>
<td>Fair</td>
<td>National Institutes of Health and a Gilead Training Fellowship</td>
</tr>
<tr>
<td>Author, year Study</td>
<td>Study design</td>
<td>Number of centers, Country</td>
<td>Study duration Followup</td>
<td>Intervention</td>
<td>Inclusion criteria</td>
<td>Patient characteristics</td>
<td>N</td>
<td>Quality rating</td>
<td>Funding source</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>-------------------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>----</td>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Chen, 2012&lt;sup&gt;20&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>6 sites Botswana</td>
<td>May (1 site) or November (5 sites) 2009 through April 2011 28 days after delivery</td>
<td>A. Continued HAART during pregnancy (n=2,189) B. Initiated HAART during pregnancy (n=1,101) C. Initiated ZDV during pregnancy (n=4,625) D. No ART (n=1,234)</td>
<td>All women who delivered live births or stillbirths at a gestational age of ≥20 weeks at 5 government facilities in Botswana</td>
<td>A vs. B vs. C vs. D Maternal age: median 32 vs. 29 vs. 27 vs. 27 years Botswana nationality: 99% vs. 98% vs. 97% vs. 64% Received antenatal care: 97% vs. 99% vs. 99% vs. 78%</td>
<td>9,504</td>
<td>Fair</td>
<td>Centers for Disease Control and Prevention, National Institutes of Health, Harvard University, Doris Duke Charitable Research Foundation</td>
</tr>
<tr>
<td>Chiappini, 2013&lt;sup&gt;31&lt;/sup&gt; EPPICC Study</td>
<td>Analysis from 8 cohort studies</td>
<td>8 cohorts from 7 countries in Europe: U.K. and Ireland’s NSHPC and CHIPS; ITLR; Madrid Cohort of HIV-Infected Children; CoRISPE-Cat; “Victor Babes” Hospital Cohort, Bucharest, Romania; MoCHIV; ECS on HIV-Infected Pregnant Women and Their Children; ECS was considered as 2 studies</td>
<td>Up to 18 months Period 1996-2010</td>
<td>A. 3 or more drugs (n=2,355) B. 2 drugs (n=255) C. 1 drug (n=681) D. No therapy (n=1,933)</td>
<td>Children born to diagnosed HIV-infected mothers between January 1, 1996 and June 30, 2010 at high risk for acquiring HIV infection whose mothers received antenatal and intrapartum antiretroviral drugs but had suboptimal viral suppression at delivery (defined as a detectable viral load [&gt;50 copies/mL] documented in the last 8 weeks of pregnancy and/or at delivery), received only intrapartum antiretroviral drugs, and received no antenatal or intrapartum antiretroviral drugs</td>
<td>Maternal age: mean NR; 70% age ≥20 years Race/ethnicity: 29% white; 40% black; 3% other Region or country: 37% Europe; 42% Africa Maternal CD4 count: mean NR; 53% ≥200 cells/mm&lt;sup&gt;3&lt;/sup&gt; Maternal viral load: mean NR; 27% ≥1,000 copies/mL Gestational age: mean NR; 6% ≤32 weeks; 16% 33 to 36 weeks; 76% ≥37 weeks</td>
<td>5,285 mother-infant pairs</td>
<td>Fair</td>
<td>European Union Seventh Framework Programme; Pediatric European Network or Treatment of AIDS Foundation</td>
</tr>
</tbody>
</table>
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duryea, 201552</td>
<td>Retrospective cohort</td>
<td>Single site Texas, U.S.</td>
<td>Through birth Period January 1984 to April 2014</td>
<td>A. ART with PI (n=597) B. ART without PI (n=230) C. No ART (n=177)</td>
<td>All HIV+ women who delivered at the institution (University of Texas Southwestern Medical Center, Dallas) during the study period</td>
<td>Maternal age at delivery: 25 to 28 years (p&lt;0.001) Race/ethnicity: black 64% to 69%, Hispanic 19%, white 11% to 16% Gestational age at presentation for prenatal care: 12 to 24 weeks (p&lt;0.001) CD4 count at presentation: 456 to 557 cells/mm³ (p&lt;0.001) CD4 count at delivery: 505 to 565 cells/mm³ (p=0.349) Duration of diagnosis: 1 to 2 years (p&lt;0.001)</td>
<td>1,004</td>
<td>Fair</td>
<td>NR</td>
</tr>
<tr>
<td>Floridia, 201353 Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy</td>
<td>Prospective cohort</td>
<td>Unclear Italy</td>
<td>Through birth Period 2001 to 2011</td>
<td>Various cART regimens</td>
<td>HIV-positive pregnant women with data from the Italian National Programme on Surveillance on Antiretroviral Treatment in Pregnancy</td>
<td>Mean maternal age at conception: 32.3 years Ethnicity: 66% white, 29% African, 4% other CD4 count at first trimester: 464 cells/mm³ HIV RNA at first trimester: 3.0 copies/mL, \log_{10} HCV coinfection: 22% HBV coinfection: 11% Treatment-naïve before pregnancy: 36% Diagnosis of HIV during current pregnancy: 24.6% Week of first ART in pregnancy: 10.4 Mode of HIV acquisition: 73.1% sexual, 13.6% PWID Maternal ART at first trimester: 55.3% NRTI, 20.4% NNRTI, 27.8% PI</td>
<td>1,257</td>
<td>Fair</td>
<td>Italian Medicines Agency</td>
</tr>
</tbody>
</table>
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

| Study Characteristics | French Perinatal Cohort Study ANRS-EPF Mandelbrot, 2015<sup>61</sup> | Prospective cohort, no control | 90 sites France (but majority from sub-Saharan Africa) | Pre-conception to postpartum Period 2000 to 2011 | cART comparing starting at different times and viral loads A. Preconception B. 1st trimester C. 2nd trimester D. 3rd trimester | Other interventions: Intrapartum ZDV 96.0% Neonatal antiretroviral prophylaxis: 91.6% ZDV monotherapy, 7.5% other Neonatal single dose NVP: 4.2% | All HIV-1+ women enrolled in the French Perinatal Cohort delivering in metropolitan France between 2000 and 2011 that received HAART (regimen containing ≥3 drugs or 1 drug other than a NRTI) during pregnancy. Women who received only reverse-transcriptase inhibitor monotherapy or dual therapy were excluded. However, women who switched from a combination therapy to monotherapy or dual therapy were included, as were the small number of women who received monotherapy with RTV-boosted PIs. Breastfeeding women were excluded. | N=8,678 Age: <25 years 8.7%, 25 to 34 years 56.5%, >34 years 34.8% Geographic origin: metropolitan France 16.6%, sub-Saharan Africa 71.6%, other 11.8% HIV diagnosis before conception: 80.4% Timing of ART initiation: before conception 47.2% (n=4,095), 1st trimester 8.2% (n=713), 2nd trimester 32.3% (n=2,803), 3rd trimester 12.3% (n=1,067) Initial ART regimen during pregnancy: triple NRTI 5.9%, PI-based 76.1%, NNRTI-based 15.8%, 3 classes 1.2%, other 1.0% Last ART regimen during pregnancy: ZDV monotherapy 0.4%, dual NRTI 1.1%, triple NRTI 3.1%, PI-based 81.2%, NNRTI-based 10.9%, 3 classes 1.3%, other 2.0% Maintained initial ART regimen throughout pregnancy: 71.4% Last viral load before delivery (copies/mL): <50 68.0%, undetectable (50 to 400) 5.9%, 50 to 399 15.2%, ≥400 10.9% CD4 count before delivery (cells/mm<sup>3</sup>): <200 9.0%, 200 to 349 21.0%, 350 to 499 28.0%, ≥500 42.0% Delivery mode: vaginal 42.7%, emergency | Eligible: 8,678 mother-infant pairs HIV status of child determined: 8,075 mother-infant pairs | Fair Agence Nationale de Recherche sur le SIDA et les Hepatites Virales |
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>French Perinatal Cohort Study ANRS-EPF C01/C011 Sibiude, 2012&lt;sup&gt;72&lt;/sup&gt;</td>
<td>See above</td>
<td>See above</td>
<td>See Period 1990 to 2009</td>
<td>A. ZDV monotherapy (n=2,975) B. NRTI dual therapy (n=1,664) C. cART therapy (n=6,738) Substudy: D. Boosted PI (n=1,066) E. Nonboosted PI (n=187)</td>
<td>All HIV-1+ women enrolled in the French Perinatal Cohort between 1990 and 2009 Substudy cohort: Singleton births from 2005 through 2009 for mothers enrolled in the CO1 component of the cohort, which recorded more detailed data</td>
<td>Caesarean 22.0%, planned Caesarean 35.3%</td>
<td>13,271</td>
<td>See above</td>
<td>French Agence Nationale de Recherche sur le SIDA</td>
</tr>
<tr>
<td>French Perinatal Cohort Study ANRS-EPF C01/C011 Sibiude, 2014&lt;sup&gt;71&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>90 centers France (but majority from sub-Saharan Africa)</td>
<td>2 years Period 1994 to 2010</td>
<td>cART</td>
<td>Same as Sibiude 2012</td>
<td>Same as Sibiude 2012</td>
<td>13,124</td>
<td>See above</td>
<td>See above</td>
</tr>
<tr>
<td>French Perinatal Cohort Study ANRS-EPF C01/C011 and nested PRIMEVA ANRS 135 RCT Sibiude, 2015&lt;sup&gt;70&lt;/sup&gt;</td>
<td>Cohort combining prospectively collected observational data and retrospective analysis of data from an RCT</td>
<td>Same as Sibiude 2014</td>
<td>Up to 24 months Period 1994 to 2010</td>
<td>A. ZDV exposure (n=3,262) B. No ZDV exposure (n=9,626)</td>
<td>Same as Sibiude 2014</td>
<td>Maternal age: mean NR; 50% ages 25 to 34 years Race/ethnicity: NR Maternal geographic origin: 22% France; 61% Africa</td>
<td>12,888</td>
<td>See above</td>
<td>Agence Nationale de Recherche sur le SIDA et les Hepatites Virales</td>
</tr>
</tbody>
</table>
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

| Fowler, 2016\(^4\) PROMISE trial | RCT, open label | 14 sites in 7 countries (India, Malawi, South Africa, Tanzania, Uganda, Zambia, Zimbabwe) | Through 6 to 14 days postpartum (antenatally period) Period 2011 to 2014 | A. ZDV-based ART (ZDV, 3TC, LPV/r) B. Tenofovir-based ART (tenofovir, FTC, LPV/r) C. ZDV alone (ZDV plus intrapartum single-dose NVP with 6 to 14 days of TDF-FTC postpartum) All infants received NVP from birth. During period 1 (April 2011 to September 2012), women without HBV were assigned only to ZDV alone or ZDV-based ART, but starting in October 2012 due to additional data on TDF, women were assigned to any regimen regardless of HBV status (period 2 = October 2012 to October 2014) | CD4 count of ≥350 cells/mm\(^3\) (or a country-specific threshold for initiating triple-drug ART, if that threshold was higher), gestation of ≥14 weeks and not in labor, no previous use of triple-drug ART, no clinical or immune-related indication for triple-drug ART, a hemoglobin level of at least 7.5 g/dL, an absolute neutrophil count of at least 750 cells/mm\(^3\), an ALT of <2.5 times the upper limit of the normal range, an estimated creatinine clearance of >60 mL/min, and no serious pregnancy complications. Receipt of 1 or 2 antiretroviral agents for the prevention of mother-to-child transmission in previous pregnancies and for ≤30 days during the current pregnancy before enrollment was permitted. Key exclusion criteria were active tuberculosis or receipt of tuberculosis treatment within 30 days before trial entry, HBV infection requiring HBV treatment (patients who did not require | Median age: 26 years Race/ethnic group: 97% black African, 3% Indian, <0.5% other Median CD4 count: 530 cells/mm\(^3\) Median viral load: 3.9 log\(_{10}\) copies/mL WHO clinical stage 1: 97% Gestational age: 26 weeks Region or country: 47% East Africa, 33% South Africa, 17% Southern Africa, 3% India Enrolled: 3,529 mother-infant pairs Analyzed: 3,490 mother-infant pairs | Fair |

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health, and some study drugs were donated by pharmaceutical companies
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
</table>
| Kakkar, 2015\(^5^4\)  
CMIS Mother-Infant Cohort | Retrospective cohort  
Canada (Montreal) | Period 1988 to 2011 | A. Boosted PIs (n=144)  
B. Unboosted PI (n=220)  
C. Other treatment (n=166)  
D. No treatment (n=59) | CMIS mother-child cohort of all HIV-positive pregnant women presenting to Centre Hospitalier Universitaire Sainte-Justine with attendance for at least 2 antenatal obstetric visits and singleton live births, at gestational age of 24 weeks or older | A vs. B vs. C vs. D  
Maternal age: median NR; 60% vs. 63% vs. 66% vs. 62% ages 25 to 35 years  
Race/ethnicity: 79% vs. 63% vs. 66% vs. 62% black; 15% vs. 28% vs. 26% vs. 34%  
Caucasian; 5% vs. 9% vs. 9% vs. 2% other | 525 mother-infant pairs | Fair | Fonds de Recherche du Quebec-Sante |
| Knapp, 2012\(^5^5\)  
IMPAACT Groups Protocol P1025 | Case-control  
Multiple sites International | Through birth Period 2002 to 2007 | Various cART regimens  
A. Congenital anomaly (n=61)  
B. No congenital anomaly (n=1,051) | Singleton children born to HIV-infected mothers enrolled in P1025 trial | Maternal age at enrollment, ≤24 years: 33%  
Maternal age at enrollment, 25 to 34 years: 53%  
Maternal age at enrollment, ≥35 years: 15%  
HIV diagnosis prior to pregnancy: 69%  
Earliest ART use during pregnancy: 47% first trimester, 52% second trimester  
HIV RNA near labor and delivery <400 copies/mL: 76% | 1,112 | Fair | National Institutes of Health, National Institute of Allergy and Infectious Diseases |
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kreitchmann, 2014&lt;sup&gt;56&lt;/sup&gt; LILAC Study</td>
<td>Prospective cohort</td>
<td>Multisite Latin America and Caribbean</td>
<td>Through birth Period 2002 to 2011</td>
<td>At least 28 days in 3rd trimester: A. HAART + PI (888; 59%) B. HAART no PI (410; 27%) C. Non-HAART (134; 9%) D. No ART (80; 5%) Total N=1,512</td>
<td>Pregnant women who were enrolled in the NISDI Perinatal and LILAC protocols with first pregnancy after study enrollment, and either a live birth or a stillbirth</td>
<td>Maternal age: mean 28.2 years Maternal education: mean 8.0 years Race/ethnicity: 91.4% Hispanic/Latino; 70% non-Hispanic/Latino; 58% white; 20.4% black; 21.6% other races</td>
<td>1,563</td>
<td>Fair</td>
<td>National Institute of Child Health and Human Development</td>
</tr>
<tr>
<td>Li, 2016&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>10 sites Tanzania</td>
<td>18 months November 2004 to September 2011</td>
<td>A. Initiated ZDV during pregnancy (1,768; 53%) B. Initiated HAART during pregnancy (512; 15%) C. Continued HAART from before pregnancy (582; 18%) D. No ART (452; 14%) Total N=3,314</td>
<td>HIV-infected pregnant women who had uninfected HIV-exposed infants at birth</td>
<td>Maternal age: median 30 years Race/ethnicity: NR</td>
<td>3,314</td>
<td>Fair</td>
<td>U.S. President's Emergency Plan for AIDS Relief</td>
</tr>
<tr>
<td>Lopez, 2012&lt;sup&gt;58&lt;/sup&gt;</td>
<td>Retrospective cohort (case control)</td>
<td>1 site Spain (Barcelona)</td>
<td>January 1986 to June 2010 Through birth</td>
<td>A. HAART entire pregnancy (n=226) B. HAART 2nd half of pregnancy only (n=72) C. PI during pregnancy (n=178) D. No HAART (n=221)</td>
<td>HIV-infected pregnant women who consecutively attended and delivered in a university referral hospital in Barcelona, Spain, covering an urban area of about 1 million inhabitants between January 1986 and June 2010. Inclusion criteria were singleton pregnancy and delivery beyond 22 weeks. Women with active PWID during pregnancy</td>
<td>HIV infected only: Maternal age: mean 30 years 8% Black; other race/ethnicity NR Low education level: 50% Prior preterm delivery: 8%</td>
<td>519</td>
<td>Fair</td>
<td>NR</td>
</tr>
</tbody>
</table>
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lu, 2014&lt;sup&gt;63&lt;/sup&gt; CPHSP Study</td>
<td>Retrospective cohort, no control</td>
<td>Canada (Ontario)</td>
<td>Through birth Period 1996 to 2008</td>
<td>A. Complete antiretroviral prophylaxis (n=251) B. Incomplete antiretroviral prophylaxis (n=336) C. No antiretroviral prophylaxis (n=58)</td>
<td>Data from women delivering 1996 to 2008 in the Ontario group of the CPHSP were excluded</td>
<td>Maternal age: NR Maternal race/ethnicity: 63% black; 28% white Maternal region or country: 52% Africa; 30% Canada Caesarean delivery: 43% Screen-detected HIV during pregnancy: NR; 13% were considered late diagnoses (diagnosed at or after delivery)</td>
<td>645 mother-child pairs</td>
<td>Fair</td>
<td>None reported</td>
</tr>
<tr>
<td>Moodley, 2016&lt;sup&gt;64&lt;/sup&gt;</td>
<td>Retrospective cross sectional analysis</td>
<td>Single center South Africa</td>
<td>July to December 2011 and January to June 2014</td>
<td>A. Dual ART (AZT/NVP; n=974) B. Triple ART (D4T/3TC/NVP; n=907) C. Fixed-dose ART (EFV/TDF-FTC; n=1,666) D. No ART (n=148)</td>
<td>Women with viable pregnancies delivering a neonate weighing ≥500 g and whose birth outcomes were recorded in the maternity register</td>
<td>NR</td>
<td>3,695</td>
<td>Fair</td>
<td>NR</td>
</tr>
<tr>
<td>Mor, 2017&lt;sup&gt;65&lt;/sup&gt;</td>
<td>Cohort</td>
<td>Multisite Israel</td>
<td>Through birth Period 1985 to 2011</td>
<td>A. Infants born before 1996 (n=80) B. Infant born after 1997 (HAART introduced; n=716)</td>
<td>All HIV-infected women who delivered in Israel and were local citizens between January 1988 and December 2011</td>
<td>A vs. B Maternal age: 27.6 vs. 30.4 years (p=0.001) Mother born in Ethiopia: 87.5% vs. 81.7% HIV transmission route: endemic country 88.6% vs. 82.6%, drug use 1.3% vs. 5.3%, heterosexual 10.1% vs. 12.1% Previous HIV-infected child(ren): 12.0% vs. 9.9% Mother did not receive HAART during pregnancy: 90.0% vs. 46.8% (p=0.001) Caesarian delivery: 11.2% vs. 44.4% (p=0.001) Mother did not receive ART during labor: 95.0% vs. 35.8%</td>
<td>796 infants born to HIV-infected mothers</td>
<td>Fair</td>
<td>No funding received</td>
</tr>
<tr>
<td>Author, year Study</td>
<td>Study design</td>
<td>Number of centers, Country</td>
<td>Study duration Followup</td>
<td>Intervention</td>
<td>Inclusion criteria</td>
<td>Patient characteristics</td>
<td>N</td>
<td>Quality rating</td>
<td>Funding source</td>
</tr>
<tr>
<td>---------------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>---</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Pintye, 2017 Partners PrEP Study and Partners Demonstration Project</td>
<td>Cohort</td>
<td>Kenya and Uganda</td>
<td>Partners PrEP: 2008 through 2012 Partners Demonstration Project: 2012–2016</td>
<td>A. TDF-containing 3-drug ART (n=208) B. Non-TDF-containing 3-drug ART (n=214)</td>
<td>Women who were HIV-infected at enrollment in Partners PrEP or Partners Demonstration Projects and became pregnant during the study period</td>
<td>Infant did not receive ART after birth: 80.0% vs. 19.9% (p=0.001) Breastfed: 1.3% vs. 1.0%</td>
<td>422 pregnancies</td>
<td>Fair</td>
<td>National Institutes of Health, University of Washington Center for AIDS Research, University of Washington Global Center for Integrated Health of Women, Adolescents, and Children</td>
</tr>
<tr>
<td>Ramokolo, 2017 PMTCT Program</td>
<td>Cross-sectional cohort</td>
<td>580 sites South Africa</td>
<td>Through 4–8 weeks postpartum Period October 2012 to May 2013</td>
<td>A. Postconception ART (n=780) B. Preconception ART (n=616) C. ZDV prophylaxis (n=873) D. No ART (n=330)</td>
<td>Mother-infant pairs attending immunization services at 1 of 580 primary health facilities offering immunization services consecutively or systematically enrolled, regardless of maternal HIV status</td>
<td>A vs. B vs. C vs. D Maternal age: 3.1% vs. 1.8% vs. 7.0% vs. 5.2% &lt;20 years; 28.5% vs. 10.0% vs. 36.2% vs. 34.9% ages 20–25 years; 27.2% vs. 23.3% vs. 26.1% vs. 24.5% ages 26–29 years; 29.8% vs. 35.2% vs. 19.1% vs. 20.7% ages 30–35 years; 14.6% vs. 29.8% vs. 11.6% vs. 14.7% &gt;35 years Education less than 7th grade: 15.1% vs. 16.9% vs. 21.8% vs. 22.1% Black race: 98.2% vs. 97.3% vs. 96.2% vs. 97.5%</td>
<td>2,599 (HIV exposed infants only)</td>
<td>Fair</td>
<td>Centers for Disease Control and Prevention; South African National Health Scholarship Programme</td>
</tr>
</tbody>
</table>
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius, 201345</td>
<td>RCT</td>
<td>Africa (3 countries)</td>
<td>January 2005 and August 2008 Duration: 28 weeks of pregnancy until 12 to 24 months after delivery</td>
<td>A. Triple ART, CD4 &lt;200 (n=118) B. ZDV plus single-dose NVP, CD4 &gt;500 cells/mm³ (n=128) C. Triple ART, CD4 200 to 500 cells/mm³ (n=412) D. ZDV plus single-dose NVP, CD4 200 to 500 cells/mm³ (n=412) Note: &gt;70% breastfed</td>
<td>HIV-infected women had to reside and plan to continue living in the study area until 2 years postdelivery, have no contraindication to receive ART, and no evidence of clinically significant conditions (obstetric, cardiac, respiratory including active tuberculosis, hepatic, gastrointestinal, endocrine, renal, hematologic, psychiatric, neurologic, or allergic) that may interfere with study interventions</td>
<td>A vs. B vs. C vs. D Maternal age: 28 vs. 26 vs. 27 vs. 27 years Secondary education or higher: 36% vs. 4% vs. 52% vs. 49%</td>
<td>1,072</td>
<td>Fair</td>
<td>NR</td>
</tr>
<tr>
<td>Short, 201368</td>
<td>Retrospective analysis</td>
<td>1 site U.K. (London) Period 1996 to 2010</td>
<td></td>
<td>A. ZDV (n=65) B. Dual NRTI (n=7) C. Triple NRTI (n=5) D. Short-term cART (n=59) E. Preconception cART (n=131) F. New continuous cART (n=56)</td>
<td>HIV-positive pregnant women managed by a single, multidisciplinary team at St Mary’s Hospital</td>
<td>Maternal age: median 32 years Race: 78% black African; other races NR Maternal history of any AIDS-defining illness: 11.5% Median gestational age: 13 weeks</td>
<td>331</td>
<td>Fair</td>
<td>NR</td>
</tr>
<tr>
<td>SMARTT and PHACS Studies Nozyce, 201464</td>
<td>Prospective cohort</td>
<td>Multisite U.S. Up to 13 years Period 2007 to 2012</td>
<td></td>
<td>Any maternal cART regimen containing ≥3 antiretroviral drugs from ≥2 drug classes, analyzed by assessment scale: WPPSI-III (n=369) WASI (n=452) WIAT-II-A (n=451) Other intervention:</td>
<td>All children enrolled in the SMARTT Static cohort (HIV-exposed) who completed a valid, age-appropriate measure of cognition and/or academic achievement in English and had information regarding in utero and neonatal</td>
<td>Male: 49% to 52% Ethnicity: 75% to 77% black, 19% to 25% Hispanic Preterm birth (&lt;37 weeks): 17% to 21% Low birth weight (&lt;2.500 g): 18% to 20% Household annual income ≤$20,000: 59% to 69% Caregiver with less than a</td>
<td>739</td>
<td>Fair</td>
<td>Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute on Drug Abuse;</td>
</tr>
</tbody>
</table>
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neonatal prophylaxis defined as antiretroviral drugs used during the first 8 weeks of life</td>
<td>ART exposure</td>
<td>high school education: 32% to 34% First viral load during pregnancy &gt;400 copies/mL: 60% to 72% Last viral load prior to delivery &gt;400 copies/mL: 19% to 33%</td>
<td></td>
<td></td>
<td>National Institute of Allergy and Infectious Diseases; Office of AIDS Research; National Institute of Mental Health; National Institute of Neurological Disorders and Stroke; National Institute on Deafness and Other Communication Disorders; National Heart, Lung, and Blood Institute; National Institute of Dental and Craniofacial Research; and the National Institute on Alcohol Abuse and Alcoholism; Harvard University and Tulane University and National Institutes of Health</td>
</tr>
</tbody>
</table>
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHACS Study Lipshultz, 2015[^{58}]</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
<td>Mean 4 years Period 2007 to 2012</td>
<td>A. HIV-exposed uninfected (n=417) B. HIV-unexposed controls (n=98)</td>
<td>SMARTT enrolled children with echocardiography and unexposed controls</td>
<td>A vs. B Maternal age: 28 vs. 26 years Race: 62% vs. 70% black; 30% vs. 26% white; 9% vs. 4% other; 39% vs. 22% Hispanic Child age at time of echocardiography: 4.0 vs. 4.8 years</td>
<td>515</td>
<td>Same as Nozyce 2014</td>
<td>National Institutes of Health</td>
</tr>
<tr>
<td>SMARTT, study of the PHACS cohort and P1025 study of the IMPAACT cohort Rough, 2018[^{67}]</td>
<td>Cohort 2 multisite cohorts U.S.</td>
<td>Period 2007 to 2016 for Dynamic cohort of the SMARTT study and 2002 to 2013 for the P1025 study</td>
<td>A. TDF-FTC + LPV/r (128; 8%) B. ZDV + 3TC + LPV/r (954; 59%) C. TDF-FTC + ATV/r (539; 33%)</td>
<td>All infants with an observed birth outcome in the SMARTT or P1025 study, when the first ART regimen that their mothers used during pregnancy was one of the following: TDF-FTC + LPV/r, ZDV + 3TC + LPV/r, or TDF-FTC + ATV/r</td>
<td>A vs. B vs. C Maternal age: 39.1% vs. 37.2% vs. 25.2% ≤24 years, 52.3% vs. 49.6% vs. 54.4% 25–34 years, 8.6% vs. 13.1% vs. 20.2% ≥35 years Race: 11.7% vs. 7.1% vs. 8.2% non-Hispanic white, 63.3% vs. 64.0% vs. 67.7% non-Hispanic black, 23.4% vs. 27.0% vs. 22.3% Hispanic, 0.8% vs. 1.2% vs. 1.7% other First CD4 count in pregnancy: 23.4% vs. 20.3% vs. 18.6% &lt;250 cells/mm(^3), 36.7% vs. 39.9% vs. 38.0% 250–500 cells/mm(^3), 36.7% vs. 38.3% vs. 41.7% &gt;500 cells/mm(^3) First viral RNA in pregnancy: 47.7% vs. 29.5% vs. 51.4% &lt;400 copies/mL, 25.8% vs. 37.8% vs. 25.4% 400–10,000 copies/mL, 25.8% vs. 32.0% vs. 22.6% &gt;10,000 copies/mL Timing of regimen initiation: 45.3% vs. 11.6% vs. 49.2% before pregnancy, 14.1% vs. 12.1% vs. 15.2% first</td>
<td>1,621</td>
<td>Fair</td>
<td>Same as Nozyce 2014</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMARTT and PHACS Studies Siberry, 2012&lt;sup&gt;69&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>Multisite U.S.</td>
<td>Through infant growth at 1 year Period through January 2011</td>
<td>A. TDF-containing ART (n=449) B. non-TDF-containing ART (n=1,580)</td>
<td>Data collected in the SMARTT of the PHACS network, restricted primary models to consider only those exposed in utero to combination antiretroviral regimens with vs. without TDF</td>
<td>Race/ethnicity: black 66%, Latino 33% Gestational age: &lt;32 weeks 3%, 32–37 weeks 17%, ≥37 weeks 76% Maternal CD4 count &lt;250 cells/mm&lt;sup&gt;3&lt;/sup&gt; at delivery: 15% HBV+: 2%</td>
<td>2,029</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
</tr>
<tr>
<td>SMARTT and PHACS Studies Watts, 2013&lt;sup&gt;75&lt;/sup&gt;</td>
<td>Prospective cohort</td>
<td>22 sites U.S.</td>
<td>Unclear Period 2007 to 2010</td>
<td>Various maternal cART regimens</td>
<td>HIV-infected mothers and their children enrolled in SMARTT of the PHACS network. This analysis limited to singleton gestations with maternal enrollment on or before October 2010.</td>
<td>Mean maternal age at delivery: 27 years Ethnicity: 65% black, 28% white, 7% other [34% Hispanic] Annual household income &lt;$20,000: 63% CD4 count &lt;200 cells/mm&lt;sup&gt;3&lt;/sup&gt;: 13% CD4 count 200 to 500 cells/mm&lt;sup&gt;3&lt;/sup&gt;: 46% CD4 count &gt;500 cells/mm&lt;sup&gt;3&lt;/sup&gt;: 36% Antiretroviral regimen: 3% none, 7% monotherapy or dual therapy, 71% combination with PI (with or without NNRTI), 10% combination with ≥3 NRTIs, 9% combination with NNRTI (no PI) First trimester use of cART: 40% Second trimester use of cART: 63% Third trimester use of cART: 76%</td>
<td>1,869</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
</tr>
</tbody>
</table>
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMARTT and PHACS Studies Williams, 2015[^1]</td>
<td>Combined data from prospective and retrospective cohorts</td>
<td>Same as Nozyce 2014</td>
<td>Period 2007-2012</td>
<td>A. Any ART (n=1,219) B. Any HAART (n=1,025) C. NNTRI (n=214) D. NRTI (n=1,211) E. PI (n=887) F. No ART exposure of any kind (n=1,298 to 2,303 depending on comparison)</td>
<td>Static (retrospective) cohort: Mothers or caregivers and their children younger than age 12 years who had detailed information on ART use during pregnancy and pregnancy outcomes Dynamic (prospective) cohort: Pregnant women and their infants between 22 weeks of gestation and 1 week after delivery All exposure was during first trimester</td>
<td>Maternal age: mean NR; 13% &gt;35 years Race/ethnicity: 66% black; 27% white; 0.5% other; 33% Latino/Hispanic Caregiver not a high school graduate: 5%</td>
<td>2,580</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
</tr>
<tr>
<td>SMARTT and PHACS Studies Williams, 2016[^2]</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
<td>Period 2007 to 2012</td>
<td>A. Any HAART exposure (n=2,211) B. NNTRI exposed (n=395) C. NRTI (n=1,907) D. PI (n=NR) E. No ART exposure of any kind (n=469)</td>
<td>SMARTT cohort of children with adverse event trigger cases, defined as language impairment, metabolic abnormality, impaired growth, neurologic diagnosis, neurodevelopmental impairment, elevated blood lactate, chemistry or hematology toxicity, or hearing impairment</td>
<td>No adverse event vs. adverse event Maternal age: mean NR; 33% vs. 33% &lt;25 years Infant characteristics 49% vs. 47% female Race/ethnicity: 68% vs. 61% black; 25% vs. 32% white; 4% vs. 4% Puerto Rican; 1% vs. 1% other; 32% vs. 37% Hispanic 17% vs. 25% low birth weight 19% vs. 24% preterm birth (&lt;37 weeks of gestation) 55% vs. 56% Caesarean delivery</td>
<td>2,680</td>
<td>Same as Nozyce 2014</td>
<td>Same as Nozyce 2014</td>
</tr>
</tbody>
</table>

[^1]: SMARTT and PHACS Studies
[^2]: Williams, 2016
## Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
<tbody>
<tr>
<td>Snijdewind, 2018&lt;sup&gt;73&lt;/sup&gt;</td>
<td>Retrospective cohort</td>
<td>26 centers The Netherlands</td>
<td>Period 1997 to 2015</td>
<td>A. PI-based (928; 67%) B. NNRTI-based (438; 31%) C. Both or NRTI (12; 1%)</td>
<td>ATHENA cohort database; HIV-positive women age &gt;18 years who gave birth to HIV-exposed and uninfected infants after a minimum 24 weeks of pregnancy; singleton births; includes women who started cART preconception as well as those who began postconception</td>
<td>Maternal age: median 29 years Region of origin: 61.3% sub-Saharan Africa, 20.7% Western Europe, 16.5% other Mode of delivery: 44.5% spontaneous labor, 13.6% elective Caesarean delivery, 6.8% emergency Caesarean delivery, 27.7% unknown CD4 count: median 520 cells/mm&lt;sup&gt;3&lt;/sup&gt; HIV RNA: 79.1% ≤500 copies/mL Infant birth weight: median 3,090 kg Duration of pregnancy: 85.3% &gt;37 weeks, 11.9% &lt;37 weeks</td>
<td>1,378</td>
<td>Fair</td>
<td>Dutch Health Ministry</td>
</tr>
<tr>
<td>Tookey, 2016&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Retrospective cohort, no control</td>
<td>U.K. and Ireland</td>
<td>Through birth Period 2003 to 2012</td>
<td>LPV/r</td>
<td>NSHPC participants with pregnancies who were due to deliver</td>
<td>Maternal age: median 30 years Maternal race/ethnicity: 15% white; 77% black; 8% other Maternal region/country: 14% U.K./Ireland; 77% Africa; 10% other</td>
<td>4,118 mothers, 4,864 pregnancies</td>
<td>Fair</td>
<td>Health Protection Agency, National Screening Committee and the Welton Foundation, Medical Research Council, National Institute for Health Research, Biomedical Research Centre at Great Ormond Street Hospital for</td>
</tr>
<tr>
<td>Author, year Study</td>
<td>Study design</td>
<td>Number of centers, Country</td>
<td>Study duration Followup</td>
<td>Intervention</td>
<td>Inclusion criteria</td>
<td>Patient characteristics</td>
<td>N</td>
<td>Quality rating</td>
<td>Funding source</td>
</tr>
<tr>
<td>-------------------</td>
<td>-------------</td>
<td>---------------------------</td>
<td>------------------------</td>
<td>--------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td>---</td>
<td>---------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
| Zash, 2016        | Cohort      | 2 hospitals Botswana      | Through birth Period May 2009 to April 2011 and April 2013 to April 2014 | A. TDF-FTC and EFV at conception (n=165)  
B. Other 3-drug ART at conception (n=2,006)  
C. TDF-FTC and EFV during pregnancy (n=1,054)  
D. Other 3-drug ART during pregnancy (n=2,172) | All women who delivered live-born or stillborn infants at 8 government maternity wards in Botswana  
Excluded births that occurred before arrival at hospital and at gestational age <24 weeks | HIV infected, years 2009–2011 vs. 2013–2014:  
Maternal age: 28.9 vs. 30.2 years  
Any medical history: 17.4% vs. 19.5%  
Hypertension in pregnancy: 19.1% vs. 17.5%  
Anemia in pregnancy: 59.0% vs. 48.1%  
Primiparous 20.6% vs. 15.9%  
No prenatal care: 5.7% vs. 4.8%  
Unknown HIV status: 4.7% vs. 1.2%  
No ART during pregnancy: 16.1% vs. 12.3%  
Initiated ART <4 weeks prior to delivery: 24.7% vs. 17.0%  
Initiated ART <28 weeks gestational age: 22.0% vs. 59.8%  
Median CD4 count: 388 vs. 415 cells/mm³ | 32,583 births, 9,445 HIV-infected women | Fair | Children, National Health Service Foundation Trust, and University College London |
### Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Author, year Study</th>
<th>Study design</th>
<th>Number of centers, Country</th>
<th>Study duration Followup</th>
<th>Intervention</th>
<th>Inclusion criteria</th>
<th>Patient characteristics</th>
<th>N</th>
<th>Quality rating</th>
<th>Funding source</th>
</tr>
</thead>
</table>
| Zash, 2017<sup>78</sup> | Surveillance cohort | 8 government hospitals Botswana | Through birth Period August 2014 to August 2016 | A. TDF-FTC-EFV (n=2,472)  
B. TDF-FTC-NVP (n=760)  
C. TDF-FTC-LPV/r (n=231)  
D. ZDV-3TC-NVP (n=1,365)  
E. ZDV-3TC-LPV/r (n=167) | All women who delivered live-born or stillborn infants at 8 government maternity wards in Botswana  
Excluded births that occurred before arrival at hospital and at gestational age <24 weeks, and HIV-positive mothers with no ART exposure, unknown ART timing, or unknown ART exposure | Maternal age: median 31 years  
Primiparous: 14.8%  
Gestational age at antenatal care presentation: median 17 weeks  
Received no prenatal care: 3.3%  
Alcohol consumption or smoking during pregnancy: 8.1%  
Caesarean delivery: 23.7%  
ART prior to conception: 5,780 infants, breakdown below:  
TDF-FTC-EFV: 2,503  
ZDV-3TC-NVP: 1,403  
TDF-FTC-NVP: 775  
Unspecified ART: 547  
TDF-FTC-LPV/r: 237  
ZDV-3TC-LPV/r: 169  
Other 3-drug ART: 104  
Nonstandard ART: 21  
Changed or terminated ART: 21  
ART after conception: 4,812 infants, breakdown below:  
TDF-FTC-EFV: 4,569  
Other ART regimen: 129  
Unspecified ART: 94  
Changed or terminated ART: 14  
ZDV monotherapy: 3  
Nonstandard ART: 3 | 47,124 total births  
11,932 HIV-exposed births  
10,592 included in analysis | Fair | National Institutes of Health |

**Abbreviations:** 3TC=lamivudine; ABV=abacavir; ANRS-EPF=French Agence Nationale de Recherche sur le SIDA-Enquête Périnatale Française; ART=antiretroviral therapy; ATV=atazanavir; ATV/r=atazanavir/ritonavir; AZT=azidothymidine cART=combination antiretroviral therapy; CD4=cluster of differentiation 4; CDC=Centers for Disease Control and Prevention; CHIPs=Collaborative HIV Paediatric Study; CMIS=Centre Maternal et Infantile sur le SIDA; CPHSP=Canadian Perinatal HIV Surveillance Program; CoRISPE-Cat=Catalan Cohort of HIV-Infected Children; D4T=stavudine; DRV=darunavir; ECS=European Collaborative Study; EFV=efavirenz; EPPICC=European Pregnancy and Paediatric HIV Cohort Collaboration; FTC=emtricitabine; HAART=highly-active antiretroviral therapy; HBV=hepatitis B virus; HCV=hepatitis C virus; IMPAACT=International Maternal Pediatric Adolescent AIDS Clinical Trials; ITLR=Italian Register for HIV Infection in Children; LILAC=Perinatal and Longitudinal Study in Latin American Countries; LPV=lopinavir; LPV/r=lopinavir/ritonavir; MoCHiV=Swiss Mother and Child HIV Cohort Study; NIH=National Institutes of Health;
Appendix B Table 2. Evidence Table of Included Studies: Study Characteristics

<table>
<thead>
<tr>
<th>Study Characteristics</th>
<th>90</th>
<th>Pacific Northwest EPC</th>
</tr>
</thead>
<tbody>
<tr>
<td>NISDI=National Institute of Child Health and Human Development International Site Development Initiative; NNRTI=nonnucleoside reverse transcriptase inhibitors; NR=not reported; NRTI=nucleoside reverse transcriptase inhibitor; NSHPC=National Study of HIV in Pregnancy and Childhood; NVP=nevirapine; PHACS=Pediatric HIV/AIDS Cohort Study; PI=protease inhibitor; PrEP=pre-exposure prophylaxis; PROMISE=Promoting Maternal and Infant Survival Everywhere; PWID=persons who inject drugs; PWTCT=Prevention of Mother to Child Transmission Program; RAL=raltegravir; RAMQ=Régie de l’Assurance Maladie du Québec; RCT=randomized, controlled trial; RNA=ribonucleic acid; RPV=rilpivirine; RTV=ritonavir; SMARTT=Surveillance Monitoring for Antiretroviral Treatment Toxicities study; TDF=tenofovir disoproxil fumarate; U.K.=United Kingdom; U.S.=United States; WASI=Wechsler Abbreviated Scale of Intelligence; WHO=World Health Organization; WIAT-II-A=Wechsler Individual Achievement Test, 2nd Edition; WPPSI-III=Wechsler Preschool and Primary Scale of Intelligence, 3rd Edition; ZDV=zidovudine.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study author, year</td>
<td>Intervention</td>
<td>HIV transmission</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------</td>
<td>-----------------</td>
</tr>
</tbody>
</table>
| Aaron, 2012<sup>46</sup> | A. Any ART initiation during pregnancy (n=137)  
B. NNRTI use (n=39)  
C. PI use (n=117) | NR | A. SGA, 10th percentile: aOR, 1.47 (95% CI, 0.60 to 3.58); 3rd percentile: aOR, 4.64 (95% CI, 0.81 to 26)  
B. SGA, 10th percentile: aOR, 0.28 (95% CI, 0.10 to 0.75); 3rd percentile: 0.16 (95% CI, 0.03 to 0.91)  
C. SGA, 10th percentile: aOR, 1.68 (95% CI, 0.79 to 3.55); 3rd percentile: aOR, 2.73 (95% CI, 0.83 to 9.00) |
| Antiretroviral Pregnancy Registry, 2018<sup>47</sup> | Preferred initial treatment drugs in U.S.:  
A. ABC (1,131; 12%)  
B. 3TC (5,008; 54%)  
C. TDF (3,535; 38%)  
D. FTC (2,785; 30%)  
E. ATV (1,279; 14%)  
F. RTV (3,155; 34%)  
G. DRV (456; 5%)  
H. RAL (291; 3%)  
Alternative initial treatment drugs in U.S.:  
I. ZDV (4,178; 45%)  
J. LPV (1,418; 15%)  
K. EFV (1,023; 11%)  
L. RPV (297; 3%) | NR | Congenital abnormalities  
First-trimester exposed vs. unexposed, unadjusted OR (our analysis):  
A. 1.04 (0.72 to 1.52)  
B. 1.26 (0.98 to 1.63)  
C. 0.77 (0.59 to 1.01)  
D. 0.85 (0.64 to 1.13)  
E. 0.77 (0.52 to 1.15)  
F. 0.74 (0.56 to 0.97)  
G. 0.88 (0.48 to 1.61)  
H. 1.14 (0.58 to 2.24)  
I. 1.38 (1.08 to 1.77)  
J. 0.74 (0.50 to 1.09)  
K. 0.84 (0.55 to 1.29)  
L. 0.36 (0.11 to 1.12) |
| Berard, 2017<sup>48</sup> Quebec Pregnancy Cohort | A. No ART exposure (n=214,042)  
B. First-trimester ART exposure (n=198) | NR | A vs. B  
Any major congenital malformation: aOR, 0.59 (95% CI, 0.33 to 1.06)  
Nervous system major malformation: aOR, 0.21 (95% CI, 0.03 to 1.83)  
Circulatory system major malformation: aOR, 0.75 (95% CI, 0.31 to 1.85)  
Digestive system major malformation: aOR, 0.80 (95% CI, 0.14 to 4.40)  
Urinary system major malformation: aOR, 0.14 (95% CI, 0.02 to 1.12)  
Musculoskeletal major malformation: aOR, 0.59 (95% CI, 0.21 to 1.68)  
Specific malformations for which there was a statistically significant difference between groups:  
Small intestine: aOR, 10.32 (95% CI, 2.85 to 37.38)  
Other digestive congenital malformations (excluding tongue, mouth, pharynx, esophagus, intestines, gall bladder, bile ducts, liver): aOR, 6.83 (95% CI, 2.18 to 21.35)  
OR adjusted for HIV diagnosis in the 6 months before and during pregnancy, maternal age, place of residence and welfare status, hospitalizations and emergency department visits, physician and specialist visits, number of other medication use and number of prescribers, maternal diabetes, hypertension, and asthma. |
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| Chagomerana, 2017<sup>48</sup> | A. ART (n=2,909)  
B. No ART (n=165) | NR | Overall preterm birth: 24% (731/3,074)  
A vs. B  
Preterm birth: 31% (690/2,219) vs. 33% (41/124); aRR, 1.14 (95% CI, 0.84 to 1.55)  
Extremely to very preterm (27–32 weeks) birth: 6% (133/2,219) vs. 13% (16/124); aRR, 2.33 (95% CI, 1.39 to 3.92) |
| Chen, 2012<sup>50</sup> | A. Continued HAART during pregnancy (n=2,189)  
B. Initiated HAART during pregnancy (n=1,101)  
C. Initiated ZDV during pregnancy (n=4,625)  
D. No ART (n=1,234) | NR | A vs. (B or C or D)  
Preterm delivery: 26.5% (543/2,050) vs. 22.7% (1,515/6,676); aOR, 1.2 (95% CI, 1.1 to 1.4)  
SGA: 26.1% (562/2,151) vs. 15.6% (1,067/6,840); aOR, 1.8 (95% CI, 1.6 to 2.1)  
Stillbirth: 6.3% (1,38/2,189) vs. 4.1% (283/6,960); aOR, 1.5 (95% CI, 1.2 to 1.8) |
| Chiappini, 2013<sup>51</sup>  
EPPICC Study | A. 3 or more drugs (n=2,355)  
B. 2 drugs (n=255)  
C. 1 drug (n=681)  
D. No therapy (n=1,933) | A. 2.8% (65/2,355); aOR, 0.36 (95% CI, 0.23 to 0.57); p<0.001  
B. 1.2% (3/255); aOR, 0.12 (95% CI, 0.04 to 0.40); p<0.001  
C. 3.1% (21/681); aOR, 0.33 (95% CI, 0.19 to 0.55); p<0.005  
D. 14.3% (158/1,107); aOR, 1 reference | Preterm birth (<37 weeks):  
A. 14% (82/597); 1 reference  
B. 13% (31/230); 0.9 (95% CI, 0.5 to 1.5)  
C. 21% (37/177); 1.0 (95% CI, 0.5 to 2.0)  
SGA (<10th percentile): 4% to 10% depending on ART regimen:  
A. 19% (116/597); 1 reference  
B. 23% (54/230); 1.3 (95% CI, 0.8 to 1.9)  
C. 22% (39/177); 1.1 (95% CI, 0.6 to 2.0) |
| Duryea, 2015<sup>52</sup> | A. ART with PI (n=597)  
B. ART without PI (n=230)  
C. No ART (n=177) | NR | Preterm birth (<37 weeks):  
A. 14% (82/597); 1 reference  
B. 13% (31/230); 0.9 (95% CI, 0.5 to 1.5)  
C. 21% (37/177); 1.0 (95% CI, 0.5 to 2.0)  
SGA (<10th percentile): 4% to 10% depending on ART regimen:  
A. 19% (116/597); 1 reference  
B. 23% (54/230); 1.3 (95% CI, 0.8 to 1.9)  
C. 22% (39/177); 1.1 (95% CI, 0.6 to 2.0) |
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Floridia, 2013&lt;sup&gt;53&lt;/sup&gt; Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy</td>
<td>Various cART regimens</td>
<td>Data on transmission available for 868 infants, of which 4 were HIV positive (0.5% [95% CI, 0.0 to 0.9])</td>
<td>Birth defects (Antiretroviral Pregnancy Registry criteria): Overall: 3.3% (42/1,257) for exposure at any time to ART during pregnancy Exposure to any ART during the first trimester: prevalence 3.2% (95% CI, 1.9 to 4.5) (23 cases with defects) vs. initial exposure to ART after the first trimester: prevalence 3.4% (95% CI, 1.9 to 4.9) (19 cases) By drug: No associations found between major birth defects and first-trimester exposure to any ART: OR, 0.94 (95% CI, 0.51 to 1.75) NRTI: OR, 0.95 (95% CI, 0.51 to 1.76) NNRTI: OR, 1.20 (95% CI, 0.56 to 2.55) PI: OR, 0.92 (95% CI, 0.43 to 1.95) Also, no associations found for individual drugs Stillbirth: 0.8% (10/1,257) Death within 2 weeks of delivery: 4 (different from the 4 infants with HIV, and none had birth defects). Reasons: 2 deaths from complications from prematurity and 2 deaths from neonatal sepsis Preterm delivery (&lt;37 weeks): 20.9% Very preterm delivery (&lt;32 weeks): 2.5% Low birth weight (&lt;2,500 g): 22.1% Very low birth weight (&lt;1,500 g): 2.5%</td>
</tr>
<tr>
<td>French Perinatal Cohort Study ANRS-EPF Mandelbrot, 2015&lt;sup&gt;61&lt;/sup&gt;</td>
<td>ART comparing starting at different times and viral loads A. Preconception B. 1st trimester C. 2nd trimester D. 3rd trimester Other interventions: Intrapartum ZDV 96.0% Neonatal antiretroviral prophylaxis: 91.6% ZDV monotherapy, 7.5% other Neonatal single dose NVP: 4.2%</td>
<td>Overall mother-to-child HIV transmission: 0.7% (56/8,075) (95% CI, 0.5 to 0.9) A vs. B vs. C vs. D Mother-to-child HIV transmission based on timing of ART initiation: 0.2% (6/3,505) vs. 0.4% (3/709) vs. 0.9% (24/2,810) vs. 2.2% (23/1,051); p&lt;0.001 Mother-to-child HIV transmission based on viral load (copies/mL) near delivery: &lt;50, 0.3 (95% CI, 0.1 to 0.4); undetectable &gt;50, 0.2 (95% CI &lt;0.1 to 1.2); 50 to 399, 1.5 (95% CI, 0.9 to 2.4); ≥400, 2.8 (95% CI, 1.8 to 4.2), p&lt;0.001; aOR, 4.0 (95% CI, 1.9 to 8.2)</td>
<td>A vs. B vs. C vs. D Live born: 99.1% (4,055/4,095) vs. 99.2% (707/713) vs. 99.1% (2,772/2,803) vs. 99.6% (1,062/1,067) Median birth weight (g): 3,020 vs. 3,065 vs. 3,018 vs. 3,040 Median length at birth (cm): 48.0 vs. 48.0 vs. 48.0 vs. 49.0 Median head circumference (cm): 34.0 vs. 34.0 vs. 34.0 vs. 34.0 5-Minute APGAR 6–10: 96.4% (3,776/4,095) vs. 97.3% (659/713) vs. 97.3% (2,618/2,803) vs. 97.7% (1,017/1,067) Gestational age at delivery: &lt;32 weeks: 4.0% (164/4,095) vs. 3.2% (23/713) vs. 3.6% (100/2,803) vs. 0.7% (7/1,067) 32 to 36 weeks: 13.4% (549/4,095) vs. 12.8% (91/713) vs. 12.0% (336/2,803) vs. 11.6% (124/1,067) ≥37 weeks: 82.6% (3,382/4,095) vs. 84.0% (599/713) vs. 84.4% (2,367/2,803) vs. 87.7% (936/1,067) Stillbirth: 1.0% (38/4,095) vs. 0.8% (6/713) vs. 0.9% (25/2,803) vs. 0.4% (4/1,067) Death before HIV diagnosis: 0.5% (22/4,095) vs. 0.6% (4/713) vs. 0.5% (15/2,803) vs. 0.3% (3/1,067)</td>
</tr>
</tbody>
</table>
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| French Perinatal Cohort Study ANRS-EPF C01/C011 Sibiude, 2012<sup>72</sup> | A. ZDV monotherapy (n=2,975)  
B. NRTI dual therapy (n=1,664)  
C. cART therapy (n=6,738)  
Substudy:  
D. Boosted PI (n=1,066)  
E. Nonboosted PI (n=187) | NR | Full cohort, A vs. B vs. C  
Premature birth: 9.6% vs. 11.3% vs. 14.7%; B vs. A: aOR, 1.24 (95% CI, 0.96 to 1.60); C vs. A: aOR, 1.69 (95% CI, 1.38 to 2.07)  
Substudy, D vs. E | |
| French Perinatal Cohort Study ANRS-EPF C01/C011 Sibiude, 2014<sup>71</sup> | cART | NR | Overall birth defects prevalence (EUROCAT classification): 0.4% (575/13,124) (95% CI, 4.0 to 4.7)  
Overall birth defects prevalence (MACCAT classification): 7.0% (914/13,124) (95% CI, 6.5 to 7.4)  
Premature delivery (<37 weeks): 14.5% (1,901/13,124)  
Low birth weight (<2,500 g): 16.2% (2,127/13,124)  
After adjustment for potential confounders, and by drug:  
Significant association found between exposure to ZDV in the first trimester and CHD: 2.3% (74/3,267); aOR, 2.2 (95% CI, 1.3 to 3.7)  
Significant association found between exposure to ddI and head and neck defects: 0.5%; aOR, 3.4 (95% CI, 1.1 to 10.4)  
Significant association found between exposure to IDV and head and neck defects: 0.9%; aOR, 3.8 (95% CI, 1.1 to 13.8)  
Significant association found between exposure to EFV and neurological defects (MACCAT classification): n=4; aOR, 3.0 (95% CI, 1.1 to 8.5); but not significant using the EUROCAT classification: aOR, 2.1 (95% CI, 0.7 to 5.9)  
No association found between birth defects and LPV or RTV (with a power >85%) nor for NVP, tenofovir, D4T, ABC (with a power >70%) | |
| French Perinatal Cohort Study ANRS-EPF C01/C011 and nested PRIMEVA ANRS 135 RCT Sibiude, 2015<sup>70</sup> | A. ZDV exposure (n=3,262)  
B. No ZDV exposure (n=9,626) | Overall mother-to-child HIV transmission: 1.3% (169/12,888) | A vs. B  
CHD: 1.5% vs. 0.77%; aOR, 2.2 (95% CI, 1.5 to 3.2)  
CHD, boys: aOR, 2.1 (95% CI, 1.2 to 3.7)  
CHD, girls: aOR, 2.0 (95% CI, 1.2 to 3.2); p=0.89 for interaction  
Echocardiography (based on RCT data only): girls more likely than boys to show LV shortening fraction at 1 month (p=0.3 for interaction); no significant differences for other measures at 1 month or 1 year | |
| Fowler, 2016<sup>44</sup> PROMISE trial | A. ZDV-based ART (ZDV, 3TC, LPV/r)  
B. Tenofovir-based ART (tenofovir, FTC, LPV/r)  
C. ZVD alone (ZDV plus intrapartum single-dose NVP with 6 to 14 days of tenofovir and FTC postpartum) | Periods 1 and 2. A vs. B vs. C  
Rate of transmission: 0.5% (7/1,385) vs. 0.6% (2/325) vs. 1.8% (25/1,386); difference A and B vs. C: -1.3 percentage points (repeated CI, -2.1 to -0.4) | Maternal any grade ≥2 adverse event: 21.1% (318/1,505) vs. 17.3% (261/1,510), p=0.008  
Maternal grade ≥2 abnormal blood chemical value: 5.8% (88/1,505) vs. 3.3% (19/1,505), p<0.001  
Any adverse pregnancy outcome: 40.0% (563/1,407) vs. 27.5% (389/1,414), p<0.001 | |
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>All infants received NVP from birth.</td>
<td>Gestational age at trial entry &lt;34 weeks: 0.5% (6/1,230) vs. 0.4% (1/274) vs. 1.3% (16/1,229), difference A and B vs. C: -0.8 percentage points (repeated CI, -1.6 to -0.1) Gestational age at trial entry ≥34 weeks: 0.6% (1/154) vs. 2.0% (1/51) vs. 5.7% (9/157), difference A and B vs. C: -4.8 percentage points (repeated CI, -8.9 to -0.6) CD4 count at trial entry, 350–499 cells/mm³: 0.7% (4/592) vs. 0.7% (1/136) vs. 2.8% (16/577), difference A and B vs. C: -2.1 percentage points (repeated CI, -3.7 to -0.5) CD4 count at trial entry, ≥500 cells/mm³: 0.4% (3/793) vs. 0.5% (1/189) vs. 1.1% (9/809), difference A and B vs. C: -0.7 percentage points (repeated CI, -1.6 to 0.2) Viral load at trial entry, &lt;1,000 copies/mL: 0.4% (1/253) vs. 0% (0/57) vs. 0% (0/299), difference A and B vs. C: 0.3 percentage points (repeated CI, -0.4 to 1.0) Viral load at trial entry, ≥1,000 copies/mL: 0.5% (6/1,129) vs. 0.7% (2/268) vs. 2.3% (25/1,083), difference A and B vs. C: -1.7 percentage points (repeated CI, -2.8 to -0.7)</td>
<td>Low birth weight, &lt;2,500 g: 23.0% (306/1,332) vs. 12.0% (161/1,347); p=0.001 Preterm delivery, &lt;37 weeks: 20.5% (288/1,406) vs. 13.1% (185/1,411); p=0.22 Any severe adverse pregnancy outcome: 7.1% (99/1,385) vs. 5.9% (83/1,399); p=0.22 Very preterm delivery, &lt;34 weeks: 3.1% (44/1,406) vs. 2.6% (37/1,411); p=0.43 Infant death through week 1: 1.2% (17/1,419) vs. 2.0% (28/1,532); p=0.13</td>
<td>Maternal any grade adverse event: 15.8% (61/385) vs. 15.8% (60/380); p=0.99 Maternal abnormal blood chemistry value: 4.7% (18/385) vs. 2.9% (11/380); p=0.26 Any adverse pregnancy outcome: 37.5% (123/328) vs. 34.7% (111/320), p=0.46 Low birth weight, &lt;2,500 g: 20.4% (65/319) vs. 16.9% (51/301); p=0.30 Preterm delivery, &lt;37 weeks: 19.7% (68/346) vs. 18.5% (62/335); p=0.77 Any severe adverse pregnancy outcome: 4.3% (14/322) vs. 9.2% (29/314); p=0.02 Very preterm delivery, &lt;34 weeks: 2.6% (9/346) vs. 6.0% (20/335); p=0.04 Infant death through week 1: 0.6% (2/346) vs. 4.4% (15/341); p=0.001</td>
</tr>
</tbody>
</table>
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kakkar, 2015&lt;sup&gt;54&lt;/sup&gt;</td>
<td>A. Boosted PI (n=144)</td>
<td>NR</td>
<td>A vs. B Preterm delivery: 19.3% vs. 10.8%; aOR, 2.17 (95% CI, 1.05 to 4.51)</td>
</tr>
<tr>
<td>CMIS Mother-Infant cohort</td>
<td>B. Unboosted PI (n=220)</td>
<td></td>
<td>C vs. B Preterm delivery: 8.8% vs. 10.8%; aOR, 0.67 (95% CI, 0.27 to 1.63)</td>
</tr>
<tr>
<td></td>
<td>C. Other treatment (n=166)</td>
<td></td>
<td>D vs. B Preterm delivery: 25% vs. 10.8%; aOR, 1.50 (95% CI, 0.33 to 6.78)</td>
</tr>
<tr>
<td></td>
<td>D. No treatment (n=59)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Knapp, 2012&lt;sup&gt;55&lt;/sup&gt;</td>
<td>Various cART regimens</td>
<td>0.63% (7/1,112)</td>
<td>Congenital anomalies (MACDP guidelines): Overall: 5.5% (61/1,112 infants), prevalence 5.49/100 live births (95% CI, 4.22 to 6.99), including 80 anomalies: cardiovascular (n=33), musculoskeletal (n=15), renal (n=9), genitourinary (n=6), craniofacial (n=4), and central nervous system (n=2)</td>
</tr>
<tr>
<td>IMPAACT Groups Protocol P1025</td>
<td>A. Congenital anomaly (n=61)</td>
<td></td>
<td>Preterm birth (&lt;37 weeks): 17% (191/1,112)</td>
</tr>
<tr>
<td></td>
<td>B. No congenital anomaly (n=1,051)</td>
<td></td>
<td>Low birth weight (&lt;2,500 g): 14% (153/1,112)</td>
</tr>
<tr>
<td>Kreitchmann, 2014&lt;sup&gt;56&lt;/sup&gt;</td>
<td>At least 28 days in 3rd trimester:</td>
<td>NR</td>
<td>Receiving ART at conception vs. no ART at conception, preterm delivery &lt;37 weeks: 1.53 (95% CI, 1.11 to 2.09)</td>
</tr>
<tr>
<td>LILAC Study</td>
<td>A. HAART + PI (888; 59%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. HAART no PI (410; 27%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Non-HAART (134; 9%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. No ARV (80; 5%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total N=1,512</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Li, 2016&lt;sup&gt;57&lt;/sup&gt;</td>
<td>A. Initiated ZDV during pregnancy (1,768; 53%)</td>
<td>NR</td>
<td>HAART vs. ZDV started during pregnancy, preterm delivery: 34 to 37 weeks: 0.85 (95% CI, 0.70 to 1.02); p=0.14 &lt;34 weeks: 0.87 (95% CI, 0.60 to 1.25); p=0.45</td>
</tr>
<tr>
<td></td>
<td>B. Initiated HAART during pregnancy (512; 15%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Continued HAART from before pregnancy (582; 18%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>D. No ART (452; 14%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lopez, 2012&lt;sup&gt;58&lt;/sup&gt;</td>
<td>A. HAART entire pregnancy (n=226)</td>
<td>NR</td>
<td>Spontaneous preterm birth: A vs. D: aOR, 0.55 (95% CI, 0.20 to 1.51)</td>
</tr>
<tr>
<td></td>
<td>B. HAART 2nd half of pregnancy only (n=72)</td>
<td></td>
<td>B vs. D: aOR, 0.55 (95% CI, 0.18 to 1.68)</td>
</tr>
<tr>
<td></td>
<td>C. PI during pregnancy (n=178)</td>
<td></td>
<td>C vs. D: aOR, 1.95 (95% CI, 0.87 to 4.38)</td>
</tr>
<tr>
<td></td>
<td>D. No HAART (n=221)</td>
<td></td>
<td>Iatrogenic preterm birth: A vs. D: aOR, 3.42 (95% CI, 0.80 to 14.63)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B vs. D: aOR, 6.16 (95% CI, 1.42 to 26.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C vs. D: aOR, 0.44 (95% CI, 0.18 to 1.10)</td>
</tr>
<tr>
<td>Lu, 2014&lt;sup&gt;59&lt;/sup&gt;</td>
<td>A. Complete antiretroviral prophylaxis (n=251)</td>
<td>A. 1% (3/251)</td>
<td></td>
</tr>
<tr>
<td>CPHSP Study</td>
<td>B. Incomplete antiretroviral prophylaxis (n=336)</td>
<td>B. 2% (8/336)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. No antiretroviral prophylaxis (n=58)</td>
<td>C. 67% (39/58)</td>
<td>NR</td>
</tr>
</tbody>
</table>
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| Moodley, 2016[62]  | A. Dual ART (AZT/NVP; n=974)  
B. Triple ART (D4T/3TC/NVP; n=907)  
C. Fixed-dose ART (EFV/TDF-FTC; n=1,666)  
D. No ART (n=148) | NR | Stillbirth:  
A vs. D: aOR, 0.08 (95% CI, 0.04 to 0.16)  
B vs. D: aOR, 0.20 (95% CI, 0.11 to 0.38)  
C vs. D: aOR, 0.18 (95% CI, 0.10 to 0.34)  
Preterm birth:  
A vs. D: aOR, 0.20 (95% CI, 0.08 to 0.51)  
B vs. D: aOR, 0.21 (95% CI, 0.08 to 0.55)  
C vs. D: aOR, 0.31 (95% CI, 0.11 to 0.90)  
Low birth weight:  
A vs. D: aOR, 0.06 (95% CI, 0.02 to 0.18)  
B vs. D: aOR, 0.09 (95% CI, 0.03 to 0.24)  
C vs. D: aOR, 0.12 (95% CI, 0.04 to 0.37)  
SGA:  
A vs. D: aOR, 0.37 (95% CI, 0.10 to 1.45)  
B vs. D: aOR, 0.29 (95% CI, 0.08 to 1.07)  
C vs. D: aOR, 0.35 (95% CI, 0.07 to 0.87) |
| Mor, 2017[63] | A. Infants born before 1996 (n=80)  
B. Infant born after 1997 (HAART introduced; n=716) | Stillbirth: Overall: 3.1% (25/796)  
A vs. B: 16.3% (13/80) vs. 1.7% (12/716); p<0.01  
Transmission with HAART and vaginal delivery: 1.5%  
Transmission with HAART and Caesarean delivery: 0.6%  
Variables on mother-to-child HIV transmission HAART vs. no HAART during pregnancy: aOR, 0.4 (95% CI, 0.1 to 0.8)  
Infant ART prophylaxis: aOR, 0.2 (95% CI, 0.1 to 0.5) | Stillbirth: Overall: 3.1% (25/796)  
A vs. B: 16.3% (13/80) vs. 1.7% (12/716); p<0.01  
Transmission with HAART and vaginal delivery: 1.5%  
Transmission with HAART and Caesarean delivery: 0.6%  
Variables on mother-to-child HIV transmission HAART vs. no HAART during pregnancy: aOR, 0.4 (95% CI, 0.1 to 0.8)  
Infant ART prophylaxis: aOR, 0.2 (95% CI, 0.1 to 0.5) |
| Pintye, 2017[65]  
Partners PrEP Study and Partners Demonstration Project | A. TDF-containing 3-drug ART (n=208)  
B. Non-TDF-containing 3-drug ART (n=214) | Stillbirth:  
Pregnancy loss: 14% (17/208) vs. 9% (7/214); aOR, 1.05 (95% CI, 0.75 to 1.46)  
Pregnancy loss, <20 weeks: 11% (13/208) vs. 7% (6/214); aOR, 1.02 (95% CI, 0.73 to 1.40)  
Pregnancy loss, >20 weeks: 2% (4/208) vs. 1% (1/214); aOR, 1.04 (95% CI, 0.95 to 1.13)  
Neonatal death: 1% (3/208) vs. 2% (4/214); aOR, 1.01 (95% CI, 0.96 to 1.06)  
Preterm birth: 6% (10/208) vs. 10% (20/214); aOR, 0.85 (95% CI, 0.74 to 0.97) | NR |
Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| Ramokolo, 2017<sup>66</sup> | A. Postconception ART (n=780)  
B. Preconception ART (n=616)  
C. ZDV prophylaxis (n=873)  
D. No ART (n=330) | NR | A vs. B vs. C vs. D  
Preterm delivery: A vs. B: aOR, 1.7 (95% CI, 1.1 to 2.5); A vs. C: aOR, 1.4 (95% CI, 0.9 to 2.0); A vs. D: aOR, 1.9 (95% CI, 1.1 to 3.1)  
Low birth weight: A vs. B: aOR, 0.9 (95% CI, 0.6 to 1.3); A vs. C: aOR, 0.8 (95% CI, 0.6 to 1.1); A vs. D: aOR, 1.1 (95% CI, 0.8 to 1.6)  
SGA: A vs. B: aOR, 0.9 (95% CI, 0.6 to 1.3); A vs. C: aOR, 0.7 (95% CI, 0.5 to 1.0); A vs. D: 0.7 (95% CI, 0.4 to 1.1)  
Underweight for age: A vs. B: aOR, 1.1 (95% CI, 0.7 to 1.6); A vs. C: aOR, 1.1 (95% CI, 0.8 to 1.6); A vs. D: aOR, 1.4 (95% CI, 0.9 to 2.2) |
| Sartorius, 2013<sup>45</sup> | A. Triple ART, CD4 <200 cells/mm<sup>3</sup> (n=118)  
B. ZDV plus single-dose NVP, CD4 >500 cells/mm<sup>3</sup> (n=128)  
C. Triple ART, CD4 200 to 500 cells/mm<sup>3</sup> (n=412)  
D. ZDV plus single-dose NVP, CD4 200 to 500 cells/mm<sup>3</sup> (n=412)  
Note: >70% breastfed | NR | A vs. B vs. C vs. D  
Severe maternal anemia (hemoglobin <8 g/dL), cumulative incidence:  
At delivery: 0.14 (95% CI, 0.09 to 0.22) vs. 0.05 (95% CI, 0.03 to 0.11) vs. 0.09 (95% CI, 0.06 to 0.12) vs. 0.08 (95% CI, 0.06 to 0.11); p=0.51  
6 months postpartum: 0.30 (95% CI, 0.23 to 0.39) vs. 0.10 (95% CI, 0.06 to 0.16) vs. 0.16 (95% CI, 0.13 to 0.20) vs. 0.17 (95% CI, 0.14 to 0.21); p=0.44  
12 months postpartum: 0.33 (95% CI, 0.26 to 0.41) vs. 0.11 (95% CI, 0.06 to 0.17) vs. 0.18 (95% CI, 0.14 to 0.21) vs. 0.19 (95% CI, 0.16 to 0.23); p=0.71  
18 months postpartum: 0.34 (95% CI, 0.27 to 0.42) vs. 0.11 (95% CI, 0.06 to 0.17) vs. 0.18 (95% CI, 0.15 to 0.22) vs. 0.21 (95% CI, 0.17 to 0.25); p=0.36  
C vs. D: aHR, 0.78 (95% CI, 0.54 to 1.11) |
| Short, 2013<sup>68</sup> | A. ZDV (n=65)  
B. Dual NRTI (n=7)  
C. Triple NRTI (n=5)  
D. Short-term cART (n=59)  
E. Preconception cART (n=131)  
F. New continuous cART (n=56) | NR | A vs. B vs. C vs. D vs. E vs. F  
Preterm delivery rate: 6.2% vs. 0% vs. 0% vs. 25.4% vs. 9.9% vs. 17.9%  
D vs. A: aOR, 5.00 (95% CI, 1.49 to 16.79) |
Appended B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMARTT and PHACS Studies</td>
<td>Any maternal cART regimen containing at least 3 antiretroviral drugs from at least 2 drug classes, analyzed by assessment scale: WPPSI-III (n=369) WASI (n=452) WIAT-II-A (n=451) Other intervention: Neonatal prophylaxis defined as antiretroviral drugs used during the first 8 weeks of life</td>
<td>NR</td>
<td>Mean cognitive and academic scores were significantly below population norms (p=0.01 to p&lt;0.001), with the exception of the WASI VIQ (p=0.48); data from figure. There were no significant differences in adjusted mean scores for any cognitive or academic outcome when comparing different cART regimens or specific drugs or cumulative duration of prenatal cART exposure</td>
</tr>
<tr>
<td>PHACS Study Lipshultz, 2015</td>
<td>A. HIV-exposed uninfected (n=417) B. HIV unexposed controls (n=98)</td>
<td>NR</td>
<td>A vs. B, adjusted mean difference z-score LV ejection fraction: 0.04 (95% CI, 0.14 to 0.21) LV M-mode shortening fraction: 0.06 (95% CI, 0.26 to 0.15) LV stress–velocity index: 0.12 (95% CI, 0.11 to 0.35) LV M-mode end diastolic short axis dimension: 0.07 (95% CI, 0.15 to 0.29) LV M-mode end diastolic postwall thickness: 0.05 (95% CI, 0.25 to 0.15) LV M-mode end diastolic septal thickness: 0.06 (95% CI, 0.25 to 0.13) LV M-mode mass: 0.02 (95% CI, 0.23 to 0.19) LV M-mode end systolic wall stress: 0.02 (95% CI, 0.29 to 0.25) LV M-mode thickness-to-dimension ratio: 0.07 (95% CI, 0.26 to 0.12)</td>
</tr>
<tr>
<td>SMARTT study of the and PHACS cohort and P1025 study of the IMPAACT cohort Rough, 2018</td>
<td>A. TDF-FTC + LPV/r (128; 8%) B. ZDV + 3TC + LPV/r (954; 59%) C. TDF-FTC + ATV/r (539; 33%)</td>
<td>NR</td>
<td>Preterm delivery, aOR: A vs. B: 0.90 (95% CI, 0.60 to 1.33) C vs. B: 0.69 (95% CI, 0.51 to 0.94) A vs. C: 1.14 (95% CI, 0.75 to 1.72) Very preterm delivery, unadjusted OR: A vs. B: 0.85 (95% CI, 0.34 to 2.13) C vs. B: 1.04 (95% CI, 0.60 to 1.83) A vs. C: 0.82 (95% CI, 0.31 to 2.17) Low birth weight, aOR: A vs. B: 1.13 (95% CI, 0.78 to 1.64) C vs. B: 0.80 (95% CI, 0.60 to 1.09) A vs. C: 1.45 (95% CI, 0.96 to 2.17) Very low birth weight, unadjusted OR: A vs. B: 0.41 (95% CI, 0.06 to 3.06) C vs. B: 0.89 (95% CI, 0.40 to 2.00) A vs. C: 0.49 (95% CI, 0.07 to 3.57) Stillbirth—Fetal loss was undefined, included stillbirth (likely also included spontaneous abortion and fetal demise)</td>
</tr>
</tbody>
</table>
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| **SMARTT and PHACS Studies**<sup>69</sup>  
Siberry, 2012 | A. TDF-containing ART (n=449)  
B. non-TDF–containing ART (n=1,580) | NR |
| | A vs. B | A vs. C | B vs. C |
| | Low birth weight (n=1,302): 19.5% vs. 19.1%; aOR, 0.73 (95% CI, 0.48 to 1.11) | SGA (n=1,148): 8.3% vs. 8.6%; aOR, 0.96 (95% CI, 0.60 to 1.52) |
| **SMARTT and PHACS Studies**<sup>75</sup>  
Watts, 2013 | Various maternal cART regimens | NR |
| | | Overall: |
| | Preterm birth (<37 weeks): 18.6% (346/1,869) |
| | Spontaneous preterm birth (occurred after preterm labor or membrane rupture, without other complications): 10.2% (191/1,869) |
| | Very preterm delivery: 2.1% (37/1,799) |
| | SGA (birth weight <10% for gestational age): 7.3% (135/1,861) |
| | First trimester exposure: |
| | Association of first-trimester exposure to PI-based cART and preterm birth: aOR, 1.55 (95% CI, 1.16 to 2.07) |
| | Association of first-trimester exposure to PI-based cART and spontaneous preterm birth: aOR, 1.59 (95% CI, 1.10 to 2.30) |
| | No association of first-trimester exposure to PI-based cART and SGA: aOR, 0.79 (95% CI, 0.49 to 1.26) |
| | No associations for regimens containing NNRTI or ≥3 NRTIs during the first trimester |
| | Exposure overall (no significant associations): |
| | PI-based cART and preterm birth: aOR, 1.49 (95% CI, 0.83 to 2.67) |
| | PI-based cART and spontaneous preterm birth: aOR, 1.41 (95% CI, 0.66 to 2.99) |
| | NNRTI-based cART and preterm birth: aOR, 1.28 (95% CI, 0.62 to 2.66) |
| | NNRTI-based cART and spontaneous preterm birth: aOR, 1.53 (95% CI, 0.62 to 3.81) |
| | ≥3 NRTI-based cART and preterm birth: aOR, 1.04 (95% CI, 0.50 to 2.14) |
| | ≥3 NRTI-based cART and spontaneous preterm birth: aOR, 0.88 (95% CI, 0.34 to 2.29) |
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
</table>
| SMARTT and PHACS Studies | A. Any ART (n=1,219)  
B. Any HAART (n=1,025)  
C. NNTRI (n=214)  
D. NRTI (n=1,211)  
E. PI (n=887)  
F. No ART exposure of any kind (n=1,298 to 2,303 depending on comparison)  
All exposure was during first trimester | NR | Any CA:  
A vs. F: aOR, 1.20 (95% CI, 0.87 to 1.67)  
B vs. F: aOR, 1.35 (95% CI, 0.98 to 1.87)  
C vs. F: aOR, 0.97 (95% CI, 0.54 to 1.74)  
D vs. F: 1.19 (95% CI, 0.86 to 1.65)  
E vs. F: 1.39 (95% CI, 1.00 to 1.92)  
For specific drugs, there was no significant difference in risk of CA for exposed vs. unexposed except:  
ddi plus D4T: aOR, 8.19 (95% CI, 1.53 to 43)  
ATV sulfate: aOR, 1.95 (95% CI, 1.24 to 3.05)  
RTV when used as a booster: aOR, 1.56 (95% CI, 1.11 to 2.20) |
| SMARTT and PHACS Studies Williams, 2015 | A. Any HAART exposure (n=2,211)  
B. NNTRI exposed (n=395)  
C. NRTI (n=1,907)  
D. PI (n NR)  
E. No ART exposure of any kind (n=469) | NR | Adverse event cases:  
A vs. E: aRR, 0.98 (95% CI, 0.82 to 1.16)  
B vs. E: aRR, 0.98 (95% CI, 0.81 to 1.18)  
C vs. E: aRR, 1.15 (95% CI, 0.73 to 1.82)  
D vs. E: aRR, 1.01 (95% CI, 0.86 to 1.17)  
Differences for specific drug/event combinations:  
HAART, metabolic cases: aRR, 0.60 (95% CI, 0.44 to 0.82)  
PIs, metabolic cases: aRR, 0.69 (95% CI, 0.52 to 0.92)  
ZDV exposure, metabolic cases: aRR, 1.61 (95% CI, 1.01 to 2.58)  
LPV exposure, metabolic cases: aRR, 0.46 (95% CI, 0.31 to 0.69)  
LPV (1st trimester), metabolic cases: aRR, 0.39 (95% CI, 0.20 to 0.78)  
RTV (as booster), metabolic cases: aRR, 0.59 (95% CI, 0.43 to 0.81)  
RTV (1st trimester), metabolic cases: aRR, 0.61 (95% CI, 0.40 to 0.95)  
NRTIs, impaired growth: aRR, 0.48 (95% CI, 0.24 to 0.96)  
Neurodevelopmental impairment:  
HAART: aRR, 0.47 (95% CI, 0.27 to 0.83)  
NNRTIs: aRR, 0.38 (95% CI, 0.14 to 1.04)  
3TC: aRR, 0.36 (95% CI, 0.36 to 1.02)  
ZVD + 3TC: aRR, 0.71 (95% CI, 0.41 to 1.17)  
3TC (1st trimester): aRR, 0.64 (95% CI, 0.35 to 1.18) |
| Snijdewind, 2018 | A. PI-based (928; 67%)  
B. NNRTI-based (438; 31%)  
C. Both or NRTI (12; 1%) | NR | Preterm delivery  
Unadjusted OR:  
A. 1 (reference)  
B. 1.30 (95% CI, 0.95 to 1.77); p=0.11  
C. 1.15 (95% CI, 0.41 to 3.19); p=0.78  
Low birth weight  
Unadjusted OR:  
A. 1 (reference)  
B. 1.19 (95% CI, 0.88 to 1.37); p=0.26  
C. 1.47 (95% CI, 0.54 to 3.97); p=0.45  
SGA |
## Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSHPC Study</strong></td>
<td>LPV/r</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tookey, 2016</td>
<td></td>
<td></td>
<td>Infant mortality: 0.5% (24/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2003 to 2007</td>
<td>Gestational age:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overall: 18/1,633 (1.1% [95% CI, 0.6 to 1.6])</td>
<td>&lt;32 weeks: 2.5% (112/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LPV/r initiation:</td>
<td>32 to 36 weeks: 10.4% (473/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Before conception: 2/6,333 (0.6% [95% CI, 0.2% to 2.2%])</td>
<td>≥37 weeks: 87% (3971/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1st trimester: 0/33 (0%)</td>
<td>Birth weight:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd trimester: 8/858 (0.9% [95% CI, 0.5% to 4.1%])</td>
<td>&lt;1,500 g: 2.3% (101/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>3rd trimester: 8/376 (2.1% [95% CI, 1.1% to 4.1%])</td>
<td>1,500 to 2,499 g: 12.4% (545/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2008 to 2012</td>
<td>≥2,500 g: 85.3% (3,749/4,762)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Overall: 12/2,406 (0.5% [95% CI, 0.2% to 0.8%])</td>
<td>Any CA: 2.9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LPV/r initiation:</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Before conception: 2/635 (0.3% [95% CI, 0.1% to 1.1%])</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1st trimester: 0/77 (0%)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>2nd trimester: 5/1,397 (0.4% [95% CI, 0.2% to 0.8%])</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>3rd trimester: 5/264 (1.9% [95% CI, 0.8% to 4.4%])</td>
<td></td>
</tr>
<tr>
<td><strong>Zash, 2016</strong></td>
<td>A. TDF-FTC-EFV at conception (n=165)</td>
<td>NR</td>
<td>Initiated ART at conception A vs. B</td>
</tr>
<tr>
<td></td>
<td>B. Other 3-drug ART at conception (n=2,006)</td>
<td></td>
<td>Stillbirth: 4.9% (8/165) vs. 6.4% (128/2,006); aOR, 0.4 (95% CI, 0.1 to 2.9)</td>
</tr>
<tr>
<td></td>
<td>C. TDF-FTC-EFV during pregnancy (n=1,054)</td>
<td></td>
<td>Preterm birth: 28% (47/165) vs. 31% (631/2,006); aOR, 0.9 (95% CI, 0.3 to 2.9)</td>
</tr>
<tr>
<td></td>
<td>D. Other 3-drug ART during pregnancy (n=2,172)</td>
<td></td>
<td>Very preterm birth: 10% (17/165) vs. 12% (236/2,006); aOR, 0.9 (95% CI, 0.1 to 8.0)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SGA, Botswana norms: 8% (14/165) vs. 24% (476/2,006); aOR, 0.4 (95% CI, 0.1 to 1.4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SGA, WHO norms: 13% (22/165) vs. 32% (636/2,006); aOR, 0.3 (95% CI, 0.1 to 1.0)</td>
</tr>
</tbody>
</table>
## Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Any adverse outcome (any stillbirth, preterm birth, and/or SGA): 33% (55/165) vs. 51% (1,030/2,006); aOR, 0.5 (95% CI, 0.1 to 1.2)</td>
</tr>
<tr>
<td>Zash, 2017(^7&amp;)</td>
<td>A. TDF-FTC-EFV (n=2,472)</td>
<td>NR</td>
<td>Initiated ART during pregnancy</td>
</tr>
<tr>
<td></td>
<td>B. TDF-FTC-NVP (n=760)</td>
<td></td>
<td>C vs. D</td>
</tr>
<tr>
<td></td>
<td>C. TDF-FTC-LPV/r (n=231)</td>
<td></td>
<td>Stillbirth: 1.7% (18/1,054) vs. 3.2% (70/2,172); aOR, 0.6 (95% CI, 0.3 to 1.3)</td>
</tr>
<tr>
<td></td>
<td>D. ZDV-3TC-NVP (n=1,365)</td>
<td></td>
<td>Preterm birth: 18.2% (192/1,054) vs. 20.7% (450/2,172); aOR, 0.7 (95% CI, 0.5 to 1.1)</td>
</tr>
<tr>
<td></td>
<td>E. ZDV-3TC-LPV/r (n=167)</td>
<td></td>
<td>SGA, Botswana norms: 11.9% (125/1,054) vs. 21.1% (459/2,172); aOR, 0.4 (95% CI, 0.3 to 0.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>SGA, WHO norms: 19.2% (202/1,054) vs. 27.7% (602/2,172); aOR, 0.5 (95% CI, 0.4 to 0.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Any adverse outcome (any stillbirth, preterm birth, and/or SGA): 27% (287/1,054) vs. 41% (880/2,172); aOR, 0.4 (95% CI, 0.3 to 0.6)</td>
</tr>
</tbody>
</table>

Preterm birth

|                    | A. 21.4% (529/2,472), reference |                  | |
|                    | B. 19.1% (145/760); RR, 0.88 (95% CI, 0.75 to 1.04); aRR, 0.88 (95% CI, 0.75 to 1.05) |
|                    | C. 23.8% (55/231); RR, 1.11 (95% CI, 0.87 to 1.41); aRR, 1.12 (95% CI, 0.88 to 1.43) |
|                    | D. 24.8% (338/1,365); RR, 1.15 (95% CI, 1.02 to 1.30); aRR, 1.14 (95% CI, 1.01 to 1.29) |
|                    | E. 29.3% (49/167); RR, 1.36 (95% CI, 1.07 to 1.74); aRR, 1.36 (95% CI, 1.06 to 1.75) |

Very preterm birth (<32 weeks)

|                    | A. 4.1% (101/2,472), reference |                  | |
|                    | B. 5.1% (39/760); RR, 1.25 (95% CI, 0.87 to 1.79); aRR, 1.23 (95% CI, 0.84 to 1.80) |
|                    | C. 5.2% (12/231); RR, 1.26 (95% CI, 0.71 to 2.27); aRR, 1.36 (95% CI, 0.76 to 2.45) |
|                    | D. 5.9% (80/1,365); RR, 1.43 (95% CI, 1.07 to 1.90); aRR, 1.44 (95% CI, 1.07 to 1.95) |
|                    | E. 9.0% (15/167); RR, 2.19 (95% CI, 1.30 to 3.67); aRR, 2.21 (95% CI, 1.29 to 3.79) |

SGA (<10th percentile)

|                    | A. 16.9% (419/2,472), reference |                  | |
|                    | B. 24.9% (189/760); RR, 1.44 (95% CI, 1.24 to 1.68); aRR, 1.44 (95% CI, 1.24 to 1.68) |
|                    | C. 27.7% (64/231); RR, 1.62 (95% CI, 1.29 to 2.03); aRR, 1.56 (95% CI, 1.25 to 1.97) |
|                    | D. 28.2% (385/1,365); RR, 1.65 (95% CI, 1.46 to 1.86); aRR, 1.66 (95% CI, 1.46 to 1.87) |
|                    | E. 20.4% (34/167); RR, 1.19 (95% CI, 0.87 to 1.63); aRR, 1.13 (95% CI, |
### Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study author, year</th>
<th>Intervention</th>
<th>HIV transmission</th>
<th>Adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>0.82 to 1.56)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Very SGA (&lt;3rd percentile)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. 7.1% (176/2472), reference</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B. 11.2% (85/760); RR, 1.55 (95% CI, 1.21 to 1.98); aRR, 1.52 (95% CI, 1.18 to 1.94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C. 13.4% (31/231); RR, 1.87 (95% CI, 1.31 to 2.67); aRR, 1.81 (95% CI, 1.26 to 2.59)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D. 12.9% (176/1,365); RR, 1.80 (95% CI, 1.47 to 2.19); aRR, 1.76 (95% CI, 1.44 to 2.16)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. 12.6% (21/167); RR, 1.75 (95% CI, 1.15 to 2.67); aRR, 1.70 (95% CI, 1.10 to 2.62)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stillbirth</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. 2.4% (59/2,472), reference</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B. 2.9% (22/760); RR, 1.21 (95% CI, 0.75 to 1.97); aRR, 1.15 (95% CI, 0.70 to 1.89)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C. 4.3% (10/231); RR, 1.81 (95% CI, 0.94 to 3.50); aRR, 1.81 (95% CI, 0.94 to 3.50)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D. 6.1% (83/1,365); RR, 2.55 (95% CI, 1.84 to 3.53); aRR, 2.31 (95% CI, 1.64 to 3.26)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. 3.6% (6/167); RR, 1.51 (95% CI, 0.66 to 3.44); aRR, 1.53 (95% CI, 0.67 to 3.49)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Neonatal death</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>A. 1.2% (29/2,472), reference</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B. 1.7% (13/760); RR, 1.46 (95% CI, 0.77 to 2.80); aRR, 1.57 (95% CI, 0.81 to 3.06)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>C. 1.7% (4/231); RR, 1.50 (95% CI, 0.53 to 4.24); aRR, 1.60 (95% CI, 0.56 to 4.76)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>D. 2.1% (28/1,365); RR, 1.82 (95% CI, 1.09 to 3.04); aRR, 1.94 (95% CI, 1.13 to 3.33)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E. 4.2% (7/167); RR, 3.64 (95% CI, 1.62 to 8.17); aRR, 4.01 (95% CI, 1.78 to 9.11)</td>
</tr>
</tbody>
</table>

**Abbreviations:** 3TC=lamivudine; ABC=abacavir; aHR=adjusted hazard ratio; ANRS-EPF=French Agence Nationale de Recherche sur le SIDA-Enquête Périnatale Française; aOR=adjusted odds ratio; APGAR=Appearance, Pulse, Grime, Activity, Respiration; aRR=adjusted risk ratio; ART=antiretroviral therapy; ATV=atazanavir; CA=congenital abnormality; cART=combination antiretroviral therapy; CD4=cluster of differentiation 4; CHD=congenital heart defect; CI=confidence interval; CMIS=Centre Maternel et Infantile sur le SIDA; CPHSP=Canadian Perinatal HIV Surveillance Program; D4T=stavudine; did=didanosine; DRV=darunavir; EFV=efavirenz; EPPICC=European Pregnancy and Paediatric HIV Cohort Collaboration; EUROCAT=European Surveillance of Congenital Anomalies; FTC=emtricitabine; HAART=highly-active antiretroviral therapy; HBV=hepatitis B virus; IMPAACT=International Maternal Pediatric Adolescent AIDS Clinical Trials; IND=indinavir; LILAC=Perinatal and Longitudinal Study in Latin American Countries; LPV=lopinavir; LPV/r=lopinavir/ritonavir; LV=left ventricle; MACDP=Metropolitan Atlanta Congenital Defects Program; NART=nonnucleoside reverse transcriptase inhibitors; NR=not reported; NRTI=nucleoside reverse transcriptase inhibitor; NSHPC=National Study of HIV in Pregnancy and Childhood; NVP=nevirapine; OR=odds ratio; PHACS=Pediatric HIV/AIDS Cohort Study; PI=protease inhibitor; PRIMEVA-ANRS=Protease Inhibitor Monotherapy Evaluation-French Agence Nationale de Recherche sur le SIDA; PROMISE=Promoting Maternal and Infant Survival Everywhere; PWTCT=Prevention of Mother to Child Transmission Program; RAL=raltegravir; RCT=randomized, controlled trial; RNA=ribonucleic acid; RTV=ritonavir; SGA=small size for gestational age; SMARTT=Surveillance Monitoring for Antiretroviral Treatment
Appendix B Table 3. Evidence Table of Included Studies: Results

<table>
<thead>
<tr>
<th>Study</th>
<th>Method</th>
<th>Drug</th>
<th>Toxicities</th>
<th>TDF=tenofovir disoproxil fumarate; U.S.=United States; VIQ=verbal intelligence quotient; WASI=Wechsler Abbreviated Scale of Intelligence; WHO=World Health Organization; WIAT-II-A=Wechsler Individual Achievement Test, 2nd Edition; WPPSI-III=Wechsler Preschool and Primary Scale of Intelligence, 3rd Edition; ZDV=zidovudine.</th>
</tr>
</thead>
</table>

Screening for HIV in Pregnant Women 105 Pacific Northwest EPC
**Appendix B Table 4. Quality Assessment of Cohort Studies**

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</th>
<th>Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)?</th>
<th>Did the study maintain groups through the study period?</th>
<th>Did the study use accurate methods for ascertaining exposures and potential confounders?</th>
<th>Were outcome assessors and/or data analysts blinded to the exposure being studied?</th>
<th>Did the article report attrition?</th>
<th>Is there high attrition?</th>
<th>Were outcomes prespecified and defined, and ascertained using accurate methods?</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aaron, 2012(^{46})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Anteretroviral Pregnancy Registry Interim Report(^{47})</td>
<td>Not relevant (volunteer database); encourages participating MDs to enter all cases</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes, but no adjustment for confounding</td>
<td>Unclear</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Berard, 2017(^{48})</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
</tr>
<tr>
<td>Chagomerana, 2017(^{49})</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Chen, 2012(^{50})</td>
<td>Yes</td>
<td>Differences in age, past adverse pregnancy outcome, receipt of antenatal care, CD4 count, parity</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Chiappini, 2013(^{51})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Duryea, 2015(^{52})</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Floridia, 2013(^{53})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>French Perinatal Cohort ANRS-EPF study Mandelbrot, 2015(^{61}) Sibiude, 2012(^{47}) Sibiude, 2014(^{68}) Sibiude, 2015(^{70})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Kakkar, 2015(^{54})</td>
<td>Yes</td>
<td>Differences in study time period, parity, ethnicity</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Knapp, 2012(^{55})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Kreitchmann, 2014(^{56})</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
</tbody>
</table>
## Appendix B Table 4. Quality Assessment of Cohort Studies

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inclusion cohort)?</th>
<th>Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)?</th>
<th>Did the study maintain groups through the study period?</th>
<th>Did the study use accurate methods for ascertaining exposures and potential confounders?</th>
<th>Were outcome assessors and/or data analysts blinded to the exposure being studied?</th>
<th>Did the article report attrition?</th>
<th>Is there high attrition?</th>
<th>Were outcomes prespecified and defined, and ascertained using accurate methods?</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Li, 2016&lt;sup&gt;57&lt;/sup&gt;</td>
<td>Yes</td>
<td>Differences in delivering prior to year 2007, CD4 count, nutritional status, and other diseases and symptoms</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Lopez, 2012&lt;sup&gt;59&lt;/sup&gt;</td>
<td>Yes</td>
<td>Differences in nulliparity and prior preterm birth for case-control analysis</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Lu, 2014&lt;sup&gt;60&lt;/sup&gt;</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Mor, 2017&lt;sup&gt;61&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Moodley, 2016&lt;sup&gt;62&lt;/sup&gt;</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Pintye, 2017&lt;sup&gt;65&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Ramokolo, 2017&lt;sup&gt;66&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Rough, 2018&lt;sup&gt;67&lt;/sup&gt;</td>
<td>Yes</td>
<td>Differences in age, timing of regimen initiation, viral load, and timing of HIV diagnosis</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Short, 2013&lt;sup&gt;68&lt;/sup&gt;</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>SMARTT/PHACS studies Nozyce, 2014&lt;sup&gt;64&lt;/sup&gt; Lipshultz, 2015&lt;sup&gt;68&lt;/sup&gt; Siberry, 2012&lt;sup&gt;69&lt;/sup&gt; Watts, 2013&lt;sup&gt;70&lt;/sup&gt; Williams, 2015&lt;sup&gt;76&lt;/sup&gt; Williams, 2016&lt;sup&gt;77&lt;/sup&gt;</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Snijdewind, 2018&lt;sup&gt;73&lt;/sup&gt;</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Tookey, 2016&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Yes</td>
<td>Not relevant</td>
<td>Not relevant</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Zash, 2016&lt;sup&gt;79&lt;/sup&gt;</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
<tr>
<td>Zash, 2017&lt;sup&gt;78&lt;/sup&gt;</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Unclear</td>
<td>No</td>
<td>Unclear</td>
<td>Yes</td>
<td>Fair</td>
<td></td>
</tr>
</tbody>
</table>
### Appendix B Table 4. Quality Assessment of Cohort Studies

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Did the study attempt to enroll all (or a random sample of) patients meeting inclusion criteria, or a random sample (inception cohort)?</th>
<th>Were the groups comparable at baseline on key prognostic factors (e.g., by restriction or matching)?</th>
<th>Did the study maintain groups through the study period?</th>
<th>Did the study use accurate methods for ascertaining exposures and potential confounders?</th>
<th>Were outcome assessors and/or data analysts blinded to the exposure being studied?</th>
<th>Did the article report attrition?</th>
<th>Is there high attrition?</th>
<th>Were outcomes prespecified and defined, and ascertained using accurate methods?</th>
<th>Quality rating</th>
</tr>
</thead>
</table>

**Abbreviations:** ANRS-EPF=French Agence Nationale de Recherche sur le SIDA-Enquête Périmatale Française; CD4=cluster of differentiation 4; IMPAACT=International Maternal Pediatric Adolescent AIDS Clinical Trials; PHACS=Pediatric HIV/AIDS Cohort Study; SMARTT=Surveillance Monitoring for Antiretroviral Treatment Toxicities.
### Appendix B Table 5. Quality Assessment of Randomized Trials

<table>
<thead>
<tr>
<th>Author, year</th>
<th>Randomization adequate?</th>
<th>Allocation concealment adequate?</th>
<th>Groups similar at baseline?</th>
<th>Eligibility criteria specified?</th>
<th>Outcome assessors masked?</th>
<th>Care provider masked?</th>
<th>Patient masked?</th>
<th>Attrition and withdrawals reported?</th>
<th>Loss to followup: differential (&gt;10%)/high (&gt;20%)?</th>
<th>Analyze persons in the groups in which they were randomized?</th>
<th>Quality rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fowler, 2016&lt;sup&gt;44&lt;/sup&gt;</td>
<td>Yes</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Yes</td>
<td>No, No</td>
<td>Yes</td>
<td>Fair</td>
</tr>
<tr>
<td>Sartorius, 2013&lt;sup&gt;45&lt;/sup&gt;</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Yes</td>
<td>Yes</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Unclear</td>
<td>Yes</td>
<td>No, No</td>
<td>Unclear</td>
<td>Fair</td>
</tr>
</tbody>
</table>